EPICORE Embase Updates: EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 129

Results Generated From:
Embase <1980 to 2025 Week 26>
Embase Weekly Updates (updates since 2025-06-24)

<1>
Accession Number
2037634074
Title
Intravenous amino acids for renal protection in patients receiving
temporary mechanical circulatory support: a secondary subgroup analysis of
the PROTECTION study.
Source
European Journal of Cardio-thoracic Surgery. 67(2) (no pagination), 2025.
Article Number: ezaf035. Date of Publication: 01 Feb 2025.
Author
Belletti A.; Pisano A.; Scandroglio A.M.; Garofalo E.; Calabro M.G.;
Ferrod F.; Monaco F.; Brambillasca C.; Baiardo Redaelli M.; Meroi F.;
Fominskiy E.; Vignale R.; Ajello S.; Venditto M.; Scquizzato T.; Porta S.;
Losiggio R.; Suriano P.; Pontillo D.; Orso D.; Tomasi E.; Paternoster G.;
Lomivorotov V.; Longhini F.; Landoni G.; Zangrillo A.; Maisano F.; Bellomo
R.; Pieri M.; D'Amico F.; Manazza M.; Marmiere M.; Marzaroli M.; Monti G.;
Oliva F.M.; Pruna A.; Turi S.; Veneziano M.; Vietri S.; Zaraca L.; Fraja
D.D.; Verniero L.; Bruni A.; Perrelli G.; Prezzi L.; Massaro C.; Ferrante
P.; Arangino C.; Angelini F.; Bacchetti G.; Vitielli M.; Gallicchio F.;
Bradic N.; Ti L.K.
Institution
(Belletti, Scandroglio, Calabro, Monaco, Brambillasca, Baiardo Redaelli,
Fominskiy, Ajello, Scquizzato, Losiggio, Pontillo, Landoni, Zangrillo,
Pieri) Department of Anesthesia and Intensive Care, IRCCS San Raffaele
Scientific Institute, Milan, Italy
(Pisano, Venditto, Porta) Monaldi Hospital, Cardiac Anesthesia and ICU,
AORN "Dei Colli, Naples, Italy
(Garofalo, Longhini) Department of Medical and Surgical Sciences, Magna
Graecia University of Catanzaro, Anesthesia and Intensive Care, Catanzaro,
Italy
(Ferrod) S.C. Anestesia e Rianimazione Cardiovascolare, A.O. Ordine
Mauriziano Umberto I di Torino, Torino, Italy
(Suriano) Dipartimento di Chirurgia Cardiovascolare, IRCCS Centro
Cadiologico Monzino, Unita Operativa di Anestesia E Terapia Intensiva,
Milan, Italy
(Meroi, Orso) Department of Emergency Santa Maria della Misericordia,
University Hospital of Udine, Azienda Sanitaria Universitaria Friuli
Centrale, Udine, Italy
(Vignale) San Carlo Hospital, Cardiovascular Anesthesia and ICU, Potenza,
Italy
(Tomasi) IRCCS San Raffaele Scientific Institute, Hospital Pharmacy,
Milan, Italy
(Paternoster) Department of Health Science Anesthesia and ICU, School of
Medicine,, University of Basilicata, San Carlo Hospital, Potenza, Italy
(Lomivorotov) Department of Anesthesiology and Perioperative Medicine,
Penn State Milton S. Hershey Medical Center, Penn State College of
Medicine, Hershey, PA, United States
(Landoni, Zangrillo, Maisano, Pieri) School of Medicine, Vita-Salute San
Raffaele University, Milan, Italy
(Maisano) Cardiac Surgery Department, San Raffaele University Hospital,
Milan, Italy
(Bellomo) Department of Critical Care, The University of Melbourne,
Melbourne, Australia
(Bellomo) Australian and New Zealand Intensive Care Research Centre,
Monash University, Melbourne, Australia
(Bellomo) Data Analytics Research and Evaluation Centre, Austin Hospital,
Melbourne, Australia
(Bellomo) Department of Intensive Care, Austin Hospital, Melbourne,
Australia
(Bellomo) Department of Intensive Care, Royal Melbourne Hospital,
Melbourne, Australia
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES: In cardiac surgery patients, acute kidney injury (AKI)
frequently occurs in the setting of haemodynamic instability and treatment
with temporary mechanical circulatory support (tMCS). Recent evidence
suggests amino acids (AA) infusion may reduce AKI rate. However, the
effect of AA infusion in patients requiring tMCS may be less effective.
 METHOD(S): We performed a secondary analysis of the PROTECTION
multicentre randomized controlled trial including all patients treated
with tMCS. Patients undergoing elective cardiac surgery with
cardiopulmonary bypass were randomized to receive 2 g/kg ideal body
weight/day of intravenous AA to a maximum of 100 g/day or matching placebo
from operating room admission until up to 3 days, receipt of
renal-replacement therapy, discharge from ICU or death. The primary
outcome of the PROTECTION study was the rate of AKI, as in this secondary
analysis. A total of 3511 patients were randomized in the study.
 RESULT(S): We studied 232 patients who received tMCS, 112 randomized
to AA infusion and 120 to placebo. The median preoperative serum
creatinine value was significantly higher among AA group patients (AA:
1.08, interquartile range 0.90-1.26; placebo: 0.98, interquartile range
0.85-1.15; P = 0.02). The rate of AKI, however, was lower in patients
randomized to AA (44.6% vs 60.8%; relative risk 0.73; 95% confidence
interval (0.57-0.94); P = 0.01; number needed to treat = 6). We found no
significant differences in secondary outcomes. CONCLUSION(S):
Short-term AA infusion appears to reduce rate of AKI among patients
requiring tMCS. Use of AA in this population at high-risk for renal
failure appears justified. Copyright © 2025 The Author(s).

<2>
Accession Number
2038348900
Title
Stroke in Heart Failure With Reduced Ejection Fraction: Systematic Review
and Meta-Analysis of Randomized Trials.
Source
JACC: Heart Failure. 13(7) (no pagination), 2025. Article Number: 102389.
Date of Publication: 01 Jul 2025.
Author
Gallone G.; Savoca F.; Miccoli D.; Bohm M.; De Ferrari G.M.; Gottlieb
S.S.; Lancellotti P.; Lindenfeld J.; Saldarriaga C.; Samad Z.; Teerlink
J.R.; Savarese G.; Ammirati E.
Institution
(Gallone, Savoca, Miccoli, De Ferrari) Division of Cardiology,
Cardiovascular and Thoracic Department, Citta della Salute e della
Scienza, Turin, Italy
(Gallone, Savoca, Miccoli, De Ferrari) Department of Medical Sciences,
University of Turin, Italy
(Bohm) Clinic III for Internal Medicine (Cardiology, Angiology, and
Intensive Care Medicine) Saarland University, Homburg/Saar, Germany
(Gottlieb) Division of Cardiovascular Medicine, University of Maryland
School of Medicine and Baltimore;, Veterans Administration Medical Center,
Baltimore, MD, United States
(Lancellotti) University of Liege Hospital, GIGA Institute, Department of
Cardiology, CHU SartTilman, Liege, Belgium
(Lindenfeld) Division of Cardiovascular Medicine, Vanderbilt University
Medical Center, Nashville, TN, United States
(Saldarriaga) CardioVID Clinic, University of Antioquia, Medellin,
Colombia
(Samad) The Aga Khan University, Karachi, Pakistan
(Teerlink) Section of Cardiology, San Francisco Veterans Affairs Medical
Center, School of Medicine, University of California-San Francisco, San
Francisco, CA, United States
(Savarese) Department of Clinical Science, Sodersjukhuset; Karolinska
Institutet, Stockholm, Sweden
(Ammirati) De Gasperis Cardio Center, Transplant Center, Niguarda
Hospital, Milano, Italy
(Ammirati) Department of Health Sciences, University of Milano-Bicocca,
Monza, Italy
Publisher
Elsevier Inc.
Abstract
Background: Patients with heart failure with reduced ejection fraction
(HFrEF) have a heightened stroke risk. However, stroke as an endpoint in
heart failure trials remains under-reported. Objective(s): The
authors sought to define the incidence, characteristics, predictors,
modifier treatments, and prognostic impact of stroke in patients with
HFrEF who were enrolled in randomized controlled trials (RCTs).
 Method(s): The authors systematically reviewed MEDLINE for RCTs of
pharmacologic and nonpharmacologic treatments in HFrEF. The annualized
stroke incidence was the primary outcome. Subgroup analyses and
meta-regressions were performed to determine the baseline modulating
characteristics and to assess the association of stroke with other
clinical outcomes. Result(s): Of 7,104 records, 188 RCTs fulfilled
inclusion criteria for the systematic review. Of these, 158 studies
(84.0%) did not report stroke outcomes and were excluded from the
meta-analysis, leading to a final cohort of 30 studies, with 61 arms and
75,327 patients. Stroke incidence was 1.1% (95% CI: 0.9%-1.3%;
I2: 74%) with high heterogeneity across trials. Higher NYHA
functional class (P < 0.001), lower systolic blood pressure (P < 0.001),
diuretic use (P = 0.001), and diabetes (P < 0.001) were associated with
stroke. No association of renin-angiotensin-aldosterone inhibitors,
beta-blockers, mineralocorticoid receptor antagonists, and transcatheter
mitral valve replacement with stroke was observed. Stroke was associated
with higher risk of all-cause and cardiovascular mortality, heart failure
hospitalization and acute coronary syndromes (P < 0.001 for all).
 Conclusion(s): Stroke was reported in a vast minority of HFrEF RCTs
with heterogeneous definitions and no reference to underlying mechanisms.
Despite under-reporting, stroke incidence is non-negligible. Stroke is
associated with HFrEF-specific characteristics and outcomes, whereas it is
not impacted by current HFrEF treatments. There is a need for dedicated
research into preventive strategies and effective treatments to address
this debilitating and deadly comorbidity. (Stroke Events in Heart Failure
With Reduced Ejection Fraction-A Systematic Review and Meta-Analysis of
Pharmacologic Randomized Trial; CRD42023418422) Copyright © 2025
American College of Cardiology Foundation

<3>
Accession Number
2039049276
Title
Incidence, reasons, and mortality risk of ICU readmission in surgical
patients: A systematic review and meta-analysis.
Source
American Journal of Surgery. 247 (no pagination), 2025. Article Number:
116460. Date of Publication: 01 Sep 2025.
Author
Lu R.; kacha S.; phothikun N.; supphapipat A.; Chanchalotorn S.;
Siripakkaphant C.; Siriniran N.; Chienprasert M.; Chittawatanarat K.
Institution
(Lu, kacha, phothikun, supphapipat, Chittawatanarat) Department of
Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
(Lu) Department of Emergency Medicine, The Affiliated Hospital, Southwest
Medical University, Sichuan, Luzhou, China
(supphapipat, Chittawatanarat) Clinical Surgical Research Center,
Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang
Mai, Thailand
(kacha, phothikun) Department of Anesthesiology, Faculty of Medicine,
Chiang Mai University, Chiang Mai, Thailand
(Chanchalotorn, Siripakkaphant, Siriniran, Chienprasert) Faculty of
Medicine, Chiang Mai University, Chiang Mai, Thailand
Publisher
Elsevier Inc.
Abstract
Background: This study investigates the incidence, reasons, and mortality
risk of ICU readmission in surgical patients. Method(s): Systematic
searches of PubMed, Embase, Cochrane, and Scopus were conducted for
studies from January 2000 to August 2024. Included studies reported ICU
readmission or in-hospital mortality in adult surgical ICU patients.
Mortality risks were compared between readmitted and non-readmitted
patients. Pooled incidence and causes of ICU readmission across diseases
were analyzed. Result(s): Among 23 studies, ICU readmission
significantly increased mortality risk (OR: 8.44, 95 % CI: 6.35-11.21).
The overall readmission incidence was 6 % (95 % CI: 0.05-0.06), with
higher rates in gastrointestinal (9 %) and thoracic (8 %) surgeries.
Respiratory issues were the most frequent cause (40 %).
 Conclusion(s): ICU readmission in surgical patients is associated
with higher mortality and longer stays. Gastrointestinal and thoracic
surgeries pose higher risks, with respiratory and cardiovascular factors
being key contributors. Copyright © 2025 Elsevier Inc.

<4>
[Use Link to view the full text]
Accession Number
2039073972
Title
Response by Campo and Pavasini to Letter Regarding Article, "complete
Versus Culprit-Only Revascularization in Older Patients with
ST-Segment-Elevation Myocardial Infarction: An Individual Patient
Meta-Analysis".
Source
Circulation. 151(23) (pp e1049-e1050), 2025. Date of Publication: 10 Jun
2025.
Author
Campo G.; Pavasini R.
Institution
(Campo, Pavasini) Cardiology Unit, Azienda Ospedaliero Universitaria di
Ferrara, Cona, Italy
Publisher
Lippincott Williams and Wilkins

<5>
Accession Number
2037979246
Title
Toward a Universal Definition for Right Heart Failure: A Work in Progress.
Source
Canadian Journal of Cardiology. 41(6) (pp 1152-1161), 2025. Date of
Publication: 01 Jun 2025.
Author
Jogendran R.; Upagupta C.; Pankiw M.; Sless R.T.; Karvasarski E.; Granton
J.T.; Wright S.P.; Mak S.
Institution
(Jogendran, Upagupta, Pankiw, Sless, Karvasarski, Granton, Mak) University
of Toronto, Toronto, ON, Canada
(Wright) University of British Columbia, Okanagan, BC, Canada
(Granton, Mak) Department of Medicine, Sinai Health and the University
Health Network, Toronto, ON, Canada
(Wright) Center for Heart, Lung and Vascular Health, University of British
Columbia, Vancouver, BC, Canada
Publisher
Elsevier Inc.
Abstract
Background: Broadly speaking, right heart failure (RHF) can be defined as
a clinical syndrome with signs and symptoms of heart failure resulting
from right ventricular dysfunction, as evidenced by abnormal structure or
function. The heterogeneity of conditions associated with RHF combined
with the challenges of characterizing the structural and functional
relationships of the right ventricle make a singular definition of RHF
elusive. We performed a concise scoping review of the literature that
provides knowledge synthesis of RHF in different clinical populations, and
extracted the recommended criteria to define the syndrome. Method(s):
Searches were conducted to identify reviews, guidelines, consensus
statements, systematic reviews, meta-analyses, and consensus statements
concerning right heart or right ventricular failure in well-described
adult human disease populations from the previous 10 years. After removal
of case reports and duplicates, publications describing syndromes in the
context of left-sided heart disease were also removed. Data extracted from
selected manuscripts included the patient population and quantitative
criteria to define RHF, categorized based on diagnostic modalities.
 Result(s): Of 9487 articles initially identified, 71 were selected
for full text review. We found that the majority of the reviewed
literature offered multifaceted diagnostic approaches, including clinical,
echocardiographic, hemodynamic, and therapeutic characteristics, with
unique additions or omissions depending on the clinical contexts.
Nomenclature for RHF was variable, and only 40% of articles articulated a
narrative definition. Conclusion(s): At this time, development of
consistent criteria and a universal definition for RHF remains a work in
process. Copyright © 2025 Canadian Cardiovascular Society

<6>
Accession Number
2034905616
Title
Comparison of the Ivor-Lewis vs McKeown Procedure in Esophageal Cancers:
An Updated Meta-Analysis and Systematic Review.
Source
American Surgeon. (no pagination), 2025. Article Number:
00031348251346537. Date of Publication: 2025.
Author
Tejada B.; Giannaris E.S.; Hashemi S.; Fountos D.M.; Ali M.M.; Mathew
J.A.; German D.E.
Institution
(Tejada, Giannaris, Hashemi, Fountos, Ali, Mathew, German) CUNY School of
Medicine, New York, NY, United States
Publisher
SAGE Publications Inc.
Abstract
Background: The Ivor Lewis and McKeown techniques are two established
approaches for esophagectomy in the treatment of esophageal cancer.
Despite their widespread use, limited direct comparisons exist to assess
the efficacy of these techniques across key intraoperative and
postoperative outcomes. We performed an updated pooled pairwise
meta-analysis to discern the relative benefits and risks associated with
each approach. Method(s): A systematic search of PubMed, Embase,
MEDLINE, and the Cochrane Library through September 2024 was conducted.
Eligible studies compared Ivor Lewis and McKeown techniques for
esophagectomy. Primary outcomes were 12-month mortality and anastomotic
complications; secondary outcomes were number of lymph nodes resected,
recurrent laryngeal nerve palsy, pulmonary complications, and chyle-leaked
complications. Result(s): A total of 9 studies comprising 15 341
patients were included. There were no significant differences in terms of
12-month mortality (OR.89, 95% CI.65 to 1.22, P =.48), the number of lymph
nodes resected (MD -1.18, 95% CI -4.51 to 2.16, P =.49), and pulmonary
complications (OR.87, 95% CI.61 to 1.24, P =.27). However, Ivor Lewis
significantly reduced the incidence of anastomotic leakage (OR.42, 95%
CI.18 to.98, P =.050), recurrent laryngeal nerve palsy (OR.13, 95% CI.06
to.27, P <.00001), and chyle-related complications (OR.63, 95% CI.39 to
1.04, P =.05) compared to the McKeown technique. Conclusion(s): This
meta-analysis reveals certain significant advantages in Ivor Lewis, while
both maintain similarities in other areas. Copyright © The
Author(s) 2025.

<7>
Accession Number
2038270824
Title
Concomitant Surgical Procedures and Aspirin Avoidance With Left
Ventricular Assist Device Therapy.
Source
JACC: Heart Failure. 13(7) (no pagination), 2025. Article Number: 102411.
Date of Publication: 01 Jul 2025.
Author
Pagani F.D.; Netuka I.; Jorde U.P.; Katz J.N.; Gustafsson F.; Connors
J.M.; Uriel N.; Soltesz E.G.; Ivak P.; Bansal A.; Bitar A.; Vega J.D.;
Goldstein D.; Danter M.; Pya Y.; Ravichandran A.; Conway J.; Adler E.D.;
Chung E.S.; Grinstein J.; Dirckx N.; Iravani B.; Mehra M.R.
Institution
(Pagani, Bitar) University of Michigan, Ann Arbor, MI, United States
(Netuka, Ivak) Institute for Clinical and Experimental Medicine, Prague,
Czechia
(Jorde, Goldstein) Division of Cardiology, Montefiore Medical Center,
Albert Einstein College of Medicine, New York, NY, United States
(Katz) Division of Cardiology, Department of Medicine, NYU Grossman School
of Medicine and Bellevue Hospital, New York, NY, United States
(Gustafsson) Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
(Connors, Mehra) Department of Medicine, Brigham and Women's Hospital,
Harvard Medical School, Boston, MA, United States
(Uriel) Division of Cardiology, Columbia University Irving Medical Center,
New York-Presbyterian Hospital, New York, NY, United States
(Soltesz) Thoracic and Cardiovascular Surgery, Cleveland Clinic,
Cleveland, OH, United States
(Bansal) Department of Cardiothoracic Surgery, Ochsner Clinic Foundation,
New Orleans, LA, United States
(Vega) Emory University Hospital, Atlanta, GA, United States
(Danter) Kansas University Medical Center, Kansas City, KS, United States
(Pya) Research Department of University Medical Center (Heart Center),
Astana, Kazakhstan
(Ravichandran) Ascension St Vincent, Indianapolis, IN, United States
(Conway) Stollery Children's Hospital, University of Alberta, Edmonton,
AB, Canada
(Adler) Division of Cardiology, Department of Medicine, University of
California-San Diego, San Diego, CA, United States
(Chung) The Lindner Research Center at The Christ Hospital, Cincinnati,
OH, United States
(Grinstein) University of Chicago, Chicago, IL, United States
(Dirckx, Iravani) Abbott, Chicago, IL, United States
Publisher
Elsevier Inc.
Abstract
Background: ARIES-HM3 (Antiplatelet Removal and Hemocompatibility Events
With the HeartMate 3 Pump) demonstrated that aspirin avoidance with a
fully magnetically levitated HeartMate 3 (HM3) left ventricular assist
device (LVAD) reduces bleeding complications and does not increase
thromboembolism. Whether a concomitant surgical procedure modifies the
observed safety and benefits remains uncertain. Objective(s): This
prespecified analysis of ARIES-HM3 studied clinical outcomes when
concomitant surgical procedures are performed during LVAD implantation
with excluding aspirin but maintaining a vitamin K antagonist.
 Method(s): Among 628 patients randomized to receive either placebo or
aspirin with a vitamin K antagonist, 589 (296 placebo and 293 aspirin)
contributed to the primary endpoint analysis. Sub-categorization with
receiving a concomitant surgical procedure (valvular procedure/coronary
artery bypass grafting or nonvalvular procedure) was done and the
composite primary endpoint of survival free from major nonsurgical (>14
days postimplant) hemocompatibility-related adverse events at 12 months
was assessed. Result(s): There were 155 (52%) and 145 (49%)
concomitant procedures in placebo and aspirin arms, respectively. The
percentage of subjects achieving primary endpoint success was higher with
the placebo group in patients with a concomitant procedure, and no
interaction was observed on primary outcomes between those with and
without concomitant surgical procedures (P<inf>int</inf> = 0.231, 0.298,
and 0.735 for any procedure, valvular/coronary artery bypass grafting, and
nonvalvular procedures, respectively). There was a similar reduction in
nonsurgical major hemorrhagic events with placebo compared with aspirin,
observed in patients with or without any concomitant procedure: 0.64 (95%
CI: 0.44-0.94) and 0.66 (95% CI: 0.46-0.93). Conclusion(s): Our
findings support the safety and efficacy of aspirin avoidance from the
antithrombotic regimen in HM3 LVAD patients undergoing concomitant
surgical procedures. (Antiplatelet Removal and Hemocompatibility Events
With the HeartMate 3 Pump [ARIES-HM3]; NCT04069156) Copyright ©
2025 The Authors

<8>
[Use Link to view the full text]
Accession Number
2039066230
Title
Colchicine in Acute Myocardial Infarction.
Source
New England Journal of Medicine. 392(7) (pp 633-642), 2025. Date of
Publication: 13 Feb 2025.
Author
Jolly S.S.; D'Entremont M.-A.; Lee S.F.; Mian R.; Tyrwhitt J.; Kedev S.;
Montalescot G.; Cornel J.H.; Stankovic G.; Moreno R.; Storey R.F.; Henry
T.D.; Mehta S.R.; Bossard M.; Kala P.; Layland J.; Zafirovska B.;
Devereaux P.J.; Eikelboom J.; Cairns J.A.; Shah B.; Sheth T.; Sharma S.K.;
Tarhuni W.; Conen D.; Tawadros S.; Lavi S.; Yusuf S.
Institution
(Jolly, D'Entremont, Lee, Mian, Tyrwhitt, Mehta, Devereaux, Eikelboom,
Sheth, Conen, Tawadros, Yusuf) Population Health Research Institute,
McMaster University, Hamilton, ON, Canada
(Jolly, D'Entremont, Lee, Mian, Mehta, Devereaux, Eikelboom, Sheth, Conen)
Hamilton Health Sciences, Hamilton, ON, Canada
(D'Entremont) Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke,
QC, Canada
(Kedev, Zafirovska) Medical Faculty, University Clinic of Cardiology,
University Ss. Cyril and Methodius, Skopje, North Macedonia
(Montalescot) Centre Hospitalier Universitaire Pitie-Salpetriere
Assistance Publique-Hopitaux de Paris, ACTION Study Group, Sorbonne
University, Paris, France
(Cornel) Dutch Network for Cardiovascular Research, Utrecht, Netherlands
(Cornel) Radboud University Medical Center, Nijmegen, Netherlands
(Cornel) Northwest Clinics, Alkmaar, Netherlands
(Stankovic) University Clinical Center of Serbia, Faculty of Medicine,
University of Belgrade, Belgrade, Serbia
(Moreno) Cardiology Department, University Hospital la Paz, Madrid, Spain
(Storey) NIHR Sheffield Biomedical Research Centre, Sheffield Teaching
Hospitals NHS Foundation Trust, Sheffield, United Kingdom
(Storey) Division of Clinical Medicine, University of Sheffield,
Sheffield, United Kingdom
(Henry) Caril and Edyth Lindner Center for Research and Education, Christ
Hospital Health Network, Cincinnati, United States
(Bossard) Cardiology Division, Faculty of Health Sciences and Medicine,
University of Lucerne, Heart Center, Luzerner Katonsspital, Lucerne,
Switzerland
(Kala) University Hospital Brno, Brno, Czechia
(Layland) Department of Cardiology, Peninsula Health, Frankston, VIC,
Australia
(Layland) Peninsula Clinical School, Monash University, Melbourne, VIC,
Australia
(Cairns) University of British Columbia, Centre for Cardiovascular
Innovation, Vancouver Coastal Health, Vancouver, Canada
(Shah) Department of Medicine, Division of Cardiology, NYU Grossman School
of Medicine, New York, United States
(Shah) Department of Medicine, Section of Cardiology, VA New York Harbor
Healthcare System, New York, United States
(Sharma) B.P. Koirala Institute of Health Sciences, Dharan, Nepal
(Tarhuni) Department of Medicine, University of Saskatchewan, Moose Jaw,
Canada
(Lavi) London Health Sciences Centre, University of Western Ontario,
London, Canada
Publisher
Massachussetts Medical Society
Abstract
Background Inflammation is associated with adverse cardiovascular events.
Data from recent trials suggest that colchicine reduces the risk of
cardiovascular events. Methods In this multicenter trial with a 2-by-2
factorial design, we randomly assigned patients who had myocardial
infarction to receive either colchicine or placebo and either
spironolactone or placebo. The results of the colchicine trial are
reported here. The primary efficacy outcome was a composite of death from
cardiovascular causes, recurrent myocardial infarction, stroke, or
unplanned ischemia-driven coronary revascularization, evaluated in a
time-to-event analysis. C-reactive protein was measured at 3 months in a
subgroup of patients, and safety was also assessed. Results A total of
7062 patients at 104 centers in 14 countries underwent randomization; at
the time of analysis, the vital status was unknown for 45 patients (0.6%),
and this information was most likely missing at random. A primary-outcome
event occurred in 322 of 3528 patients (9.1%) in the colchicine group and
327 of 3534 patients (9.3%) in the placebo group over a median follow-up
period of 3 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85
to 1.16; P=0.93). The incidence of individual components of the primary
outcome appeared to be similar in the two groups. The least-squares mean
difference in C-reactive protein levels between the colchicine group and
the placebo group at 3 months, adjusted according to the baseline values,
was -1.28 mg per liter (95% CI, -1.81 to -0.75). Diarrhea occurred in a
higher percentage of patients with colchicine than with placebo (10.2% vs.
6.6%; P<0.001), but the incidence of serious infections did not differ
between groups. Conclusions Among patients who had myocardial infarction,
treatment with colchicine, when started soon after myocardial infarction
and continued for a median of 3 years, did not reduce the incidence of the
composite primary outcome (death from cardiovascular causes, recurrent
myocardial infarction, stroke, or unplanned ischemia-driven coronary
revascularization). Copyright © 2024 Massachusetts Medical
Society.

<9>
Accession Number
2037753435
Title
Intrapleural Fibrinolytics Versus Thoracic Surgery for Complicated Pleural
Infections: A Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. 34(6) (pp 627-638), 2025. Date of Publication:
01 Jun 2025.
Author
Rodrigues A.L.S.D.O.; Salomao I.F.A.; Scabello I.F.; Vieira C.M.;
Cavalcante D.V.S.; de Melo Neto G.J.; de Lima D.P.; de Carvalho R.L.C.
Institution
(Rodrigues, Scabello, de Lima, de Carvalho) University Center of Joao
Pessoa (UNIPE), Paraiba, Joao Pessoa, Brazil
(Salomao) Department of Anesthesiology, Hospital Regional Unimed Missoes,
Santo Angelo, Brazil
(Vieira) Federal University of Amazonas (UFAM), Amazonas, Manaus, Brazil
(Cavalcante) Federal University of Maranhao (UFMA), Sao Luis - Maranhao,
Brazil
(de Melo Neto) University Center Facid (UniFacid), Teresina, Brazil
(de Lima, de Carvalho) Department of Thoracic Surgery, Hospital
Metropolitano Dom Jose Maria Pires Joao Pessoa, Paraiba, Brazil
Publisher
Elsevier Ltd
Abstract
Background: Intrapleural fibrinolytic therapy (IPFT) is an option for
complicated pleural effusion (CPE). However, concerns remain about its use
compared with thoracic surgery (TS). Therefore, we conducted a systematic
review and meta-analysis to assess the length of stay associated with IPFT
compared to TS in treating CPE. Method(s): We searched PubMed,
Embase, and Cochrane Library databases for studies that compared TS with
IPFT in patients with complicated pleural infections. We used a
random-effects model with a 95% confidence interval (CI) to pool the data.
R version 4.4.1 was used for statistical analysis and heterogeneity was
examined using I2 statistics. Result(s): A total of 16
studies, including 13 randomised controlled trials, involving a total of
764 were analysed. Of whom, 40% underwent IPFT. The success rate was
higher in the TS group (odds ratio 0.3; 95% CI 0.11-0.78; p=0.014;
I2=47%), and had a significantly shorter length of stay (mean
difference 2.76; 95% CI 1.40-4.13; p<0.001; I2=92%) compared
with the IPFT group. There were no statistical differences between groups
in the mortality endpoint. Considering only the paediatric population,
there were also no statistically significant differences for length of
stay (mean difference 1.32; 95% CI -2.37 to 5.01; p=0.08;
I2=91%) or success rates (odds ratio 0.86; 95% CI 0.27-2.74;
p=0.74; I2=0%). Conclusion(s): Our findings suggest that
TS is an effective treatment for pleural infections. There is no
significant increase in adverse events, and both treatments are equally
effective and safe. Copyright © 2024 Australian and New Zealand
Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society
of Australia and New Zealand (CSANZ)

<10>
Accession Number
2039049590
Title
Precision and Safety in Modern PCI: Integrating Physiology and Risk
Mitigation.
Source
Heart Lung and Circulation. 34(6) (pp 537-540), 2025. Date of Publication:
01 Jun 2025.
Author
Sarraf M.; Nagaraja V.
Institution
(Sarraf, Nagaraja) Department of Cardiovascular Diseases, Mayo Clinic
College of Medicine, Rochester, MN, United States
Publisher
Elsevier Ltd

<11>
[Use Link to view the full text]
Accession Number
2038640118
Title
Impact of Point-of-care Allogeneic Red Blood Cell Washing on Markers of
Transfusion-related Respiratory Complications: A Phase II Randomized
Clinical Trial.
Source
Anesthesiology. 143(1) (pp 98-113), 2025. Date of Publication: 01 Jul
2025.
Author
Kor D.J.; Warner M.A.; Norris P.J.; Armour S.; Wittwer E.D.; Santrach
P.J.; Meade L.A.; Conn C.M.; Schulte P.J.; Pendegraft R.S.; Di Germanio
C.; Podgoreanu M.; Welsby I.J.
Institution
(Kor, Armour, Wittwer, Meade) Department of Anesthesiology and
Perioperative Medicine, Mayo Clinic, Rochester, MN, United States
(Warner) Division of Critical Care, Department of Anesthesiology and
Perioperative Medicine, Mayo Clinic, Rochester, MN, United States
(Norris) Vitalant Research Institute, San Francisco, CA, United States
(Norris) Departments of Pathology and Laboratory Medicine, University of
California-San Francisco, San Francisco, CA, United States
(Santrach, Conn) Department of Laboratory Medicine and Pathology, Mayo
Clinic, Rochester, MN, United States
(Schulte, Pendegraft) Department of Quantitative Health Sciences, Mayo
Clinic, Rochester, MN, United States
(Di Germanio) Immunology Core, Vitalant Research Institute, San Francisco,
CA, United States
(Di Germanio) Laboratory Medicine, University of California-San Francisco,
San Francisco, CA, United States
(Podgoreanu) Department of Anesthesiology, Duke University Medical Center,
Raleigh, NC, United States
(Welsby) Duke University Medical Center, Durham, NC, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Transfusion-related acute lung injury (TRALI) and
transfusion-associated circulatory overload (TACO) are leading causes of
transfusion-related morbidity and mortality. Soluble factors in
erythrocyte supernatant may increase risk for these complications. The
authors hypothesized that point-of-care allogeneic erythrocyte washing may
be an effective intervention to mitigate elevations in soluble factors as
well as physiologic responses associated with transfusion-associated
respiratory complications in the setting of cardiac surgery.
 Method(s): This is a two-center, nonblinded, randomized clinical
trial evaluating point-of-care washed versus standard issue allogeneic
erythrocyte transfusions administered during or on the day of cardiac
surgery. The primary analysis was performed via modified intention to
treat. The primary outcomes assessed were changes in intermediate markers
of lung injury as well as cardiopulmonary physiologic responses to
erythrocyte transfusion. Secondary outcomes included the duration of
intensive care unit and hospital stay, durations of mechanical ventilation
and oxygen supplementation, presence of TRALI or TACO, and mortality.
 Result(s): Among 154 analyzed patients (81 washed, 73 standard
issue), the median age was 66 yr, and 77 (50.0%) were women. The median
(interquartile range) number of allogeneic erythrocyte units transfused on
the day of surgery was 3.0 (2.0 to 5.0) in the washed erythrocyte group
and 3.0 (2.0 to 4.0) in the standard issue group (P = 0.13). No
between-group differences were identified in any of the assessed recipient
lung injury biomarkers (all P values > adjusted alpha). Durations of
intensive care unit stay (median [interquartile range], 3.0 [2.0 to 5.0]
vs. 3.0 [2.0 to 4.0] days; P = 0.117) and hospital length of stay (12.0
[9.0 to 17.0] vs. 12.0 [9.0 to 17.0] days; P = 0.801) were similar, as
were the number of ventilator-free days at day 28 (27.0 [27.0 to 27.0] vs.
27.0 [26.0 to 27.0]; P = 0.699) and oxygen-free days at day 28 (24.0 [19.0
to 26.0] vs. 24.0 [22.0 to 26.0]; P = 0.400). No significant differences
were noted in mortality rate or in incidence rates for TRALI, TACO, and
acute kidney injury. Conclusion(s): Among patients undergoing
cardiovascular surgery with high risk of erythrocyte transfusion,
point-of-care washing of allogeneic erythrocyte transfusions did not
mitigate changes in intermediate markers of lung injury or cardiopulmonary
physiologic responses to erythrocyte transfusion and was not associated
with improved clinical outcomes. Copyright © 2025 American
Society of Anesthesiologists. All Rights Reserved.

<12>
Accession Number
2038114832
Title
Postoperative Pain Intensity After Single-port, Double-port, and
Triple-port Video-assisted Lung Lobectomy: A Three-arm Parallel Randomized
Clinical Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(7) (pp 1755-1762),
2025. Date of Publication: 01 Jul 2025.
Author
Kosinski S.; Putowski Z.; Stachowicz J.; Czajkowski W.; Wilkojc M.;
Zietkiewicz M.; Zielinski M.
Institution
(Kosinski, Stachowicz, Czajkowski, Wilkojc, Zielinski) Klara Jelska's
Pulmonary Hospital, Zakopane, Poland
(Kosinski) Jagiellonian University Medical College,
Orthopaedic-Rehabilitation University Hospital, Zakopane, Poland
(Putowski) Jagiellonian University Medical College, Centre for Intensive
and Perioperative Care, Cracow, Poland
(Zietkiewicz) Jagiellonian University Medical College, John Paul II
Hospital, Cracow, Poland
Publisher
W.B. Saunders
Abstract
Objective: Video-assisted thoracic surgery (VATS) has evolved from a
multiport approach to a one-port approach to reduce the degree of surgical
trauma. However, there is no consensus on the number of incisions leading
to less postoperative pain. Early postoperative pain was compared after
three technical variants of VATS lobectomy under multimodal analgesia,
including thoracic epidural analgesia. Design(s): This study was
designed as a prospective, randomized, controlled clinical trial with
three parallel arms. Setting(s): Single-center study.
 Participant(s): A total of 112 adult patients with ASA statuses I to
III who were scheduled to undergo elective VATS lobectomy for early-stage
non-small cell lung cancer were enrolled. Intervention(s): Patients
were randomly assigned to one of three groups: single-port, double-port,
and triple-port VATS lobectomy. The same postoperative analgesia protocol
was used in each group. Measurements and Main Results: The primary
outcome was postoperative pain intensity at rest and when coughing within
the first 72 hours after surgery. The secondary outcomes were cumulative
opioid consumption and the composite rate of postoperative complications.
A total of 112 patients were enrolled in the study, 91 of whom completed
the study protocol. There were no significant differences between the
study groups in terms of pain intensity either at rest (p = 0.319) or when
coughing (p = 0.202). There was no difference in the incidence of
postoperative complications. Conclusion(s): This study revealed no
differences in pain intensity in the early postoperative period between
three different technical variants of VATS lobectomy when an analgesia
protocol based on thoracic epidural anesthesia was used. Copyright
© 2025 Elsevier Inc.

<13>
Accession Number
2034853557
Title
The Effects of Dexmedetomidine on Postoperative Delirium in Adult Cardiac
Surgical Patients: A Bayesian Meta-Analysis and Trial Sequential Analysis.
Source
Acta Anaesthesiologica Scandinavica. 69(6) (no pagination), 2025. Article
Number: e70069. Date of Publication: 01 Jul 2025.
Author
Keith N.; Harrowell L.; Alexandrou E.; Aneman A.; Frost S.A.
Institution
(Keith, Alexandrou, Aneman, Frost) Intensive Care, Liverpool Hospital,
Liverpool, Australia
(Keith, Harrowell, Alexandrou, Frost) University of Wollongong,
Wollongong, Australia
(Harrowell) Liverpool Hospital, Liverpool, Australia
(Alexandrou, Frost) Critical Care in Collaboration and Evidence
Translation (CCRiCET), Sydney, Australia
(Alexandrou, Aneman) University of New South Wales, Kensington, Australia
Publisher
John Wiley and Sons Inc
Abstract
Background: An acute episode of delirium among adults following cardiac
surgery is associated with increased length of stay in intensive care,
prolonged mechanical ventilation, and increased risk of mortality. This
robust systematic review with Bayesian meta-analysis, including trial
sequential analysis, has been undertaken to explore the use of
dexmedetomidine to reduce the occurrence of delirium. Method(s): A
systematic search for relevant published clinical trial reports was
registered on PROSPERO (CRD42023460126) and guided by the PRISMA statement
guidelines. Databases included Cochrane, CINAHL, PubMed, Embase, Medline
and PsychInfo. Studies included were randomised controlled trials
reporting on the adult population (> 18 years) undergoing cardiac surgery,
comparing dexmedetomidine to another drug or placebo. Trials of paediatric
populations, protocols and reviews were excluded. The primary outcome
examined was the effect of dexmedetomidine on the incidence of delirium in
postoperative cardiac surgery in the Intensive Care Unit (ICU). Secondary
outcomes of interest were the occurrence of hypotension, bradycardia,
length of ICU stay and sedation utilised in the control and comparator
groups. Trial sequential analysis and meta-regression were used to explore
heterogeneity. Risk ratios (RRs) and Bayesian posterior probabilities are
presented. The prior for this was empirical, being based on distributions
for emergency and critical care systematic reviews from the Cochrane
Database. The Cochrane ROB-2 tool was utilised to assess risk of bias, and
the GRADE approach for certainty of evidence is presented. Result(s):
A total of 699 randomised control trials were identified. After the
removal of duplicates and screening for eligibility, 27 studies were
included in the meta-analysis. The Robust Bayesian Model Averaging summary
effect for delirium prevention was estimated to be 0.76 (95% credible
interval [CrI] 0.56-1.00) for using dexmedetomidine, with a posterior
probability of 97% of any treatment effect. Meta-regression suggested that
the baseline risk of delirium is a strong indicator of increased
effectiveness, and trial sequential analysis indicates potential
effectiveness. A low risk of bias was evident in 19 of the 27 studies, 6
studies had some risk of bias, and 2 studies were judged to be high risk.
The certainty of evidence used across the 27 studies was determined to be
low overall. Conclusion(s): Dexmedetomidine may reduce the risk of
delirium among adults following cardiac surgery; however, uncertainty
remains due to heterogeneity. Therefore, adequately powered and
well-designed multi-centre trials are needed to address this current
uncertainty. Editorial Comment: The effects of dexmedetomidine on
postoperative delirium in adult cardiac surgical patients: a Bayesian
meta-analysis and trial sequential analysis. This systematic review with
meta-analysis concerning evidence for possible effects of dexmedetomidine
on post-cardiac surgery delirium presents detailed analysis showing a
possible treatment drug effect on reducing post-operative delirium in this
type of cohort, though still with some uncertainty. Copyright ©
2025 The Author(s). Acta Anaesthesiologica Scandinavica published by John
Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica
Foundation.

<14>
Accession Number
2034838898
Title
Saline-based modified del Nido cardioplegia versus multidose St. Thomas
cardioplegia in canine mitral valve repair: A randomized controlled trial.
Source
Veterinary Surgery. (no pagination), 2025. Date of Publication: 2025.
Author
Kurogochi K.; Takahashi A.; Nii Y.; Chen A.; Nishiyama M.; Furusato S.;
Sugiya H.; Uechi M.
Institution
(Kurogochi, Takahashi, Nii, Chen, Nishiyama, Furusato, Sugiya, Uechi)
JASMINE Veterinary Cardiovascular Medical Center, Yokohama, Japan
(Kurogochi) Department of Clinical Sciences, North Carolina State
University, College of Veterinary Medicine, Raleigh, NC, United States
(Furusato) Department of Health Data Science, Yokohama City University,
Yokohama, Japan
Publisher
John Wiley and Sons Inc
Abstract
Objective: To compare the utility of a saline-based modified del Nido
(mDN) cardioplegia solution with a conventional institutional technique
(multidose St. Thomas blood cardioplegia) for mitral valve repair (MVR) in
dogs. Study design: Prospective, randomized, open-label trial. Animals:
Forty client-owned dogs with myxomatous mitral valve disease (stage B2 and
C) eligible for MVR were divided into control and modified mDN groups.
 Method(s): Cardioplegia was induced in the control group using 50%
blood containing St. Thomas solution every 10 min. In the mDN group, a
cardioplegia solution containing 20% blood was administered once or when
required. As the primary outcome, serum cardiac troponin I levels were
compared 12 h postoperatively between the groups. The other clinical
findings were evaluated as secondary outcomes. Result(s): Troponin
levels 12 h after surgery were a median of 27.8 ng/mL (interquartile
range, 15.1-43.2) in the control group and 19.4 ng/mL (15.2-33.6) in the
mDN group (p =.478). The sinus rhythm recovery time following aortic
cross-clamp removal was 362 s (103-995) in the control group and 60 s
(44-605) in the mDN group (p =.027). The total amount of crystalloid
cardioplegia solution required was 12.6 mL/kg (11.3-15.0) in the control
group and 23.6 mL/kg (18.0-35.1) in the mDN group (p <.001).
 Conclusion(s): Cardiac troponin I levels did not show differences
between the groups. The saline-based mDN cardioplegia facilitated earlier
sinus rhythm recovery. Clinical significance: Saline-based mDN
cardioplegia may be a viable alternative for canine MVR. Copyright
© 2025 Japan Animal Specialty Medical Institute Inc. Veterinary
Surgery published by Wiley Periodicals LLC on behalf of American College
of Veterinary Surgeons.

<15>
Accession Number
2038941247
Title
The effects of a modified deep serratus anterior plane block on surgical
stress and perioperative neurocognitive disorders in elderly patients
undergoing thoracic surgery: a randomized clinical study.
Source
Journal of Thoracic Disease. 17(5) (pp 3238-3248), 2025. Date of
Publication: 30 May 2025.
Author
Lei W.; Cheng J.; Bignami E.; Gonzalez M.; Sun Q.; Sun J.; Cheng Y.
Institution
(Lei, Sun, Sun, Cheng) Department of Anesthesiology, Affiliated Hangzhou
First People's Hospital, School of Medicine, Westlake University,
Hangzhou, China
(Cheng, Sun) Department of Anesthesiology, The Second Affiliated Clinical
College of Wenzhou Medical University, Wenzhou, China
(Cheng) Department of Anesthesiology, Sir Run Run Shaw Hospital College of
Medicine Zhejiang University, Hangzhou, China
(Bignami) Anesthesiology, Critical Care and Pain Medicine Division,
Department of Medicine and Surgery, University of Parma, Parma, Italy
(Gonzalez) Department of Thoracic Surgery, Lausanne University Hospital,
University of Lausanne, Lausanne, Switzerland
(Sun) Department of Anesthesiology, The Second Affiliated Clinical College
of Wenzhou Medical University, 109 West Xuehua Road, Pujiao Street,
Lucheng District, Wenzhou, China
Publisher
AME Publishing Company
Abstract
Background: Perioperative stress response is an important risk factor for
perioperative neurocognitive disorder (PND) in elderly patients. This
study aimed to evaluate and compare the effects of a modified deep
serratus anterior plane block (DSPB) combined with general anesthesia on
surgical stress and PND in elderly patients undergoing thoracic surgery.
 Method(s): A total of 66 patients undergoing thoracic surgery were
randomly assigned to receive either a single-shot DSPB or local block
after tracheal intubation using ropivacaine 0.5% (20 mL). The primary
outcomes were the visual analog scale (VAS) scores at each time point. The
secondary outcomes included the Montreal Cognitive Assessment (MoCA) score
before surgery and after discharge from the hospital (or seventh day
postoperatively), malondialdehyde (MDA), superoxide dismutase (SOD), and
serum cortisol levels, drug consumption, vital signs, and blood gas
analysis. Result(s): Ultimately, 60 patients were enrolled in the
study. The VAS scores were significantly lower in the DSPB group than the
local block group (all P<0.05). There was a statistically significant
difference in the blood gas analysis index total carbon dioxide
(TCO<inf>2</inf>) content (27.71+/-3.49 vs. 29.31+/-2.26 mmHg) between the
two groups (P<0.05). The length of hospitalization was shorter in the DSPB
group than the local block group (6.03+/-1.35 vs. 7.20+/-1.49 days), and
the difference was statistically significant (P<0.05). There were no
statistically significant differences between the two groups in terms of
the MoCA scores before surgery and after hospitalization (or the seventh
day postoperatively), stress indices, vital signs, bispectral index (BIS)
value, blood gas analysis (except TCO<inf>2</inf>), and drug use during
extubation at each time point (all P>0.05). Conclusion(s): Compared
with the local block, the elderly patients undergoing thoracic surgery who
received the DSPB had a superior analgesic effect, a lower VAS score, and
shorter length of hospitalization. As a DSPB does not require ultrasound
equipment, it is simpler and easier to operate than a local block, and is
especially suitable for widespread implementation in small
hospitals. Copyright © AME Publishing Company.

<16>
Accession Number
2039095713
Title
Unilateral access versus bilateral access in transfemoral transcatheter
aortic valve replacement: A systematic review and meta-analysis.
Source
Indian Heart Journal. (no pagination), 2025. Date of Publication: 2025.
Author
Jain H.; Shahabi M.; Shafiq A.; Agrawal S.P.; Saad M.S.; Sharaf B.L.;
Gordon P.C.; Abbott J.D.; Vallabhajosyula S.
Institution
(Jain) Department of Cardiology, All India Institute of Medical Sciences,
Jodhpur, India
(Shahabi, Shafiq) Department of Internal Medicine, Dow University of
Health Sciences, Karachi, Pakistan
(Agrawal) Department of Internal Medicine, New York Medical
College/Landmark Medical Center, Woonsocket, RI, United States
(Saad, Sharaf, Gordon, Abbott, Vallabhajosyula) Division of Cardiology,
Department of Medicine, Warren Alpert Medical School of Brown University,
Providence, RI, United States
(Saad, Sharaf, Gordon, Abbott, Vallabhajosyula) Brown University Health
Cardiovascular Institute, Providence, RI, United States
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) procedures
frequently require a second arterial access to perform aortic root
angiography. In recent times, there has been an increase in the use of
unilateral access, however, the outcomes data are conflicting.
 Method(s): A systematic database search was conducted to retrieve
studies comparing unilateral to bilateral access in TAVR. Risk ratios (RR)
with 95 % confidence intervals (CI) were pooled using the Mantel-Haenszel
random-effects model. Outcomes of interest included minor vascular
complications, major vascular complications, 30-day stroke, and 30-day
all-cause mortality. Result(s): Three studies with a total of 2,181
patients undergoing TAVR (unilateral 368, bilateral 1813) were included in
this meta-analysis. Unilateral access was comparable to bilateral access
for minor vascular complications (RR: 0.88; 95 % CI: 0.48-1.62), major
vascular complications (RR: 0.61, 95 % CI: 0.14-2.75), stroke (RR: 0.95;
95 % CI: 0.42, 2.17) and all-cause mortality (RR: 0.52; 95 % CI: 0.04,
6.93). Conclusion(s): Unilateral access for TAVR was associated with
similar short-term outcomes and safety profiles compared to bilateral
access for TAVR. Copyright © 2025 Cardiological Society of India

<17>
Accession Number
2039108286
Title
Comment on: "Mechanical outcomes of coronary stenting guided by
intravascular ultrasound versus optical coherence tomography: A systematic
review and meta-analysis with trial sequential analysis of randomized
trials".
Source
International Journal of Cardiology. 437 (no pagination), 2025. Article
Number: 133489. Date of Publication: 15 Oct 2025.
Author
Guo X.; Yu R.; Wu Q.
Institution
(Guo, Yu, Wu) Department of Cardiovascular Medicine, Lanzhou University
Second Hospital, Lanzhou, China
Publisher
Elsevier Ireland Ltd

<18>
[Use Link to view the full text]
Accession Number
2039032350
Title
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve
Implantation.
Source
New England Journal of Medicine. 392(14) (pp 1396-1405), 2025. Date of
Publication: 10 Apr 2025.
Author
Raposeiras-Roubin S.; Amat-Santos I.J.; Rossello X.; Gonzalez Ferreiro R.;
Gonzalez Bermudez I.; Lopez Otero D.; Nombela-Franco L.; Gheorghe L.; Diez
J.L.; Baladron Zorita C.; Baz J.A.; Munoz Garcia A.J.; Vilalta V.;
Ojeda-Pineda S.; De La Torre Hernandez J.M.; Cordoba Soriano J.G.;
Regueiro A.; Bordes Siscar P.; Salgado Fernandez J.; Garcia Del Blanco B.;
Martin-Reyes R.; Romaguera R.; Moris C.; Garcia Blas S.; Franco-Pelaez
J.A.; Cruz-Gonzalez I.; Arzamendi D.; Romero Rodriguez N.; Diez-Del Hoyo
F.; Camacho Freire S.; Bosa Ojeda F.; Astorga Burgo J.C.; Molina Navarro
E.; Caballero Borrego J.; Ruiz Quevedo V.; Sanchez-Recalde A.; Peral
Disdier V.; Alegria-Barrero E.; Torres-Llergo J.; Feltes G.; Fernandez
Diaz J.A.; Cuellas C.; Jimenez Britez G.; Sanchez-Rubio Lezcano J.;
Barreiro-Pardal C.; Nunez-Gil I.; Abu-Assi E.; Iniguez-Romo A.; Fuster V.;
Ibanez B.
Institution
(Raposeiras-Roubin, Rossello, Fuster) Centro Nacional de Investigaciones
Cardiovasculares Carlos III, Madrid, Spain
(Gonzalez Ferreiro, Gonzalez Bermudez, Baz, Iniguez-Romo) Cardiology
Department, University Hospital Alvaro Cunqueiro, Instituto de
Investigacion Sanitaria Galiciasur, Vigo, Spain
(Raposeiras-Roubin) University of Santiago de Compostela, Santiago de
Compostela, Spain
(Amat-Santos, Rossello, Lopez Otero, Baladron Zorita, Baz, Ojeda-Pineda,
Garcia Del Blanco, Garcia Blas, Cruz-Gonzalez, Iniguez-Romo) Centro de
Investigacion Biomedica en Red en Enfermedades Cardiovasculares, Madrid,
Spain
(Amat-Santos, Baladron Zorita) Cardiology Department, University Clinical
Hospital of Valladolid, Valladolid, Spain
(Rossello, Peral Disdier) Cardiology Department, University Hospital Son
Espases, Instituto de Investigacion Sanitaria Islas Baleares, Palma de
Mallorca, Spain
(Rossello) Universitat de les Illes Balears, Palma, Spain
(Lopez Otero) Cardiology Department, University Hospital Montecelo,
Pontevedra, Spain
(Nombela-Franco, Nunez-Gil) Cardiology Department, University Clinical
Hospital, San Carlos, Madrid, Spain
(Gheorghe) Cardiology Department, University Hospital Puerta Del Mar,
Cadiz, Spain
(Diez) Cardiology Department, University Hospital la Fe, Valencia, Spain
(Munoz Garcia) Cardiology Department, University Hospital Virgen de la
Victoria, Malaga, Spain
(Vilalta) Cardiology Department, University Hospital German Trias i Pujol,
Badalona, Spain
(Ojeda-Pineda, Ibanez) Cardiology Department, University Hospital Reina
Sofia, Cordoba, Spain
(De La Torre Hernandez) Cardiology Department, University Hospital Marques
de Valdecilla, Instituto de Investigacion Sanitaria Valdecilla, Santander,
Spain
(Cordoba Soriano) Cardiology Department, University Hospital of Albacete,
Albacete, Spain
(Regueiro) Cardiology Department, University Clinical Hospital, Barcelona,
Spain
(Bordes Siscar) Cardiology Department, University General Hospital of
Alicante, Alicante, Spain
(Salgado Fernandez) Cardiology Department, University Hospital Juan
Canalejo, A Coruna, Spain
(Garcia Del Blanco) Cardiology Department, University Hospital Vall
d'Hebron, Barcelona, Spain
(Martin-Reyes) Cardiology Department, University Hospital la Luz, Madrid,
Spain
(Romaguera) Cardiology Department, University Hospital Bellvitge,
Barcelona, Spain
(Moris) Cardiology Department, University Hospital Central de Asturias,
Oviedo, Spain
(Garcia Blas) Cardiology Department, University Clinical Hospital of
Valencia, Valencia, Spain
(Franco-Pelaez, Ibanez) Cardiology Department, University Hospital
Fundacion Jimenez Diaz, Instituto de Investigacion Sanitaria-Fundacion
Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
(Cruz-Gonzalez) Cardiology Department, University Clinical Hospital of
Salamanca, Salamanca, Spain
(Arzamendi) Cardiology Department, University Hospital Santa Creu i Sant
Pau, Biomedical Research Institute IIB-Sant Pau, Barcelona, Spain
(Romero Rodriguez) Cardiology Department, University Hospital Virgen Del
Rocio, Seville, Spain
(Diez-Del Hoyo) Cardiology Department, University Hospital 12 de Octubre,
Madrid, Spain
(Camacho Freire) Cardiology Department, University Hospital Juan Ramon
Jimenez, Huelva, Spain
(Bosa Ojeda) Cardiology Department, University Hospital of Canarias,
Tenerife, Spain
(Astorga Burgo) Cardiology Department, University Hospital of Cruces,
Baracaldo, Spain
(Molina Navarro) Cardiology Department, University Hospital Virgen de Las
Nieves, Granada, Spain
(Caballero Borrego) Cardiology Department, University Hospital San
Cecilio, Granada, Spain
(Ruiz Quevedo) Cardiology Department, University Hospital of Navarra,
Pamplona, Spain
(Sanchez-Recalde) Cardiology Department, University Hospital Ramon y
Cajal, Madrid, Spain
(Alegria-Barrero) Cardiology Department, University Hospital Torrejon,
University Francisco de Vitoria, Madrid, Spain
(Torres-Llergo) Cardiology Department, University Hospital of Jaen, Jaen,
Spain
(Feltes) Cardiology Department, University Hospital Vithas Arturo Soria,
Madrid, Spain
(Feltes, Nunez-Gil) University Europea of Madrid, Madrid, Spain
(Fernandez Diaz) Cardiology Department, University Hospital Puerta Del
Hierro, Madrid, Spain
(Cuellas) Cardiology Department, University Hospital of Leon, Leon, Spain
(Jimenez Britez) Cardiology Department, Clinica Teknon, Barcelona, Spain
(Sanchez-Rubio Lezcano) Cardiology Department, University Hospital Miguel
Servet, Zaragoza, Spain
(Barreiro-Pardal) Anesthesiology Department, University Hospital
Montecelo, Pontevedra, Spain
(Nunez-Gil) Cardiology Department, University Hospital of Torrejon, Ribera
Salud Group, Madrid, Spain
(Abu-Assi) Cardiology Department, University Hospital of Povisa, Ribera
Salud Group, Vigo, Spain
(Fuster) Cardiovascular Institute, Icahn School of Medicine at Mount
Sinai, New York, United States
Publisher
Massachussetts Medical Society
Abstract
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the
risk of heart-failure admission among high-risk patients. However, most
patients with valvular heart disease, including those undergoing
transcatheter aortic-valve implantation (TAVI), have been excluded from
randomized trials. Methods We conducted this randomized, controlled trial
in Spain to evaluate the efficacy of dapagliflozin (at a dose of 10 mg
once daily) as compared with standard care alone in patients with aortic
stenosis who were undergoing TAVI. All the patients had a history of heart
failure plus at least one of the following: renal insufficiency, diabetes,
or left ventricular systolic dysfunction. The primary outcome was a
composite of death from any cause or worsening of heart failure, defined
as hospitalization or an urgent visit, at 1 year of follow-up. Results A
total of 620 patients were randomly assigned to receive dapagliflozin and
637 to receive standard care alone after TAVI; after exclusions, a total
of 1222 patients were included in the primary analysis. A primary-outcome
event occurred in 91 patients (15.0%) in the dapagliflozin group and in
124 patients (20.1%) in the standard-care group (hazard ratio, 0.72; 95%
confidence interval [CI], 0.55 to 0.95; P=0.02). Death from any cause
occurred in 47 patients (7.8%) in the dapagliflozin group and in 55 (8.9%)
in the standard-care group (hazard ratio, 0.87; 95% CI, 0.59 to 1.28).
Worsening of heart failure occurred in 9.4% and 14.4% of the patients,
respectively (subhazard ratio, 0.63; 95% CI, 0.45 to 0.88). Genital
infection and hypotension were significantly more common in the
dapagliflozin group. Conclusions Among older adults with aortic stenosis
undergoing TAVI who were at high risk for heart-failure events,
dapagliflozin resulted in a significantly lower incidence of death from
any cause or worsening of heart failure than standard care
alone. Copyright © 2025 Massachusetts Medical Society.

<19>
Accession Number
2039066539
Title
Long-term secondary prevention with colchicine in patients with CAD: an
updated systematic review and meta-analysis.
Source
European Journal of Internal Medicine. (no pagination), 2025. Date of
Publication: 2025.
Author
Boracchi P.; Marano G.; Luconi E.; Cimminiello C.
Institution
(Boracchi, Marano) Medical Statistics Unit, Department of Biomedical and
Clinical Sciences, University of Studies of Milan, Milan, Italy
(Luconi) Department of Clinical and Community Sciences University of
Studies of Milan, Milan, Italy
(Cimminiello) Arianna Foundation on Anticoagulation, Via P. Fabbri 1/3,
Bologna, Italy
Publisher
Elsevier B.V.
Abstract
The CLEAR SYNERGY trial failed to demonstrate any benefit of colchicine in
patients with acute myocardial infarction (MI). In this meta-analysis of
the randomized clinical trials (RCTs) of colchicine in coronary artery
disease (CAD), we updated the estimates of effect on cardiovascular events
in patients with CAD. We searched for the largest RCTs of colchicine in
CAD patients. The effect was assessed in a pooled analysis of individual
events such as MI, urgent coronary revascularization (UR), stroke,
cardiovascular mortality, and total mortality, for each of these endpoints
using hazard ratios (HR) and their 95 % confidence intervals (CI),
estimated by the Cox model. Fixed-effects or random-effects models were
used. A similar approach was used for the composite of MI, UR, and
cardiovascular mortality (MACE 1) and stroke, MI, total mortality (MACE
2). Safety was also assessed. Five studies were selected with a total of
18,656 patients. Colchicine reduced the risk of MI by 21 %, HR 0.79 (95 %
CI: 0.68 - 0.92).Its effect was neutral on total and cardiovascular
mortality. The composite endpoints MACE 1 and MACE 2 were reduced by
colchicine, HR 0.81 (95 % CI: 0.68 - 0.98), and HR 0.88 (95 % CI: 0.79 -
0.98), respectively. There were no differences in non-cardiovascular
mortality, cancer, and serious gastrointestinal and infectious events. The
benefit of colchicine appears attenuated compared to past analyses, but is
still valuable in reducing the risk of MI and the composite of MI, UR, and
cardiovascular death. The safety appears reassuring in relation to all
serious adverse reactions. Copyright © 2025 European Federation
of Internal Medicine

<20>
Accession Number
2039066258
Title
Right Ventricular Function and Echocardiographic Pressure-Volume Loops:
Overview and Perioperative Clinical Implications.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Ahmed U.; Mahmood F.; Nicoara A.; Kiarad V.
Institution
(Ahmed, Mahmood, Kiarad) Department of Anesthesia, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, MA, United States
(Nicoara) Department of Anesthesiology, Duke University Hospital, Durham,
NC, United States
Publisher
W.B. Saunders
Abstract
Right ventricular (RV) mechanics have critical roles in cardiovascular
physiology, yet their assessment remains challenging owing to the right
ventricle's complex geometry and unique interaction with the pulmonary
vascular system. This review explores RV structural, functional, and
physiologic considerations, emphasizing their interplay with pulmonary
hypertension (PH), heart failure, and perioperative outcomes. Traditional
pressure- and volume-centric methods of RV evaluation, including
echocardiography and right heart catheterization, often fail to provide
comprehensive, load-independent measures of RV function. The integration
of these measures for pressure-volume (PV) loop analysis has emerged as a
valuable tool, offering insights into RV contractility, compliance, and
ventriculoarterial coupling. This review highlights advances in
intraoperative and noninvasive PV loop methodologies, including
echocardiography-derived techniques and integration with catheter-based
pressure measurements. These approaches enable detailed assessment of RV
function, enhancing prognostic capabilities in such conditions as PH,
heart failure with preserved ejection fraction, and postsurgical
interventions like left ventricular assist device implantation and valve
replacement. Despite the potential of RV PV loop analysis, its clinical
adoption has been limited by technical complexities, cost, and the need
for specialized expertise. This underscores the importance of
standardizing PV loop acquisition techniques and validating surrogate
markers, such as tricuspid annular plane systolic excursion/pulmonary
artery systolic pressure ratio, to improve accessibility and utility. By
providing a comprehensive overview of current and emerging methods for RV
assessment, this review aims to foster a deeper understanding of RV
mechanics, driving innovation in diagnostic, therapeutic, and prognostic
strategies for cardiac surgeries. Copyright © 2025 Elsevier Inc.

<21>
Accession Number
2036585882
Title
Erector spinae plane block for pain management after total hip
arthroplasty. A systematic review and meta-analysis.
Source
Chirurgia Narzadow Ruchu i Ortopedia Polska - Polish Orthopaedics. 89(4)
(pp 170-177), 2024. Date of Publication: 18 Nov 2024.
Author
Reysner T.; Kowalski G.; Resyner M.; Geisler-Wojciechowska A.; Grochowicka
M.; Wieczorowska-Tobis K.
Institution
(Reysner, Kowalski, Resyner, Geisler-Wojciechowska, Grochowicka,
Wieczorowska-Tobis) Department of Palliative Medicine, University of
Medical Sciences, Poznan, Poland
Publisher
Exemplum Scientific Publishing House
Abstract
Purpose. The Erector Spinae Plane Block (ESPB) is a widely used regional
anesthesia technique in breast, thoracic, and spine surgery. However, its
effectiveness and pain-relief capabilities in total hip arthroplasty have
not been definitively established. This meta-analysis seeks to establish
the analgesic effectiveness of ESPB in total hip arthroplasty. Methods. As
per PRISMA guidelines, we carried out a meta-analysis of prospective
randomized clinical trials that compared the effects of ESPB in the
control group and different peripheral nerve blocks in total hip
arthroplasty. The study was registered in the International Register of
Systematic Reviews (PROSPERO) and can be accessed online
(www.crd.york.uk/prospero, CRD42024498350). Results. Six studies involving
299 participants were critically evaluated and included for analysis. The
results showed that ultrasound-guided ESPB led to a decrease in
postoperative opioid consumption 24 hours after surgery compared to a
placebo (mean difference -4.29, 95% CI -5.33 to -3.25; p < 0.00001).
However, there were no significant differences in postoperative pain
scores at Department of Palliative Medicine, Poznan University of Medical
Sciences, Poznan, Poland 3-6 hours and 24 hours between the two groups.
Conclusion. ESPB improved the effectiveness of pain relief in total hip
arthroplasty, particularly without nerve block analgesia. More
high-quality, well-defined RCTs are urgently required to assess the pros
and cons of ESPB for total hip arthroplasty. Copyright © 2024,
Exemplum Scientific Publishing House. All rights reserved.

<22>
Accession Number
2027173493
Title
Risk factors associated with surgical site infections in patients
undergoing cardiothoracic surgery: A systematic review and meta-analysis.
Source
International Wound Journal. 21(4) (no pagination), 2024. Article Number:
e14573. Date of Publication: 01 Apr 2024.
Author
Zhang Y.; Tan S.; Chen S.; Fan X.
Institution
(Zhang, Tan, Fan) Department of Cardiovascular Surgery, Guangdong
Provincial Hospital of Chinese Medicine, Guangdong Province, Guangzhou,
China
(Chen) Department of Cardiology, Shengjing Hospital of China Medical
University, Liaoning Province, Shenyang, China
Publisher
John Wiley and Sons Inc
Abstract
Surgical site infections (SSIs) following cardiothoracic surgery can pose
significant challenges to patient recovery and outcome. This systematic
review and meta-analysis aim to identify and quantify the risk factors
associated with SSIs in patients undergoing cardiothoracic surgery. A
comprehensive literature search adhering to Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines and based on the
PICO paradigm was conducted across four databases: PubMed, Embase, Web of
Science and the Cochrane Library, without any temporal restrictions. The
meta-analysis incorporated studies detailing the risk factors for
post-operative sternal infections, especially those reporting odds ratios
(OR) or relative risks with 95% confidence intervals (CI). Quality
assessment of the studies was done using the Newcastle-Ottawa Scale.
Statistical analysis was executed using the chi-square tests for
inter-study heterogeneity, with further analyses depending on
I2 values. Sensitivity analyses were performed, and potential
publication bias was also assessed. An initial dataset of 2442 articles
was refined to 21 articles after thorough evaluations based on inclusion
and exclusion criteria. Patients with diabetes mellitus have an OR of 1.80
(95% CI: 1.40-2.20) for the incidence of SSIs, while obese patients
demonstrate an OR of 1.63 (95% CI: 1.40-1.87). Individuals who undergo
intraoperative blood transfusion present an OR of 1.13 (95% CI:
1.07-1.18), and smokers manifest an OR of 1.32 (95% CI: 1.03-1.60). These
findings unequivocally indicate a pronounced association between these
factors and an elevated risk of SSIs post-operatively. This meta-analysis
confirms that diabetes, obesity, intraoperative transfusion and smoking
heighten the risk of SSIs post-cardiac surgery. Clinicians should be alert
to these factors to optimise patient outcomes. Copyright © 2023
The Authors. International Wound Journal published by Medicalhelplines.com
Inc and John Wiley & Sons Ltd.

<23>
Accession Number
2034828373
Title
Stroke prevention in atrial fibrillation: A narrative review of current
evidence and emerging strategies.
Source
European Journal of Clinical Investigation. (no pagination), 2025. Date
of Publication: 2025.
Author
Askarinejad A.; Lane D.A.; Sadeghipour P.; Haghjoo M.; Lip G.Y.H.
Institution
(Askarinejad, Lane, Lip) Liverpool Centre for Cardiovascular Sciences at
University of Liverpool, Liverpool John Moores University and Liverpool
Heart & Chest Hospital, Liverpool, United Kingdom
(Askarinejad, Lane, Lip) Department of Cardiovascular and Metabolic
Medicine, Institute of Life Course and Metabolic Medicine, University of
Liverpool, Liverpool, United Kingdom
(Lane, Lip) Department of Clinical Medicine, Aalborg University, Aalborg,
Denmark
(Sadeghipour, Haghjoo) Rajaie Cardiovascular, Medical, and Research
Center, Iran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Lip) Medical University of Bialystok, Bialystok, Poland
Publisher
John Wiley and Sons Inc
Abstract
Background: Atrial fibrillation (AF), the most prevalent cardiac
arrhythmia, is associated with a significantly increased risk of mortality
and morbidity from stroke, thromboembolism and dementia. Recent advances
in stroke prevention strategies necessitate an updated approach to
management. Result(s): Published evidence shows that the Atrial
Fibrillation Better Care (ABC) pathway significantly improves stroke
prevention outcomes in AF patients, reducing mortality, stroke incidence
and bleeding events. Characterisation of AF using the 4S-AF framework
helped guide personalised treatment selection and was associated with
improved clinical outcomes. For patients unsuitable for anticoagulation,
left atrial appendage occlusion has been identified as a viable
alternative. Digital health technologies demonstrate increasing utility in
early AF detection to enable timely stroke prevention interventions. There
is evidence for the dynamic nature of stroke (and bleeding) risk, as well
as arrhythmia burden and AF progression over time, in addition to changes
in ABC pathway adherence. Conclusion(s): Effective stroke prevention
in AF requires a comprehensive holistic approach incorporating appropriate
risk stratification, guideline-adherent anticoagulation and management of
underlying cardiovascular conditions and other comorbidities. The ABC
pathway, supported by characterisation using the 4S-AF framework, provides
a structured approach to optimise outcomes. Regular reassessment of risk,
along with careful selection of anticoagulation strategies, remains
crucial. Integration of digital health technologies and structured care
pathways shows promise in improving patient outcomes. Copyright ©
2025 The Author(s). European Journal of Clinical Investigation published
by John Wiley & Sons Ltd on behalf of Stichting European Society for
Clinical Investigation Journal Foundation.

<24>
Accession Number
2033988929
Title
Three-Dimensional-Printed Models Reduce Adverse Events of Left Atrial
Appendage Occlusion: A Systematic Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 105(7) (pp 1688-1694),
2025. Date of Publication: 01 Jun 2025.
Author
Santos J.D.; Beloy F.J.; Sulague R.M.; Okudzeto H.; Medina J.R.; Cartojano
T.D.; Cruz N.; Mortalla E.D.; Kpodonu J.
Institution
(Santos, Cruz) Our Lady of Fatima University College of Medicine,
Valenzuela City, Philippines
(Beloy) Ateneo School of Medicine and Public Health, Pasig City,
Philippines
(Sulague) Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles,
CA, United States
(Okudzeto) Dodowa Health Research Center, Greater Accra Region, Dodowa,
Ghana
(Medina) Manila Central University College of Medicine, Caloocan City,
Philippines
(Cartojano, Mortalla) Cebu Institute of Medicine, Cebu City, Philippines
(Kpodonu) Beth Israel Deaconess Medical Center, Boston, MA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background and Aims: Left atrial appendage occlusion (LAAO) has an
excellent safety profile but there is growing evidence of adverse
long-term sequelae of peri-device leak and device-related thrombus. This
study seeks to determine if guidance from 3D-printed models of left atrial
appendages reduces the incidence of side effects. Method(s): A
systematic literature search was conducted in the following databases:
Pubmed, Google Scholar, and Europe PMC. Cohort studies that directly
compared outcomes using 3D-printed model simulations before undergoing
LAAO versus using conventional imaging only among patients with
nonvalvular atrial fibrillation, CHA<inf>2</inf>DS<inf>2</inf>-VASc scores
>= 1, and relative or absolute contraindications to long-term
anticoagulation were included. Clinical outcomes included incidence of
peri-device leak, mismatch, and device-related thrombus. Meta-analysis was
done using the random-effects model. Result(s): Only three cohort
studies were eligible for meta-analysis with a mean follow-up period of 25
months. This included a total of 204 patients (mean age, 75 years). Using
3D printed models of left atrial appendage based on transesophageal
echocardiogram and cardiac computed tomography had statistically
significantly less incidence of peri-device leak (log OR -2.47; 95% CI:
-3.70 to 1.24; p = 0.00), incidence of mismatch (log OR -1.61; 95% CI:
-2.50 to 0.73; p = 0.00) and shorter procedural time (mean difference
-24.86; 95% CI: -31.75 and -27.11; p = 0.00). Although the incidence of
device-related thromboembolism was 49% less in the 3D printing-guided
group, the difference was not statistically significant (p = 0.58).
 Conclusion(s): Less incidence of peri-device leak and mismatch were
observed with 3D printing-guided left atrial appendage occlusion. A highly
powered randomized controlled trial may have to be done to confirm the
findings. Copyright © 2025 Wiley Periodicals LLC.

<25>
Accession Number
2034828621
Title
A randomized controlled trial on the impact of anesthetic agents on renal
function in cardiac surgery with cardiopulmonary bypass.
Source
Molecular and Cellular Biochemistry. (no pagination), 2025. Date of
Publication: 2025.
Author
Fan T.; Zhao Z.; Liu J.; Ma W.; Tian J.; Ma G.
Institution
(Fan, Zhao, Liu, Ma, Tian, Ma) The First Affiliated Hospital of Xinxiang
Medical University, Henan, China
Publisher
Springer
Abstract
Acute kidney injury (AKI) is a frequent and severe problem following heart
surgery, particularly in procedures involving cardiopulmonary bypass
(CPB). This research investigates the Randomized Controlled Trial (RCT) on
the impact of agents of anesthetic on renal function in patients receiving
elective cardiac surgery and CPB, comparing propofol-based and volatile
anesthetic-based regimens. A sum of 61 patients was randomly assigned into
two regions: one receiving a propofol-based regimen and the other, a
volatile anesthetic regimen, both combined with opioid analgesia. Renal
function was assessed preoperatively and postoperatively at 24 and 48 h
using serum creatinine and cystatin C levels. Perioperative inflammatory
markers were deliberate to evaluate inflammation-mediated renal impairment
multivariate logistic regression identified risk factors for AKI, and
independent t-tests compared renal function parameters between regimens.
Patients receiving propofol exhibited significantly lower rates of AKI
(p<0.05) and reduced inflammatory marker levels associated to the volatile
anesthetic regimen. These results present that propofol anesthesia
provides a protecting influence on renal function, likely due to its
anti-inflammatory properties. The research emphasizes the necessity of
choosing the right anesthetic for postoperative kidney outcomes by
tailoring anesthetic regimens to mitigate AKI risk in high-risk
populations. Propofol's protective role against AKI offers potential
clinical value, particularly in cardiac surgeries requiring CPB. Further
investigation with bigger cohorts and continued follow-up are necessary
for verifying these findings and exploring their broader applicability in
cardiac anesthesia. Copyright © The Author(s), under exclusive
licence to Springer Science+Business Media, LLC, part of Springer Nature
2025.

<26>
Accession Number
2039003203
Title
The relationship of baseline high-sensitivity C-reactive protein with
incident cardiovascular events and all-cause mortality over 20 years.
Source
eBioMedicine. 117 (no pagination), 2025. Article Number: 105786. Date of
Publication: 01 Jul 2025.
Author
Hartley A.; Rostamian S.; Kaura A.; Chrysostomou P.; Welsh P.; Ariti C.;
Sattar N.; Sever P.; Khamis R.
Institution
(Hartley, Rostamian, Kaura, Chrysostomou, Ariti, Sever, Khamis) National
Heart and Lung Institute, Imperial College London, United Kingdom
(Welsh, Sattar) Institute of Cardiovascular and Medical Sciences,
University of Glasgow, Glasgow, United Kingdom
Publisher
Elsevier B.V.
Abstract
Background: The prediction of future cardiovascular events in those with
risk factors is important for the appropriate optimisation of preventative
therapies for those at greatest risk. The value of high sensitivity
C-reactive Protein (hsCRP) has been questioned in this regard. The
objectives of this post-hoc analysis of a randomised controlled trial were
to investigate the usefulness of baseline serum hsCRP for predicting very
long-term cardiovascular events in patients with hypertension in the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study.
 Method(s): The ASCOT Legacy Study reports events up to 20 years of
follow-up of the UK participants in the Lipid Lowering Arm of the original
ASCOT trial. We examined outcomes related to serum hsCRP levels measured
using a commercial ELISA, in tertiles or continuously, adjusting for
classical cardiovascular risk factors as well as treatment allocation
within ASCOT. The primary outcome was non-fatal myocardial infarction (MI)
and fatal coronary heart disease (CHD); whilst secondary outcomes were
all-cause mortality, total coronary events and procedures, total
cardiovascular events and stroke. Finding(s): After excluding 3286
participants without hsCRP data, 5294 participants were included in the
final cohort. The highest tertile of hsCRP was associated with the
following outcomes compared to the lowest tertile: non-fatal myocardial
infarction (MI) and fatal CHD (HR 1.32 [1.05-1.67]); total coronary events
and procedures (HR 1.27 [1.09-1.47]); total cardiovascular events (HR 1.22
[1.08-1.37]); and all-cause mortality (HR 1.25 [1.10-1.42]). However,
there was insufficient evidence regarding the association between hsCRP
levels and stroke events. Addition of hsCRP in tertiles resulted in an
improved net reclassification index for the prediction of non-fatal MI and
fatal CHD at 20 years (9.68%, p < 0.0001). Interpretation(s): Higher
baseline serum hsCRP levels can independently predict cardiovascular
events and all-cause mortality at long-term follow-up in stable patients
with hypertension. Funding(s): British Heart Foundation Clinical
Research Fellowship (FS/17/16/32560), Wellcome Trust Clinical Research
Fellowship (220572/Z/20/Z), and Sansour Fund at Imperial Healthcare
Charity. The substudy of ASCOT Biomarker Programme was supported by
Pfizer, New York, NY, USA. Infrastructure support was provided by the NIHR
Imperial Biomedical Research Centre as well as the Imperial British Heart
Foundation Research Excellence Award (4) (RE/24/130023). Copyright
© 2025 The Author(s)

<27>
Accession Number
2038970866
Title
Frailty in older adults: A systematic review of risk factors and early
intervention pathways.
Source
Intractable and Rare Diseases Research. 14(2) (pp 93-108), 2025. Date of
Publication: 2025.
Author
Deng Y.; Yamauchi K.; Song P.; Karako T.
Institution
(Deng) Graduate School of Rehabilitation Medicine, Hamamatsu University
School of Medicine, Shizuoka, Hamamatsu, Japan
(Yamauchi) Department of Rehabilitation Medicine, Hamamatsu University
School of Medicine, Shizuoka, Japan
(Song, Karako) National College of Nursing, Japan, Tokyo, Japan
(Song) Center for Clinical Sciences, Japan Institute for Health Security,
Tokyo, Japan
(Karako) National Center for Global Health and Medicine, Japan Institute
for Health Security, Tokyo, Japan
Publisher
International Advancement Center for Medicine and Health Research Co.,
Ltd.
Abstract
SUMMARY: Frailty is an independent risk factor linked to a higher
likelihood of various diseases. With limited healthcare resources
worldwide - especially in developing countries - the factors that
contribute to frailty need to be understood across different populations
and a universal model needs to be developed. This could help reduce the
burden on healthcare systems and lessen the negative health effects of
frailty. This review aims to summarize current evidence on the key factors
influencing frailty and its impact on disease outcomes in different
countries. The goal is to facilitate the development of strategies that
can help prevent or even reverse frailty. Studies were included if they
examined physical frailty using validated assessment tools in older adults
and explored how various factors affect its development and progression. A
comprehensive search of the PubMed database was conducted from March 1 to
March 31, 2024 using the keywords "vulnerability" and "influencing
factors." Studies published between January 1, 2001, and March 31, 2025
were considered. A total of 1,614 articles were initially identified, with
50 studies ultimately meeting the predefined inclusion and exclusion
criteria. The findings indicate that frailty is influenced by a wide range
of interrelated risk and protective factors, which in turn have various
effects on different disease outcomes. These interconnected factors
highlight both the complexity and the potential for targeted intervention.
The review provides a comprehensive understanding of the factors
associated with frailty in older adults across diverse settings and
underscores the urgent need to develop a robust, evidence-based frailty
model to facilitate the early identification, prevention, and possibly
reversal of frailty. Copyright © 2025 International Advancement
Center for Medicine and Health Research Co., Ltd.. All rights reserved.

<28>
Accession Number
2039028891
Title
Efficacy and Safety of Desmopressin in Terms of Bleeding and Transfusion
in Cardiac Surgery With Cardiopulmonary Bypass: A Systematic Review and
Meta-Analysis.
Source
Heart Lung and Circulation. (no pagination), 2025. Date of Publication:
2025.
Author
Picchio M.; Marcucci C.; Jaques C.; Mauron S.; Zuercher M.
Institution
(Picchio, Marcucci, Mauron, Zuercher) Department of Anesthesiology,
University Hospital of Lausanne (CHUV), Lausanne, Switzerland
(Marcucci) Faculty of Biology and Medicine, University of Lausanne (UNIL),
Lausanne, Switzerland
(Jaques) Medical Library, University Hospital of Lausanne (CHUV) and
University of Lausanne (UNIL), Lausanne, Switzerland
Publisher
Elsevier Ltd
Abstract
Bleeding and transfusion during cardiac surgery are major sources of
complications. Surgery and cardiopulmonary bypass can induce coagulopathy,
including platelet dysfunction. Desmopressin has been shown to reduce
bleeding and transfusion requirements, although with conflicting results.
This study aimed to systematically evaluate the available evidence
regarding the efficacy and safety of desmopressin in cardiac surgery with
cardiopulmonary bypass. The Embase, MEDLINE, Cochrane Central, Web of
Science, and ClinicalTrials.gov databases were searched for prospective
studies comparing desmopressin with placebo in cardiac surgery with
cardiopulmonary bypass. A meta-analysis with bleeding at 24 hours as the
primary outcome and the amount and incidence of blood product transfusions
as secondary outcomes was performed. Safety outcomes included
re-exploration rate, thromboembolic events, and mortality. Thirty-four
(34) studies comprising 2,523 patients were included. Bleeding at 24 hours
was reduced in the desmopressin group (weighted mean difference, 96.20 mL;
95% confidence interval [CI] -148.44 to -43.96; p=0.0003 with
heterogeneity [I2]=76%). The amount of blood products
transfused (red blood cells) was reduced in the desmopressin group
(standardised mean difference [SMD], -0.32; 95% CI -0.58 to -0.05). No
significant difference was found for transfusion of platelets (SMD, -0.16;
95% CI -0.58 to 0.26) or fresh frozen plasma (SMD, -0.30; 95% CI -0.67 to
-0.06). No significant differences were observed between the two groups
with respect to safety outcomes. Results of the present meta-analysis
demonstrated that desmopressin reduced blood loss and the amount of red
blood cell transfusions after cardiac surgery. However, this result should
be interpreted with caution, given the considerable heterogeneity among
the studies. Copyright © 2025 The Author(s)

<29>
Accession Number
2034824185
Title
The Effect of Prophylactic Use of Antifibrinolytics During Pediatric
Non-Cardiac Surgeries on Bleeding and Transfusions: A Systematic Review
and Meta-Analysis.
Source
Paediatric Anaesthesia. (no pagination), 2025. Date of Publication: 2025.
Author
Hickey K.S.; Smith M.; Karam O.; Demetres M.; Faraoni D.; Duron V.; Wu
Y.S.; Nellis M.E.
Institution
(Hickey) Department of Pediatric Critical Care, Mount Sinai Kravis
Children's Hospital, New York, NY, United States
(Smith, Nellis) Division of Pediatric Critical Care, Department of
Pediatrics, New York-Presbyterian/Weill Cornell Medicine, New York, NY,
United States
(Karam) Pediatric Critical Care Medicine, Yale School of Medicine, New
Haven, CT, United States
(Demetres) Samuel J. Wood Library and C.V. Starr Biomedical Information
Center, Weill Cornell Medicine, New York, NY, United States
(Faraoni) Division of Cardiac Anesthesia. Department of Anesthesiology,
Critical Care and Pain Medicine, Boston Children's Hospital, Harvard
Medical School, Boston, MA, United States
(Duron, Wu) Department of Surgery, Columbia University Irving Medical
Center/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York,
NY, United States
Publisher
John Wiley and Sons Inc
Abstract
Objectives: The objective of this meta-analysis is to determine the effect
of intraoperative tranexamic acid, aminocaproic acid, and aprotinin on
bleeding in pediatric surgery. Study Design: A literature search was
performed for the meta-analysis and systematic review in the following
databases from inception until April 2023: Ovid MEDLINE, Ovid EMBASE, and
The Cochrane Library. Studies included patients under 18 years of age,
non-cardiac surgery, and administration of antifibrinolytics. Forest plots
were used for statistical analysis. Primary outcomes were intraoperative
blood loss and intraoperative blood transfusions. Result(s): One
hundred thirty articles met inclusion. Tranexamic acid compared to control
resulted in an estimated blood loss of -410.0 mL p-value = < 0.001 for
scoliosis surgery, -14.0 mL/kg p-value = < 0.001 for craniofacial surgery,
and -21.0 mL p-value < 0.001 for tonsillectomy/adenoidectomy surgery.
Aminocaproic acid compared to control resulted in an estimated blood loss
of -464.0 mL p-value < 0.001 for scoliosis surgery. Tranexamic acid
compared to aminocaproic acid resulted in an estimated blood loss of
-391.0 mL p-value < 0.001 for scoliosis surgery. For blood transfusion
during craniosynostosis surgery, tranexamic acid compared to control
resulted in a mean decrease of -7 mL/kg p-value = 0.010 and aprotinin
compared to control resulted in a mean decrease of -20.0 mL/kg p-value <
0.001. The analysis for VRO/VDRO and hip reconstruction did not reach
statistical significance. Conclusion(s): In craniofacial, scoliosis,
and tonsillectomy/adenoidectomy surgery, prophylactic administration of
tranexamic acid results in lower estimated blood loss. Tranexamic acid and
aprotinin are effective for reducing transfusion in craniofacial surgery.
For scoliosis surgery, tranexamic acid is more efficacious than
aminocaproic acid. More literature is needed to assess the efficacy of
tranexamic acid in VRDO/VRO and hip reconstruction surgery and the
efficacy of different dosing regimens. Copyright © 2025 John
Wiley & Sons Ltd.

<30>
Accession Number
2034777668
Title
A phase 3 study of ravulizumab to protect patients with chronic kidney
disease from cardiac surgery-associated acute kidney injury and major
adverse kidney events (ARTEMIS).
Source
Trials. 26(1) (no pagination), 2025. Article Number: 181. Date of
Publication: 01 Dec 2025.
Author
Ostermann M.; Corteville D.C.; Doi K.; Koyner J.L.; Lamy A.; Li G.;
Solinsky C.M.; Winterberg P.D.; Smith W.T.; Mehta R.L.; Murray P.T.; Shaw
A.D.; Zarbock A.; Engelman D.T.
Institution
(Ostermann) Critical Care and Nephrology, NHS Foundation Trust, Guy's and
St Thomas, London, United Kingdom
(Corteville) Department of Cardiology, Rochester Regional Health,
Rochester, United States
(Doi) Emergency and Critical Care Medicine, The University of Tokyo
Hospital, Tokyo, Japan
(Koyner) Section of Nephrology, The University of Chicago, Chicago, United
States
(Lamy) Division of Cardiac Surgery and Population Health Research
Institute, McMaster University, Hamilton, Canada
(Li, Solinsky, Winterberg, Smith) Alexion, AstraZeneca Rare Disease,
Boston, United States
(Mehta) Department of Medicine, San Diego School of Medicine, University
of California, San Diego, United States
(Murray) University College Dublin Clinical Research Centre, UCD School of
Medicine, Dublin, Ireland
(Shaw) Department of Intensive Care and Resuscitation, Cleveland Clinic,
Cleveland, United States
(Zarbock) Department of Anesthesiology, Intensive Care and Pain Medicine,
University of Munster, Munster, Germany
(Engelman) Heart & Vascular Program Baystate Health, University of
Massachusetts Chan Medical School-Baystate, Springfield, United States
(Winterberg) Present Address: Vera Therapeutics, Brisbane, United States
(Smith) Present Address: Novartis, East Hanover, United States
(Shaw) Present Address: Critical Care and ECMO Division of ABIOMED, J & J
MedTech, Cleveland, United States
Publisher
BioMed Central Ltd
Abstract
Background: Cardiac procedures, particularly those requiring
cardiopulmonary bypass (CPB), are associated with the development of
cardiac surgery-associated acute kidney injury (CSA-AKI). Development of
CSA-AKI occurs as a result of inflammation, uncontrolled complement
activation, and kidney cell damage. In patients with preoperative renal
impairment, such as those with chronic kidney disease (CKD), there is an
increased risk of both CSA-AKI and poorer clinical outcomes. Currently,
there are limited effective, targeted pharmacological interventions for
the prevention or treatment of CSA-AKI, although emerging therapies are
being investigated, particularly in patients with existing CKD. The
ARTEMIS (RAvulizumab to PRotect PaTients with Chronic Kidney DisEase froM
CSA-AKI and Subsequent Major Adverse Kidney Events) trial will assess the
efficacy and safety of ravulizumab (a complement C5 inhibitor) in reducing
the risk of major adverse kidney events (MAKE) in patients with
preoperative CKD undergoing non-emergent cardiac surgery with CPB.
 Method(s): This trial is currently recruiting patients with CKD who
have planned cardiac surgery requiring CPB including coronary artery
bypass grafting, valve replacement or repair, or combined procedures. This
is a phase 3, randomized, double-blind, placebo-controlled, global study
assessing the efficacy and safety of a single preoperative dose of
ravulizumab. These outcomes will be assessed using the occurrence of MAKE
and its components, as well as the occurrence and severity of CSA-AKI
throughout the study period. Discussion(s): Complement activation is
known to occur during and after cardiac procedures as a result of CPB and
ischemia-reperfusion injury, leading to a cycle of cell damage and death.
Therefore, it is hypothesized that preoperative administration of
ravulizumab will provide immediate and complete complement inhibition,
which will be sustained throughout the surgical period, preventing the
uncontrolled complement activation associated with the development of
CSA-AKI, thus minimizing poor outcomes for patients. Trial registration:
ClinicalTrials.gov NCT05746559. Registered on February 27,
2023. Copyright © The Author(s) 2025.

<31>
Accession Number
2038978056
Title
Role of Perioperative Oral Thyroid Hormone Supplementation in Infants
Undergoing Surgery for Congenital Heart Disease.
Source
European Journal of Cardiovascular Medicine. 15(5) (pp 800-804), 2025.
Date of Publication: 01 May 2025.
Author
Panchal J.; Sirandas A.; Parmar D.
Institution
(Panchal, Parmar) Department of Cardiac Anaesthesia, U N Mehta Institute
of Cardiology and Research Centre, Gujarat, Ahmedabad, India
(Sirandas) Department of Cardiac Anaesthesia, U N Mehta Institute of
Cardiology and Research Centre, Gujarat, Ahmedabad, India
Publisher
Healthcare Bulletin
Abstract
Background: Congenital heart disease (CHD) frequently requires early
surgical correction under cardiopulmonary bypass (CPB), which is known to
disrupt thyroid hormone balance, leading to non-thyroidal illness syndrome
(NTIS). Thyroid hormones are vital for cardiac performance, metabolism,
and hemodynamic stability, especially in infants. This study evaluates the
role of perioperative oral thyroid hormone supplementation in improving
thyroid profiles and clinical outcomes in infants undergoing open-heart
surgery for CHD. Material(s) and Method(s): A prospective,
randomized, double-blinded controlled trial was conducted from June 2022
to June 2024 at U.N. Mehta Institute of Cardiology, Ahmedabad. A total of
100 infants (<=1 year) undergoing CHD surgery under CPB were randomized
into two groups: Group T (n=50) received oral thyronorm (10 mcg/kg
preoperatively and 5 mcg/kg daily postoperatively for 4 days), and Group P
(n=50) received placebo. Serum levels of T3, T4, and TSH were measured
preoperatively and at 6, 24, 48, and 72 hours postoperatively. Secondary
outcomes included vasoactive inotropic score (VIS), cardiac function, time
to extubation, and ICU stay. Result(s): Thyronorm supplementation
significantly elevated serum T3 and T4 levels postoperatively at 24, 48,
and 72 hours (p < 0.001) compared to the placebo group. However, there was
no statistically significant difference between groups in TSH levels, VIS,
cardiac function, duration of mechanical ventilation, or ICU length of
stay (p > 0.05 for all comparisons). Conclusion(s): Perioperative
oral thyronorm effectively restored thyroid hormone levels in infants
undergoing cardiac surgery under CPB. However, it did not significantly
improve clinical outcomes such as inotropic requirement, extubation time,
or ICU stay. Routine use may be unnecessary in low-risk infants but could
be explored further in complex or high-risk surgical
categories. Copyright © 2025 Healthcare Bulletin. All rights
reserved.

<32>
Accession Number
2034812960
Title
Optimal Thromboembolism Prevention for Patients With Atrial Fibrillation
on Long-Term Dialysis.
Source
PACE - Pacing and Clinical Electrophysiology. (no pagination), 2025. Date
of Publication: 2025.
Author
Hashimoto K.; Fujisaki T.; Aikawa T.; Iwagami M.; Miyamoto Y.; Slipczuk
L.; Biase L.D.; Briasoulis A.; Yasuhara J.; Takagi H.; Kuno T.
Institution
(Hashimoto) Westmead Applied Research Centre, University of Sydney,
Sydney, NSW, Australia
(Fujisaki) Department of Cardiovascular Medicine, National Cerebral and
Cardiovascular Center, Osaka, Japan
(Fujisaki) Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University, Kumamoto, Japan
(Aikawa) Department of Cardiovascular Biology and Medicine, Juntendo
University Graduate School of Medicine, Tokyo, Japan
(Iwagami) Department of Digital Health, Social Medicine Group, Institute
of Medicine, University of Tsukuba, Tsukuba, Japan
(Iwagami) Department of Non-Communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London, United Kingdom
(Miyamoto) Department of Real-world Evidence, The University of Tokyo,
Tokyo, Japan
(Slipczuk, Biase, Kuno) Division of Cardiology, Montefiore Health
System/Albert Einstein College of Medicine, New York, NY, United States
(Briasoulis) Division of Cardiovascular Medicine, University of Iowa, Iowa
City, IA, United States
(Yasuhara) Department of Pediatric Cardiology, Monash Heart and Monash
Children's Hospital, Monash Health, Melbourne, Australia
(Takagi) Department of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Kuno) Division of Cardiology, Jacobi Medical Center, Albert Einstein
College of Medicine, New York, NY, United States
(Kuno) Division of Cardiology, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Optimal strategies for thromboembolism prevention, including
vitamin K antagonists (VKA), direct oral anticoagulants (DOAC), and left
atrial appendage occlusion (LAAO), for patients with atrial fibrillation
(AF) and on dialysis have not been fully investigated. We aimed to
investigate the efficacy and safety of thromboembolism prevention
strategies in AF patients on dialysis through a network meta-analysis.
 Method(s): Multiple databases were searched through January 2024. The
primary efficacy endpoint was thrombotic events, defined as ischemic
stroke or systemic thromboembolism, whereas the primary safety endpoint
was major bleeding. These strategies were ranked using P-scores.
 Result(s): Our study identified 28 eligible studies (including 3
randomized controlled trials) that enrolled 144,630 AF patients on
dialysis. The risks of thrombotic events in any DOAC and VKA were
comparable to no-anticoagulant, whereas LAAO was associated with a lower
risk of thrombotic events (HR [95% CI]: 0.19 [0.06-0.60]). Compared to
no-anticoagulant, VKA, regular-dose rivaroxaban, and dabigatran were
associated with a higher risk of major bleeding, but rivaroxaban 10 mg
daily, and apixaban 2.5 or 5 mg twice daily were not. LAAO, rivaroxaban 10
mg daily and apixaban 2.5 or 5 mg twice daily were highly ranked in
efficacy and safety outcomes. Conclusion(s): LAAO may possibly be the
reasonable therapeutic option for AF patients on dialysis, but rivaroxaban
10 mg daily and apixaban 2.5 or 5 mg twice daily can also be considered.
Further studies are warranted to confirm these findings. Copyright
© 2025 Wiley Periodicals LLC.

<33>
Accession Number
2034833832
Title
Correction to: Randomized clinical trial of continuous transversus
thoracis muscle plane block for patients undergoing open heart valve
replacement surgery (Journal of Cellular and Molecular Medicine, (2024),
28, 7, 10.1111/jcmm.18184).
Source
Journal of Cellular and Molecular Medicine. 29(11) (no pagination), 2025.
Article Number: e70648. Date of Publication: 01 Jun 2025.
Author
Anonymous
Publisher
John Wiley and Sons Inc
Abstract
Zhan Y, Li L, Chen S, Peng Y, Zhang Y. Randomized Clinical Trial of
Continuous Transversus Thoracis Muscle Plane Block for Patients Undergoing
Open Heart Valve Replacement Surgery. J Cell Mol Med. 2024; 28:e18184.
doi: 10.1111/jcmm.18184. In the article, references 12, 13, 14, 17, and 18
were incorrect and should be replaced. The incorrect references are: 12.
Ueshima H, Otake H. Continuous transversus thoracic muscle plane block is
effective for the median sternotomy. J Clin Anesth. 2017;37:174. 13.
Ueshima H, Otake H. Where is an appropriate injection point for an
ultrasound-guided transversus thoracic muscle plane block? J Clin Anesth.
2016;33:190-191. 14. Ueshima H, Takeda Y, Ishikawa S, Otake H.
Ultrasound-guided transversus thoracic muscle plane block: a cadaveric
study of the spread of injectate. J Clin Anesth. 2015;27:696. 17. Ueshima
H, Hara E, Marui T, Otake H. The ultrasound-guided transversus thoracic
muscle plane block is effective for the median sternotomy. J Clin Anesth.
2016;29:8. 18. Ueshima H, Otake H. Ultrasound-guided transversus thoracic
muscle plane block: complication in 299 consecutive cases. J Clin Anesth.
2017;41:60. The correct references are: 12. Avneet Singh, Indumati,
Dheeraj Kapoor, Suman Dhillon, Jasmine K Narula, Sidharth Garg. Continuous
Bilateral Transversus Thoracic Muscle Plane Block: An Analgesia Boon for
Scoliotic Patients Undergoing Cardiac Surgery. Ann Card Anaesth. 2024 Jan
1;27(1):61-64. 13. Samerchua Artid, Leurcharusmee Prangmalee, Supphapipat
Kittitorn, Unchiti Kantarakorn, Lapisatepun Panuwat, Maikong Naraporn,
Kantakam Perada, Navic Pagorn, Mahakkanukrauh Pasuk. Optimal techniques of
ultrasound-guided superficial and deep parasternal intercostal plane
blocks: a cadaveric study. Region Anesth Pain M. 2024-05-07;49(5):320-325.
14. Harbell Monica W, Langley Natalie R, Seamans David P, Kraus Molly B,
Carey Frederick J, Craner Ryan C.Deep parasternal intercostal plane nerve
block: an anatomical study. Region Anesth Pain M.
2024-03-04;49(3):179-183. 17. Mohamed Ahmed Hamed, Maged Labib Boules,
Mina Mahrou Sobhy, Mahdy Ahmed Abdelhady.The Analgesic Efficacy of
Ultrasound-Guided Bilateral Transversus Thoracic Muscle Plane Block After
Open-Heart Surgeries: A Randomized Controlled Study.J Pain Res.
2022-01-01;15:675-682. 18. Jian-Jun Xue, Yi-Yang Cui, Jason W Busse, Long
Ge, Ting Zhou, Wei-Hua Huang, Sheng-Shuang Ding, Jie Zhang, Ke-Hu Yang.
Transversus thoracic muscle plane block for pain during cardiac surgery: a
systematic review and meta-analysis. Int J Surg. 2023 Aug
1;109(8):2500-2508. The online version of the article was corrected. We
apologize for these errors. Copyright © 2025 The Author(s).
Journal of Cellular and Molecular Medicine published by Foundation for
Cellular and Molecular Medicine and John Wiley & Sons Ltd.

<34>
Accession Number
2029060880
Title
When Our Best Friend Becomes Our Worst Enemy: The Mitochondrion in Trauma,
Surgery, and Critical Illness.
Source
Journal of Intensive Care Medicine. 40(7) (pp 695-714), 2025. Date of
Publication: 01 Jul 2025.
Author
Torp M.-K.; Stenslokken K.-O.; Vaage J.
Institution
(Torp, Stenslokken, Vaage) Section of Physiology, Department of Molecular
Medicine, Institute of Basic Medical Science, University of Oslo, Oslo,
Norway
(Torp) Department of Research, Ostfold Hospital Trust, Gralum, Norway
(Vaage) Department of Research and Development, Division of Emergencies
and Critical Care, Oslo University Hospital, Oslo, Norway
(Vaage) Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Publisher
SAGE Publications Inc.
Abstract
Common for major surgery, multitrauma, sepsis, and critical illness, is a
whole-body inflammation. Tissue injury is able to trigger a generalized
inflammatory reaction. Cell death causes release of endogenous structures
termed damage associated molecular patterns (DAMPs) that initiate a
sterile inflammation. Mitochondria are evolutionary endosymbionts
originating from bacteria, containing molecular patterns similar to
bacteria. These molecular patterns are termed mitochondrial DAMPs
(mDAMPs). Mitochondrial debris released into the extracellular space or
into the circulation is immunogenic and damaging secondary to activation
of the innate immune system. In the circulation, released mDAMPS are
either free or exist in extracellular vesicles, being able to act on every
organ and cell in the body. However, the role of mDAMPs in trauma and
critical care is not fully clarified. There is a complete lack of
knowledge how they may be counteracted in patients. Among mDAMPs are
mitochondrial DNA, cardiolipin, N-formyl peptides, cytochrome C, adenosine
triphosphate, reactive oxygen species, succinate, and mitochondrial
transcription factor A. In this overview, we present the different mDAMPs,
their function, release, targets, and inflammatory potential. In light of
present knowledge, the role of mDAMPs in the pathophysiology of major
surgery and trauma as well as sepsis, and critical care is
discussed. Copyright © The Author(s) 2024.

<35>
Accession Number
2034823998
Title
Coronary Artery Bypass Grafting With or Without Concomitant Surgical
Ventricular Reconstruction in Ischemic Cardiomyopathy Patients.
Source
Cardiovascular Drugs and Therapy. (no pagination), 2025. Date of
Publication: 2025.
Author
Liao J.; Zhou Z.; Zhang Y.; Miao Z.; Li G.; Xiao H.; Ren Q.; Jian B.; Wu
Z.; Liang M.
Institution
(Liao, Zhou, Zhang, Miao, Li, Xiao, Ren, Jian, Wu, Liang) Department of
Cardiac Surgery, First Affiliated Hospital of Sun Yat-Sen University, 58
Zhongshan II Road, Guangzhou, China
(Zhou) Department of Anesthesiology, Brigham and Women's Hospital, Harvard
Medical School, Boston, MA, United States
Publisher
Springer
Abstract
Purpose: The present study aims to compare the long-term outcomes of
surgical ventricular reconstruction (SVR) combined with coronary artery
bypass grafting (CABG) versus CABG alone in patients with ischemic
cardiomyopathy (ICM). Method(s): A systematic literature search was
conducted in PubMed, Embase, Scopus, Cochrane Library, and Web of Science
until November 2024. Studies comparing SVR + CABG and CABG in patients
with ischemic cardiomyopathy (left ventricular ejection fraction less than
40%) were included. The primary outcome included long-term mortality, and
the secondary outcomes included hospital mortality, rehospitalization for
cardiac causes, and other cardiac function indicators. Result(s):
Twelve studies with a total of 3188 patients were included, with 1629
undergoing SVR + CABG and 1559 undergoing CABG. Patients who underwent SVR
+ CABG had a higher survival rate (HR 0.82; 95% CI, 0.69-0.96;
I2 = 4%; P = 0.01) and a more significant postoperative left
ventricular end-systolic volume index (ESVI) reduction (MD 15.53; 95% CI,
6.41-24.65; I2 = 93%; P = 0.01). In the subgroup analysis, the
Dor (endoventricular circular patch plasty) surgery provided additional
survival benefits compared with CABG (HR 0.83; 95% CI, 0.70-0.97;
I2 = 9%; P = 0.02). The reconstructed Kaplan-Meier curves show
that the survival rates in the SVR + CABG, Dor, Non-Dor, Mannequin-free,
Mannequin, and CABG groups were 81.13%, 82.02%, 76.38%, 83.23%, 69.40%,
and 71.42% at 60 months, respectively. Conclusion(s): Compared with
CABG, SVR + CABG is associated with higher survival, a more significant
reduction in ESVI, fewer rehospitalizations for cardiac causes, and more
patients gaining postoperative New York Heart Association class
improvement. Copyright © The Author(s), under exclusive licence
to Springer Science+Business Media, LLC, part of Springer Nature 2025.

<36>
Accession Number
2034819376
Title
Role of HTK solution in protecting cardiomyocytes against oxidative stress
by upregulating Nrf2 during cardiac arrest and resuscitation: a rat model
with a right thoracotomy.
Source
Perfusion (United Kingdom). (no pagination), 2025. Article Number:
02676591241307365. Date of Publication: 2025.
Author
Qiu B.; Wang L.; Ding P.; Wang A.; Zhang X.; Li Q.; Wang C.; Feng S.
Institution
(Qiu, Wang, Wang) Department of Cardiothoracic Surgery, Affiliated Jinling
Hospital, Nanjing Medical University, Nanjing, China
(Wang) Department of Thoracic and Cardiovascular Surgery, Nanjing First
Hospital, Nanjing Medical University, Nanjing, China
(Ding, Zhang) Department of Cardiothoracic Surgery, Children's Hospital of
Nanjing Medical University, Nanjing, China
(Li, Feng) Department of Anesthesiology, Women's Hospital of Nanjing
Medical University, Nanjing Women and Children's Healthcare Hospital,
Nanjing Medical University, Jiangsu, China
Publisher
SAGE Publications Ltd
Abstract
Introduction: The objective of this study was to establish a rat model for
cardiopulmonary bypass (CPB) with cardiac arrest and resuscitation and to
investigate the regulatory role of HTK solution in protecting
cardiomyocytes against oxidative stress by upregulating Nrf2.
 Method(s): 40 rats were randomly assigned to four groups: the control
(Ctrl), the histidine-tryptophan-ketoglutarate (HTK), 4:1 blood
cardioplegia (BC) and del Nido cardioplegia (DN) groups. The
cardiopulmonary bypass (CPB) procedure was implemented and sustained for a
duration of 1 hour. Subsequent to the cessation of CPB, the rats were
subjected to monitoring and observation for an additional 2 hours.
Following this observation period, the heart and blood samples were
procured for subsequent analysis. Result(s): The MDA was
significantly higher in the HTK group, BC group, and DN group compared to
the Ctrl group. The HTK group had lower MDA levels than the BC group.
Regarding MPO activity, it increased in the HTK group, BC group, and DN
group relative to the Ctrl group. Both the BC and DN groups exhibited
elevated MPO levels compared to the HTK group. SOD levels were
significantly lower in the HTK, BC, and DN groups compared to the Ctrl
group. The HTK group had higher SOD levels than the BC group. With respect
to miRNA-210-3P and Nrf2, the expression were more efficient in the HTK,
BC, and DN groups compared to the Ctrl group. The BC and DN groups showed
reduced expression efficiency over the HTK group. Western blot analysis
indicated that the ratio of Nrf2 target was higher in the HTK group, BC
group, and DN group in comparison to the Ctrl group. Both the BC and DN
groups had lower protein content compared to the HTK group.
Immunohistochemistry scoring of HIF1-alpha and nuclear Nrf2 revealed
higher scores in the HTK, BC, and DN groups compared to the Ctrl group.
The HTK group achieved higher scores than both the BC and DN groups.
 Conclusion(s): Varied degrees of oxidative stress damage were
exhibited by three distinct cardioplegia solutions. The HTK group
demonstrated a superior antioxidant effect. The protective response of the
HTK solution against oxidative stress may be linked to the up-regulation
of Nrf2. Copyright © The Author(s) 2025.

<37>
Accession Number
2039023428
Title
Digoxin in rheumatic heart disease: Rationale and design of a multicenter,
placebo-controlled double-blind randomized controlled trial (Dig-RHD
trial).
Source
American Heart Journal. 289 (pp 38-47), 2025. Date of Publication: 01 Nov
2025.
Author
Devasenapathy N.; Biswas S.; Kini P.; Satheesh S.; Gupta M.D.; Mp G.;
Sethi R.; Yadav S.; Asotra S.; Gopalakrishnan A.; Gupta S.; Kapoor A.;
Meena C.B.; Math R.S.; Krishnan S.; Bansal S.; Boopathy N.; Jhajhria R.;
Kaushik B.; Wadhwa N.; Soni M.; Rastogi A.; Ghosh A.; Jha V.; Karthikeyan
G.
Institution
(Devasenapathy, Biswas, Soni) Academic Clinical Trials Unit, The George
Institute for Global Health, New Delhi, India
(Kini) Department of Cardiology, Sri Sathya Sai Institute of Higher
Medical Sciences, Bengaluru, India
(Satheesh) Department of Cardiology, Jawaharlal Institute of Postgraduate
Medical Education and Research, Puducherry, India
(Gupta, Mp) Department of Cardiology, Govind Ballabh Pant Hospital, New
Delhi, India
(Sethi) Department of Cardiology, King George's Medical University,
Lucknow, India
(Yadav, Karthikeyan) Department of Cardiology, All India Institute of
Medical Sciences, New Delhi, India
(Asotra) Department of Cardiology, Indira Gandhi Medical College, Shimla,
India
(Gopalakrishnan) Department of Cardiology, Sree Chitra Tirunal Institute
for Medical Sciences and Technology, Trivandrum, India
(Gupta, Kapoor) Department of Cardiology, Sanjay Gandhi Post Graduate
Institute of Medical Sciences, Lucknow, India
(Meena) Department of Cardiology, Sawai Man Singh Medical College,
Rajasthan, Jaipur, India
(Math, Krishnan) Department of Cardiology, Sri Jayadeva Institute of
Cardiovascular Sciences and Research, Bangalore, India
(Bansal) Department of Cardiology, Vardhman Mahavir Medical College and
Safdarjung Hospital, New Delhi, India
(Boopathy) Department of Cardiology, Sri Ramachandra Institute of Higher
Education and Research, Chennai, India
(Jhajhria, Kaushik, Wadhwa, Karthikeyan) Clinical Development Services
Agency, Translational Health Science and Technology Institute, Haryana,
Faridabad, India
(Rastogi, Ghosh) Department of Biostatistics, The George Institute for
Global Health, New Delhi, India
(Jha) The George Institute for Global Health, New Delhi, India
Publisher
Elsevier Inc.
Abstract
Background: Rheumatic heart disease (RHD), is a public health problem in
low and middle-income countries. It causes high morbidity and mortality
due to heart failure (HF), but there are no randomized trials of
HF-treatments in these patients. Digoxin is an inexpensive drug that is
widely used in RHD despite a lack of data on its effect on clinical
outcomes. The Digoxin in RHD (Dig-RHD) trial will evaluate the impact of
the drug on clinical outcomes in patients with RHD. Method(s): The
Dig-RHD trial is an investigator-initiated multicenter, pragmatic,
randomized placebo-controlled, parallel-arm, superiority trial.
Symptomatic adult patients with RHD were randomized to receive oral
digoxin or matching placebo on a background of usual care. The primary
outcome is a composite of all-cause death, new-onset or worsening HF. Key
secondary outcomes are, all-cause death, HF-related death, hospitalization
for HF, sudden death, and self-reported quality of life. Patients were
enrolled at 12 academic medical centers in India, beginning in February
2022. Enrolment of 1769 patients was completed in August 2024. One interim
review of the data by the independent Data Safety Monitoring Board, after
half the primary outcome events had accrued, indicated no safety signals.
The last follow-up visits are scheduled to complete in December 2025.
 Conclusion(s): Dig-RHD is the first randomized trial of digoxin in
RHD powered for clinical outcomes, and the results will have major
implications for the routine management of patients with RHD. (Clinical
trial registration: CTRI/2021/04/032858) Copyright © 2025
Elsevier Inc.

<38>
Accession Number
2034824174
Title
Dexmedetomidine as a Ropivacaine Adjuvant in a Thoracic Paravertebral
Block Combined With an Erector Spinae Plane Block for Improving Early
Quality of Recovery After Transapical Transcatheter Aortic Valve
Implantation.
Source
Kaohsiung Journal of Medical Sciences. (no pagination), 2025. Date of
Publication: 2025.
Author
Dong G.-L.; Qiu R.-E.; Xu C.-Z.
Institution
(Dong, Qiu, Xu) Department of Anesthesiology, The Quzhou Affiliated
Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou,
China
Publisher
John Wiley and Sons Inc
Abstract
The study aimed to investigate the effectiveness of dexmedetomidine (Dex)
as an adjuvant for ropivacaine in a thoracic paravertebral block (TPVB)
combined with an erector spinae plane block (ESPB) for improving early
quality of recovery and postoperative pain after transapical transcatheter
aortic valve implantation (TAVI). A total of 89 patients who were
scheduled to undergo transapical TAVI under general anesthesia were
allocated into Group RS and Group RD by using a computer-generated
random-number list. Group RS (n = 45) received 35 mL of 0.5% ropivacaine
with 5 mL of a normal saline mixture in TPVB combined with ESPB and Group
RD (n = 44) received 35 mL of 0.5% ropivacaine with 1 mug/kg Dex in 5 mL
of normal saline. The RD group exhibited significantly higher global
QoR-15 scores with lower visual analog scale (VAS) scores at 12 and 24 h
postoperatively than the RS group. The RD group needed fewer press times
of PCIA than the RS group. The postoperative sufentanil consumption was
significantly less in the RD group than that in the RS group. A longer
time to first use of flurbiprofen with less remedial doses of flurbiprofen
consumption within 48 h postoperatively was required for the RD group than
that for the RS group. The two groups did not differ in the incidence of
side effects. The findings of the study suggest that adding Dex to
ropivacaine in TPVB combined with ESPB is effective in improving early
quality of recovery and alleviating postoperative pain for patients
undergoing transapical TAVI under general anesthesia. Copyright ©
2025 The Author(s). The Kaohsiung Journal of Medical Sciences published by
John Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical
University.

<39>
Accession Number
2034812698
Title
Robotic-assisted mediastinal lymphadenectomy in lung cancer: a narrative
review.
Source
Journal of Robotic Surgery. 19(1) (no pagination), 2025. Article Number:
263. Date of Publication: 01 Dec 2025.
Author
Adamica D.; Tulinsky L.; Kepicova M.; Dzurnakova P.; Ihnat P.; Mittak M.;
Varga A.; Neoral C.; Martinek L.
Institution
(Adamica, Tulinsky, Kepicova, Ihnat, Mittak, Varga, Martinek) Department
of Surgery, University Hospital Ostrava, 17. Listopadu 1790, Ostrava,
Czechia
(Adamica, Tulinsky, Kepicova, Ihnat, Mittak, Varga, Neoral, Martinek)
Department of Surgical Studies, Faculty of Medicine, University of
Ostrava, Syllabova 19, Ostrava, Czechia
(Dzurnakova) Department of Anesthesiology and Intensive Care Medicine,
University Hospital Ostrava, 17. Listopadu 1790, Ostrava, Czechia
Publisher
Springer Nature
Abstract
The objective of this study is to undertake a narrative review of the
oncological adequacy of mediastinal lymphadenectomy performed via
robot-assisted thoracic surgery (RATS) in comparison with video-assisted
thoracic surgery (VATS) and thoracotomy for non-small cell lung cancer
(NSCLC). The focus of the review is on lymph node yield, nodal station
dissection, and nodal upstaging rates. A narrative review of literature
published in the last decade was conducted using PubMed, Cochrane, and Web
of Science databases. Studies examining mediastinal lymphadenectomy
outcomes for RATS, VATS, or thoracotomy were included in the discussion.
The analysis of 19 studies from diverse geographical regions showed that
in six out of nine comparative studies, RATS demonstrated superior lymph
node retrieval compared to VATS, with statistically significant
differences. RATS achieved comparable or superior nodal station dissection
rates and showed particular advantages in upstaging from clinical N0 to
pathological N2 status. Additionally, RATS demonstrated favourable
perioperative outcomes with reduced morbidity and mortality rates compared
to conventional approaches. RATS represents a reliable and oncologically
sound approach to mediastinal lymphadenectomy, with potential advantages
over conventional techniques. Its enhanced visualization and precision
make it an increasingly utilised option for NSCLC treatment in centres
with robotic capabilities. Copyright © The Author(s), under
exclusive licence to Springer-Verlag London Ltd., part of Springer Nature
2025.

<40>
[Use Link to view the full text]
Accession Number
2039084223
Title
Percutaneous Mitral Valve Repair Versus Surgery in Patients With Mitral
Regurgitation: A Meta-Analysis.
Source
Cardiology in Review. (no pagination), 2025. Date of Publication: 2025.
Author
Ali M.A.; Ali M.F.; Sabir A.; Alvi A.S.; Arif A.; Khawaja S.; Qayyum R.;
Vardag Z.B.; Ikram M.; Arshad H.; Naveed M.A.; Neppala S.; Ahmed M.; Ahmed
R.; Hussain A.; Paray N.B.
Institution
(Ali) Khyber Medical College Peshawar, Peshawar, Pakistan
(Ali) Jinnah Postgraduate Medical Center, Karachi, Pakistan
(Sabir) Department of Cardiac Surgery, Rawalpindi Institute of Cardiology,
Rawalpindi, Pakistan
(Alvi) Fatima Memorial College of Medicine and Dentistry, Lahore, Pakistan
(Arif) Sahara Medical College, Narowal, Pakistan
(Khawaja) Services Institute of Medical Sciences, Lahore, Pakistan
(Qayyum) Indus Hospital Gda, Gwadar, Pakistan
(Vardag) Continental Medical College, Lahore, Pakistan
(Ikram) Frontier Medical and Dental College Abbottabad, Abbottabad,
Pakistan
(Arshad) Shifa College of Medicine, Islamabad, Pakistan
(Naveed) Dow University of Health Sciences, Karachi, Pakistan
(Neppala) Division of Cardiology, Ut Health Science Center, San Antonio,
TX, United States
(Ahmed) Rawalpindi Medical University, Rawalpindi, Pakistan
(Ahmed) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
(Ahmed) Department of Cardiology, Royal Brompton Hospital, London, United
Kingdom
(Hussain) Department of Cardiac Surgery, Vanderbilt University Medical
Center, Nashville, TN, United States
(Paray) Royal Devon University Healthcare Nhs Foundation Trust, Exeter,
United Kingdom
Publisher
Lippincott Williams and Wilkins
Abstract
While studies confirm the feasibility of percutaneous mitral valve repair,
its short- and long-term outcomes compared with mitral valve surgery
remain debated. This meta-analysis aims to evaluate the clinical outcomes
with a percutaneous approach and surgery. A comprehensive literature
search of major databases that included PubMed, Embase, and the Cochrane
Library was performed from inception to November 2024. Randomized
controlled trials (RCTs) and propensity-adjusted observational studies
that reported clinical outcomes following percutaneous mitral valve repair
versus mitral valve surgery in patients with mitral regurgitation were
included in the review. The pooled estimates were calculated using a
random effects model. A total of 6 studies (n = 5411 patients) were
included. The pooled analysis demonstrated no statistically significant
difference between the 2 approaches for all-cause death at 1 month [risk
ratio (RR) = 1.13, 95% confidence interval (CI): 0.54-2.37], and 1 year
(RR = 1.98, 95% CI: 0.91-4.32). The risk of stroke was significantly
reduced in the percutaneous group (RR = 0.42, 95% CI: 0.23-0.74); however,
the pooled estimates remained comparable for hospitalization for heart
failure (RR = 0.88, 95% CI: 0.38-2.04), all-cause rehospitalization (RR =
1.03, 95% CI: 0.55-1.95), sepsis (RR = 0.25, 95% CI: 0.06-1.13), atrial
fibrillation (RR = 0.44, 95% CI: 0.10-2.06), and Grade 3+ or 4+ mitral
regurgitation (RR = 3.02, 95% CI: 0.74-12.37). Compared with surgery, the
percutaneous approach demonstrates a similar safety profile and a reduced
risk of stroke. However, long-term mortality is comparable between the 2
techniques, indicating that a patient-tailored approach will lead to
optimal results. Copyright © 2025 Wolters Kluwer Health, Inc.

<41>
Accession Number
2038737231
Title
Early Aortic Valve Replacement Versus Conservative Management: A
Meta-Analysis of Randomized Controlled Trials.
Source
Structural Heart. 9(6) (no pagination), 2025. Article Number: 100461. Date
of Publication: 01 Jun 2025.
Author
Shah T.; Shah Y.; Lansky A.J.; Giri J.; Fanaroff A.; Nathan A.
Institution
(Shah, Giri, Fanaroff, Nathan) Division of Cardiovascular Medicine,
Hospital of the University of Pennsylvania, Philadelphia, PA, United
States
(Shah) Department of Internal Medicine, Strong Memorial Hospital,
Rochester, NY, United States
(Lansky) Division of Cardiology, Yale School of Medicine, New Haven, CT,
United States
(Lansky) Barts Heart Centre, London and Queen Mary University of London,
London, United Kingdom
Publisher
Cardiovascular Research Foundation

<42>
Accession Number
2039037447
Title
Everolimus-eluting versus biolimus-eluting stents with biodegradable
polymers in unselected patients undergoing percutaneous coronary
intervention: five-year results of the randomised, non-inferiority SORT
OUT VIII trial.
Source
EuroIntervention. 21(11) (pp e629-e638), 2025. Date of Publication: 01 Jun
2025.
Author
Stottrup N.B.; Christiansen E.H.; Raungaard B.; Kahlert J.; Terkelsen
C.J.; Kristensen S.D.; Thim T.; Jakobsen L.; Jensen R.V.; Eftekhari A.;
Freeman P.; Jensen S.E.; Veien K.T.; Jensen L.O.; Maeng M.
Institution
(Stottrup, Christiansen, Terkelsen, Kristensen, Thim, Jakobsen, Jensen,
Veien, Maeng) Department of Cardiology, Aarhus University Hospital,
Aarhus, Denmark
(Stottrup, Christiansen, Terkelsen, Kristensen, Thim, Jensen, Maeng)
Department of Clinical Medicine, Health, Aarhus University, Aarhus,
Denmark
(Raungaard, Eftekhari, Freeman, Jensen) Department of Cardiology, Aalborg
University Hospital, Aalborg, Denmark
(Kahlert) Department of Clinical Epidemiology, Aarhus University Hospital,
Aarhus, Denmark
(Veien, Jensen) Department of Cardiology, Odense University Hospital,
Odense, Denmark
Publisher
Europa Group
Abstract
BACKGROUND: Long-term outcomes following implantation of drug-eluting
coronary stents are necessary to determine safety and efficacy. AIMS: We
aimed to report the 5-year outcomes of the SYNERGY thin-strut
biodegradable-polymer everolimus-eluting platinum-chromium stent (EES)
versus the BioMatrix NeoFlex biodegradable-polymer biolimus-eluting
stainless-steel stent (BES). METHOD(S): This randomised, multicentre,
all-comer, non-inferiority trial was undertaken at three sites in Western
Denmark. Patients with a clinical indication for percutaneous coronary
intervention were eligible for inclusion. Patients were randomly assigned
(1:1) to either EES or BES. Outcomes included target lesion failure (TLF:
cardiac death, myocardial infarction not clearly attributable to a
non-target lesion, or target lesion revascularisation), all myocardial
infarctions, and very late stent thrombosis at 5-year follow-up.
 RESULT(S): We included 2,764 patients and randomly assigned 1,385
patients to treatment with EES and 1,379 patients to treatment with BES.
TLF occurred in 150 patients (10.8%) assigned to the EES and in 165
(12.0%) assigned to the BES (rate ratio [RR] 0.88, 95% confidence interval
[CI]: 0.71-1.10). The incidence of myocardial infarction was lower in the
EES group (EES: n=85 [6.1%], BES: n=116 [8.4%]; RR 0.71, 95% CI:
0.54-0.95), while very late stent thrombosis was rare for both stent types
(EES: n=12 [0.9%], BES: n=9 [0.7%]; RR 1.32, 95% CI: 0.56-3.14).
 CONCLUSION(S): At 5-year follow-up, TLF was comparable for EES and
BES. The incidence of myocardial infarction, however, was lower in
patients randomised to EES versus BES implantation. Copyright ©
Europa Group 2025. All rights reserved.

<43>
Accession Number
2038988750
Title
Intravenous methadone for perioperative acute and chronic pain management
in Chinese adult cardiac surgical patients: A protocol for pilot
randomized controlled trial.
Source
PLOS ONE. 20(6 June) (no pagination), 2025. Article Number: e0323820. Date
of Publication: 01 Jun 2025.
Author
Wong H.M.K.; Wong W.T.; Liu X.; Au S.S.W.; Wong R.H.L.
Institution
(Wong, Wong, Liu, Au) Department of Anesthesia and Intensive Care, The
Chinese University of Hong Kong, Hong Kong
(Wong) Division of Cardiothoracic Surgery, Department of Surgery, Prince
of Wales Hospital, Hong Kong
Publisher
Public Library of Science
Abstract
Background Postoperative pain is significant in cardiac surgical patients.
Perioperative analgesia with intermittent administration of opioids can
result in significant fluctuations in serum opioid concentrations.
Methadone should provide a rapid onset and long-term pain relief upon a
single intravenous dose at induction of anesthesia, and may reduce chronic
postsurgical pain (CPSP) in cardiac surgical patients. The feasibility of
using intravenous methadone in Chinese cardiac surgical patients, and its
effect on acute and chronic pain management after cardiac surgery will be
evaluated. Methods A single-center, prospective, randomized-controlled
pilot trial. Adult cardiac surgical patients will be randomized to receive
0.2 mg/kg methadone or morphine at induction of anesthesia.
Patient-controlled analgesia morphine protocol, oral paracetamol and
dihydrocodeine will be given for postoperative analgesia. Venous blood
sampling for plasma methadone concentration will be obtained at regular
intervals from study drug infusion to 96 hours after administration. The
primary outcome will be a description of study feasibility, encompassing
recruitment and retention, protocol adherence and stakeholder
acceptability. Secondary outcomes include the time of ventilator weaning
to spontaneous breathing, time of extubation, morphine requirements within
24 hours and 72 hours after surgery, time to first morphine rescue,
postoperative pain scores, patient satisfaction, and length of stay in ICU
and hospital. Opioid-related side effects including sedation, nausea and
vomiting, and time to first bowel opening will be recorded. CPSP will be
assessed with Neuropathic Pain Scale and Pain Catastrophizing Scale at 3
and 6 months after surgery. Discussion Randomized controlled trials on
intravenous methadone in cardiac surgical patients are scarce, with none
in Chinese populations. This study, supported by plasma methadone
concentration analysis, will establish a basis for future large-scale
research aimed at improving recovery through optimized pain
management. Copyright © 2025 Wong et al.

<44>
Accession Number
2034789279
Title
Single-centre, single-blind, randomized, active-controlled phase-3
non-inferiority study to investigate the safety and efficacy of the
cardioplegic solution CardioplexolTM.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2025. Article
Number: 1587713. Date of Publication: 2025.
Author
Tevaearai Stahel H.T.; Weiss G.; Landowski P.; Folkmann S.; Harrer M.;
Voet B.; Grabenwoger M.
Institution
(Tevaearai Stahel) Cardiovascular Department, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland
(Weiss, Landowski, Folkmann, Harrer, Grabenwoger) Department of
Cardiovascular Surgery, Clinic Floridsdorf, Vienna, Austria
(Weiss, Landowski, Folkmann, Harrer, Grabenwoger) Karl Landsteiner
Institute of Cardiovascular Research, Vienna, Austria
(Voet) Voet Consulting, Berlin, Germany
(Grabenwoger) Medical Faculty, Sigmund Freud Private University, Vienna,
Austria
Publisher
Frontiers Media SA
Abstract
Objectives: Effective and reliable cardioplegic cardiac arrest is crucial
for maximizing myocardial protection and preserving postoperative
contractile function. Aim of this study was to demonstrate, in line with
an ongoing European registration procedure, the efficacy and safety of the
new CardioplexolTM solution. Method(s): Single-centre, single-blind,
randomized, active-controlled phase-3 non-inferiority trial comparing
CardioplexolTM and Buckberg solutions during cardiac surgery. Patients
planed for elective CABG, valve surgery and/or aortic root surgery, were
considered eligible after meeting all inclusion and exclusion criteria.
Peak troponin-T (TnT) during the first 24 h post-reperfusion was defined
as primary endpoint. Intraoperative and ICU-related secondary endpoints
were also evaluated, as were safety endpoints. Result(s): Out of 248
operated patients, 226 (100 CardioplexolTM, 126 Buckberg) were considered
for per-protocol analysis. Peak-TnT was similar in both groups (0.77 vs.
0.78 ng/ml) and non-inferiority of CardioplexolTM was confirmed. Delay
before complete cardiac arrest (11 vs. 71 s, p < 0.001) and cross-clamp
time (51.2 vs. 60.7 min, p < 0.001) were shorter after CardioplexolTM. The
defibrillation rate was also significantly reduced (10% vs. 52%, p <
0.001). Although not statistically significant, cumulative dose of
catecholamines within 24 h postreperfusion (6,202 vs. 7,170 microg/kg, p =
0.07), and ICU stay (38.1 vs. 44.0 h, p = 0.110) also appeared reduced
after CardioplexolTM. Mortality was lower after CardioplexolTM (1 pt. vs.
5 pts.). Safety parameters were comparable in both groups.
 Conclusion(s): Efficacy and safety of CardioplexolTM were
demonstrated. Clinical Trial Registration:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004198-10/resu
lts, Eudra CT-No: 2011-004198-10. Copyright 2025 Tevaearai Stahel,
Weiss, Landowski, Folkmann, Harrer, Voet and Grabenwoger.

<45>
Accession Number
2036583415
Title
Comparison of the Effects of Blood Cardioplegia and Del Nido Cardioplegia
on Postoperative Intensive Care Needs, Drainage, and Renal Functions in
Patients Undergoing Isolated Coronary Artery Bypass.
Source
Brazilian Journal of Cardiovascular Surgery. 40(4) (no pagination), 2025.
Article Number: e20240237. Date of Publication: 2025.
Author
Sarigol Y.; Yildirim S.; Isik M.; Tanyeli O.; Dereli Y.; Ege E.; Gormus N.
Institution
(Sarigol, Yildirim, Isik, Tanyeli, Dereli, Ege, Gormus) Department of
Cardiovascular Surgery, Necmettin Erbakan University, Faculty of Medicine
Hospital, Konya, Turkey
Publisher
Sociedade Brasileira de Cirurgia Cardiovascular
Abstract
Objective: A variety of cardioplegia techniques with different components
are implemented to ensure myocardial protection, in addition to keeping
the operational field immobile and free of blood during cardiac surgery.
The implemented cardioplegia has unwanted negative effects on other end
organs. In this study, our aim was to compare the effects of Del Nido
cardioplegia and blood cardioplegia solutions on postoperative intensive
care duration, drainage, and renal functions for patients undergoing
cardiopulmonary bypass and bypass graft operations. Method(s):
Selections were made from patients undergoing elective bypass graft
operations in our clinic from January 1, 2022 to December 31, 2023.
Patients were randomly selected, retrospectively assessed, and divided
into two groups - Del Nido group (Group 1) and blood cardioplegia group
(Group 2). Comparisons were made between these groups in terms of
intensive care duration, drainage, and renal functions. Result(s):
The study included 120 patients. The Del Nido cardioplegia group included
60 patients, with 60 patients in the blood cardioplegia group. Comparisons
between the groups found that the aortic cross-clamping duration was
significantly high in Group 1 (P = 0.014). The noradrenaline dose given to
Group 1 was high (P = 0.004). In terms of renal injury, significant degree
of elevation was present in Group 1 (P = 0.027). The longer aortic
cross-clamping duration in Group 1 may be assessed as a determinant factor
for noradrenaline dose and acute kidney injury. Conclusion(s): This
study concluded that it will be appropriate to choose the cardioplegia
method by performing broader meta-analysis studies and minimizing limiting
factors. Copyright © 2025, Sociedade Brasileira de Cirurgia
Cardiovascular. All rights reserved.

<46>
Accession Number
2038944941
Title
Maximum extension and regression rate of cutaneous sensory block:
superficial vs. deep parasternal intercostal plane blocks in patients
undergoing open cardiac surgery.
Source
Journal of Clinical Anesthesia. 105 (no pagination), 2025. Article Number:
111888. Date of Publication: 01 Jul 2025.
Author
Dost B.; Turunc E.; Kaya C.; Sahin C.A.; Genc C.; Yucel S.M.; Demirag
M.K.; Karakaya D.
Institution
(Dost, Turunc, Kaya, Sahin, Karakaya) Department of Anesthesiology and
Reanimation, Ondokuz Mayis University, Faculty of Medicine, Samsun, Turkey
(Genc) Department of Anesthesiology and Reanimation, Samsun University,
Faculty of Medicine, Samsun, Turkey
(Yucel, Demirag) Department of Cardiovascular Surgery, Ondokuz Mayis
University, Faculty of Medicine, Kurupelit, Samsun, Turkey
Publisher
Elsevier Inc.
Abstract
Background: Superficial and deep parasternal intercostal plane (S-PIP and
D-PIP, respectively) blocks provide effective analgesia following median
sternotomy; however, data regarding their sensory distribution and
regression patterns are scarce. Therefore, we compared the extent of
sensory blockade 30 min following the administration of the blocks and
evaluated its regression over 24 h. Method(s): Patients who underwent
open cardiac surgery under the S-PIP or D-PIP block were included in this
single-center, prospective study. Sensory assessment using cold
stimulation and dermatomal mapping was conducted 30 min, 12 h, and 24 h
following the administration of the blocks. The primary outcome was the
proportion of the blocked thoracic area at 30 min. Opioid consumption and
pain scores at 12 and 24 h were the secondary outcomes. Result(s):
Thirty patients were included in this study (n = 15 per group). The total
blocked area at 30 min in the S-PIP and D-PIP groups was similar (48.48
+/- 9.50 % vs. 46.51 +/- 10.01 %, p = 0.584). Both blocks provided
consistent coverage of the T2-T6 nerves, with additional involvement of T1
and T7 in some patients. Significant sensory blockade persisted at 12 h
and partially regressed after 24 h. No significant differences were
observed between the groups in terms of postoperative opioid consumption
(10 [5] mg vs. 9 [3] mg, p = 0.121) or pain scores. Conclusion(s):
The S-PIP and D-PIP blocks provided comparable and extensive sensory
coverage of the anterior thorax. Consistent dermatomal involvement between
T2 and T6 was observed, with occasional spread to T1 and T7. Copyright
© 2025 Elsevier Inc.

<47>
Accession Number
2038177480
Title
SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic
valve implantation (COMPARE-TAVI 1): a multicentre, randomised,
non-inferiority trial.
Source
The Lancet. 405(10487) (pp 1362-1372), 2025. Date of Publication: 19 Apr
2025.
Author
Terkelsen C.J.; Freeman P.; Dahl J.S.; Thim T.; Norgaard B.L.; Mogensen
N.S.B.; Tang M.; Eftekhari A.; Povlsen J.A.; Poulsen S.H.; Pedersen L.;
Hjort J.; Ellert J.; Christiansen E.H.; Sorensen H.T.; Nissen H.
Institution
(Terkelsen, Thim, Norgaard, Povlsen, Poulsen, Christiansen) Department of
Cardiology, Aarhus University Hospital, Aarhus, Denmark
(Hjort) Department of Clinical Medicine, Aarhus University Hospital,
Aarhus, Denmark
(Tang) Department of Cardiothoracic and Vascular Surgery, Aarhus
University Hospital, Aarhus, Denmark
(Freeman, Eftekhari) Department of Cardiology, Aalborg University
Hospital, Aalborg, Denmark
(Dahl, Mogensen, Ellert, Nissen) Department of Cardiology, Odense
University Hospital, Odense, Denmark
(Pedersen, Sorensen) Department of Clinical Epidemiology, Aarhus
University Hospital and Aarhus University, Aarhus, Denmark
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is a
guideline-directed treatment for severe aortic stenosis and degenerated
aortic bioprostheses. When new transcatheter heart valve (THV) platforms
for TAVI are launched, they should be compared with best-in-practice
contemporary THVs for their short-term and long-term performance. The
COMPARE-TAVI 1 trial was designed to provide a head-to-head comparison of
the SAPIEN 3 or SAPIEN 3 Ultra THVs and the Myval or Myval Octacor THVs.
 Method(s): This multicentre, all-comers, randomised, non-inferiority
trial was done at three university hospitals in Denmark. Eligible patients
were aged 18 years or older, scheduled for transfemoral TAVI, and eligible
for treatment with SAPIEN 3 THVs or Myval THVs. Patients were randomly
assigned (1:1) to treatment with SAPIEN 3 (29 mm diameter) or SAPIEN 3
Ultra (20 mm, 23 mm, or 26 mm diameter) THVs or Myval or Myval Octacor
THVs (20-32 mm diameter). The TAVI procedure was performed according to
local practice and under local anaesthesia unless leaflet laceration was
performed. The primary endpoint was a composite of death, stroke, moderate
or severe aortic regurgitation, or moderate or severe haemodynamic THV
deterioration at 1 year according to Third Valve Academic Research
Consortium criteria. All patients assigned to THV treatment were included
in the intention-to-treat analysis, and all patients who were treated as
randomly assigned were included in the per-protocol analysis. With an
expected event rate of 13%, the prespecified non-inferiority margin was
5.3%. This trial is registered with ClinicalTrials.gov, NCT04443023, and
is closed to accrual. Finding(s): Between June 15, 2020, and Nov 3,
2023, 1031 patients were enrolled. Enrolment was paused twice because of
patent-related legal proceedings. Of 1031 patients, 517 patients were
randomly assigned to SAPIEN 3 THVs and 514 to Myval THVs. The median
patient age was 81.6 years (IQR 77.6-85.0), and 415 (40%) of 1031 patients
were female and 616 (60%) were male. The primary endpoint occurred in 67
(13%) of 517 patients randomly assigned to SAPIEN 3 THVs versus 71 (14%)
of 514 patients randomly assigned to Myval THVs (risk difference -0.9%
[one-sided upper 95% CI 4.4%]; p<inf>non-inferiority</inf>=0.019).
 Interpretation(s): Myval THVs were non-inferior to SAPIEN 3 THVs in
terms of a 1-year composite endpoint of death, stroke, moderate or severe
aortic regurgitation, or moderate or severe haemodynamic THV
deterioration. Funding(s): Meril Life Sciences, Vingmed Denmark, the
Danish Heart Foundation, and the Central Denmark Region. Copyright
© 2025 Elsevier Ltd

<48>
Accession Number
2039115647
Title
Medication Adherence and Contributing Factors in Patients with Heart
Failure Within the Middle East: A Systematic Review.
Source
Global Heart. 20(1) (no pagination), 2025. Article Number: 47. Date of
Publication: 2025.
Author
Alfaqeeh M.; Abdullah R.; Zakiyah N.; Suwantika A.A.; Postma M.J.;
Rahmawati F.; Widayanti A.W.; Ibrahim B.
Institution
(Alfaqeeh, Zakiyah, Suwantika) Department of Pharmacology and Clinical
Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia
(Abdullah, Rahmawati) Department of Pharmacology and Clinical Pharmacy,
Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
(Zakiyah, Suwantika) Center of Excellence for Pharmaceutical Care
Innovation, Universitas Padjadjaran, Bandung, Indonesia
(Postma) Center for Health Technology Assessment, Universitas Padjadjaran,
Bandung, Indonesia
(Postma) Department of Health Sciences, University Medical Center
Groningen, University of Groningen, Groningen, Netherlands
(Postma) Department of Economics, Econometrics and Finance, Faculty of
Economics and Business, University of Groningen, Groningen, Netherlands
(Widayanti) Department of Pharmaceutics, Faculty of Pharmacy, Universitas
Gadjah Mada, Yogyakarta, Indonesia
(Ibrahim) Department of Clinical Pharmacy and Pharmacy Practices, Faculty
of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia
Publisher
Ubiquity Press
Abstract
Medication adherence among heart failure (HF) patients in the Middle East
remains a critical, under-explored issue. This systematic review examines
medication adherence rates and their influencing factors in this region. A
search of PubMed, Scopus, and Google Scholar identified 12 studies
published between 2013 and 2023, revealing an average non-adherence rate
of 60%. Influential factors include socioeconomic status, education,
psychiatric conditions, and medication-related issues. Significant gaps in
research methodologies and reporting were noted. The review highlights the
impact of socio-economic determinants on adherence and calls for more
robust research and targeted interventions to address these barriers.
Improving patient education and healthcare provider communication are
crucial to enhancing adherence rates. These findings underscore the
importance of addressing regional challenges through tailored approaches
and suggest further studies are needed to develop effective strategies for
improving adherence among HF patients in the Middle East. Copyright
© 2025 Ubiquity Press. All rights reserved.

<49>
Accession Number
2038782589
Title
Study protocol of the multicentre, randomised, triple-blind,
placebo-controlled MERCURI-2 trial: promoting effective renoprotection in
cardiac surgery patients by inhibition of sodium glucose cotransporter
(SGLT)-2.
Source
BMJ Open. 15(5) (no pagination), 2025. Article Number: e095504. Date of
Publication: 16 May 2025.
Author
Oosterom-Eijmael M.; Monteiro De Oliveira N.P.; Niesten E.D.; Tolsma M.;
Snellen F.T.F.; Gerritse B.M.; Scohy T.V.; Rettig T.; Godfried M.B.; Voogd
M.F.; Wink J.; Van Der Werff L.M.M.; Eberl S.; Preckel B.; Hermanides J.;
Van Raalte D.H.; Hulst A.H.
Institution
(Oosterom-Eijmael, Eberl, Preckel, Hermanides, Hulst) Department of
Anesthesiology, Amsterdam University Medical Center, Amsterdam,
Netherlands
(Oosterom-Eijmael, Van Raalte) Department of Endocrinology, Amsterdam
University Medical Center, Amsterdam, Netherlands
(Oosterom-Eijmael, Van Raalte) Amsterdam Cardiovascular Sciences Research
Institute, Amsterdam, Netherlands
(Monteiro De Oliveira, Niesten) Department of Anesthesiology, Medisch
Spectrum Twente, Enschede, Netherlands
(Tolsma, Snellen) Department of Anesthesiology and Intensive Care, Isala
Clinics, Zwolle, Netherlands
(Gerritse, Scohy) Anaesthesiology, Amphia Ziekenhuis, North Brabant,
Breda, Netherlands
(Rettig) Anesthesiology, Intensive Care and Pain Medicine, Amphia Hospital
Site Molengracht, Noord-Brabant, Breda, Netherlands
(Godfried) Department of Anesthesiology, Onze Lieve Vrouwe Gasthuis,
Noord-Holland, Amsterdam, Netherlands
(Voogd) Department of Anesthesiology, Medisch Centrum Leeuwarden,
Leeuwarden, Netherlands
(Wink, Van Der Werff) Department of Anesthesiology, Leiden University
Medical Center, Leiden, Netherlands
Publisher
BMJ Publishing Group
Abstract
Introduction Acute kidney injury (AKI) is a major complication after
cardiac surgery and is associated with postoperative morbidity and
mortality. Currently, no effective therapy exists to reduce the incidence
of postoperative AKI. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
are effective in reducing AKI in outpatient settings for patients with
chronic kidney disease. We hypothesised that perioperative SGLT2
inhibition will also reduce AKI incidence after cardiac surgery according
to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Methods and
analysis We designed a multicentre, randomised, placebo-controlled,
triple-blinded, superiority trial. A total of 784 patients, aged above 18
years, undergoing cardiac surgery will be included with stratification for
sex and type 2 diabetes in a 1:1 ratio. Patients will receive either
dapagliflozin 10 mg or placebo from the day before until 2 days after
surgery. Serum creatinine will be measured preoperatively and daily for
the first 7 days after the operation, and urine output will be measured
until the urinary catheter is removed. The primary outcome is the
incidence of postoperative AKI according to the KDIGO criteria. Ethics and
dissemination The medical ethics committee of the Amsterdam University
Medical Centre (UMC) and the Dutch competent authority approved the study
protocol (currently, version 9, 19 January 2024). This is an
investigator-initiated study. The Amsterdam UMC, as sponsor, retains
ownership of all data and publication rights. After completion of the
trial, results will be disseminated to participants, patient societies and
physicians via a network meeting and digital newsletter. Results will be
submitted for publication in a peer-reviewed international medical journal
and presented on (inter)national congresses. Trial registration number
Clinicaltrials.gov identifier: NCT05590143. Copyright © 2025 BMJ
Publishing Group. All rights reserved.

<50>
Accession Number
645968898
Title
Effectiveness of Virtual Reality Glasses on Surgical Fear and Anxiety in
Patients Before Open-heart Surgery: A Double-blind Randomized Controlled
Trial.
Source
Journal of perianesthesia nursing : official journal of the American
Society of PeriAnesthesia Nurses. 40(3) (pp 682-688), 2025. Date of
Publication: 01 Jun 2025.
Author
Erol Akar T.; Unver S.
Institution
(Erol Akar) Trakya University Hospital, Department of Ophthalmology
Diseases, Edirne, Turkey
(Unver) Trakya University, Faculty of Health Sciences, Department of
Surgical Nursing, Edirne, Turkey
Abstract
PURPOSE: Fear and anxiety in open-heart surgery patients can adversely
affect their physiological well-being and recovery. Although virtual
reality glasses (VR-G) have been advanced for preoperative anxiety
management, their effectiveness specifically for open-heart surgery
patients remains under-researched. This study aims to evaluate the
efficacy of watching a video through VR-G on surgical fear and anxiety
levels of patients undergoing open-heart surgery. DESIGN: A randomized
controlled and double-blind study. METHOD(S): In total, 90 patients
were randomly assigned to the VR-G intervention group or control group. On
the surgery morning, intervention group patients watched a 360-degree
video with nature sounds through VR-G before being transferred to the
operating theater. The surgical fear and anxiety levels of the patients
were evaluated at three stages using the Surgical Fear Questionnaire and
Visual Analog Scale-Anxiety: initial evaluation in the morning, second
evaluation before being transferred, and third evaluation in the waiting
room of the operating theater. FINDINGS: The surgical fear level of the
intervention group at the third evaluation was significantly lower than
the control group (P < .000). There was no significant difference between
the anxiety levels of the study groups (P > .05). CONCLUSION(S):
Watching a 360-degree video with nature sounds through VR-G is an
effective intervention in reducing surgical fear levels of patients before
undergoing open-heart surgery. Use of VR-G interventions may be a
practical and fast-resulting nursing strategy to manage patients' surgical
fear in the preoperative period. REGISTRATION: NCT06165861. Copyright
© 2025 The American Society of PeriAnesthesia Nurses. Published by
Elsevier Inc. All rights reserved.

<51>
Accession Number
2034815839
Title
Prophylactic cardiac denervation to prevent post-operative atrial
fibrillation after coronary artery bypass grafting: a systematic review
and meta-analysis.
Source
Journal of Interventional Cardiac Electrophysiology. (no pagination),
2025. Date of Publication: 2025.
Author
Ali J.; Khan M.H.; Majeed Z.; Elsnhory A.B.; Argueta A.E.S.; Afiridi L.;
Nawaz A.; Abuelazm M.; Khan U.; Aamir M.; Dani S.
Institution
(Ali, Argueta, Afiridi) Department of Medicine, Saint Peter's University
Hospital, New Brunswick, NJ, United States
(Khan) Department of Medicine, Saidu Medical College, Swat, Pakistan
(Majeed) Department of Medicine, King Edward Medical University, Lahore,
Pakistan
(Elsnhory) Emergency Medicine Department, Al-Azhar University, Cairo,
Egypt
(Nawaz) Department of Radiology, Pakistan Atomic Energy Commission
Hospital, Islamabad, Pakistan
(Abuelazm) Faculty of Medicine, Tanta University, Tanta, Egypt
(Khan) Division of Cardiology, University of Maryland School of Medicine,
Baltimore, MD, United States
(Aamir) Department of Cardiology, Lehigh Valley Health Network, Allentown,
PA, United States
(Dani) Department of Cardiology, Lahey Hospital & Medical Center,
Burlington, MA, United States
Publisher
Springer
Abstract
Background: Despite revolutionary advances in the field of percutaneous
coronary intervention (PCI), a significant number of patients with
coronary artery disease (CAD) require coronary artery bypass grafting
(CABG), which is associated with postoperative atrial fibrillation (POAF)
risk. This meta-analysis evaluates the efficacy and safety of prophylactic
cardiac denervation (PCD) during CABG to prevent POAF. Method(s): A
systematic search was conducted across PubMed, CENTRAL, Web of Science,
Scopus, and Embase until December 2024. Pooled data were reported using
risk ratio (RR) for dichotomous outcomes and mean difference (MD) for
continuous outcomes, with a 95% confidence interval (CI). This systematic
review and meta-analysis is registered with PROSPERO ID: CRD42025631310.
 Result(s): Five studies with 1266 patients were included in the final
analysis. Compared to CABG alone, CABG plus PCD did not show any
significant difference in the incidence of POAF (RR 0.77, [95% CI 0.38,
1.56], p = 0.47, I2 = 83%) and all-cause mortality (RR 0.70,
[95% CI 0.19, 2.51], p = 0.58, I2 = 0). Additionally, there was
no significant difference between both groups in cross-clamp time (MD:
0.68, [95% CI - 1.22, 2.57], p = 0.48, I2 = 26%),
cardiopulmonary bypass time (MD - 0.04 [95% CI - 5.29, 5.21], p = 0.99,
I2 = 82%), length of hospital stay (MD - 0.13 [95% CI - 0.55,
0.29], p = 0.54, I2 = 59%), blood loss (MD 2.22, [95% CI -
23.60, 28.03], p = 0.87, I2 = 0%), and number of grafts (MD
0.21, [95% CI - 0.07, 0.49], p = 0.13, I2 = 91%).
 Conclusion(s): CABG with adjuvant PCD did not show significant
efficacy in preventing the incidence of POAF compared to CABG alone. This
calls for further research focusing on investigating combined preventive
strategies, rather than relying solely on PCD, and developing risk
stratification tools to identify patients most likely to benefit from
autonomic modulation. Copyright © The Author(s), under exclusive
licence to Springer Science+Business Media, LLC, part of Springer Nature
2025.

<52>
Accession Number
2038982844
Title
Effect of virtual reality (VR) therapy on pain sensation in patients
undergoing hand surgery under ultrasound-guided regional anesthesia: a
randomized controlled trial.
Source
Regional Anesthesia and Pain Medicine. (no pagination), 2025. Date of
Publication: 2025.
Author
Nijs K.; Treunen T.; Jalil H.; Lensen M.; Wintmolders H.; Keunen B.;
Vanloon M.; Callebaut I.; Geebelen L.; Van de Velde M.; Stessel B.
Institution
(Nijs) Department of Anesthesiology and Pain Medicine, Jessa Hospital
Campus Virga Jesse, Flanders, Hasselt, Belgium
(Nijs, Van de Velde) Department of Cardiovascular Sciences, KU Leuven,
Leuven, Flanders, Belgium
(Treunen, Lensen) Department of Anesthesiology and Pain Medicine, Jessa
Ziekenhuis vwz, Hasselt, Flanders, Belgium
(Treunen, Lensen) Department of Anesthesiology and Pain Medicine, UZ
Leuven, Leuven, Flanders, Belgium
(Jalil, Keunen, Vanloon, Callebaut, Geebelen, Stessel) Anaesthesiology and
Pain Medicine, Jessa Ziekenhuis vwz, Hasselt, Belgium
(Wintmolders) Department of Anaesthesiology and Pain Medicine, Jessa
Ziekenhuis Campus Virga Jesse, Flanders, Hasselt, Belgium
(Callebaut, Stessel) Faculty of Medicine and Life Sciences, UHasselt,
Diepenbeek, Belgium
(Van de Velde) Anesthesiology and Pain Medicine, KU Leuven, Leuven,
Belgium
Publisher
BMJ Publishing Group
Abstract
Background and objectives During ultrasound-guided regional anesthesia and
surgery, patients receive sensory input, which combined with stress and
anxiety, can exacerbate or cause pain. Virtual reality therapy could
provide digital sedation. Our aim is to assess the effect of virtual
reality therapy on pain levels during the placement of regional anesthesia
and surgery. Methods This prospective randomized controlled superiority
trial enrolled 120 patients undergoing elective hand surgery to
investigate the effect of perioperative virtual reality therapy,
consisting of a visual and audible three-dimensional, passive program.
Patients were randomized to virtual reality therapy (n=60) or no virtual
reality therapy (n=60) during regional anesthesia block placement and
surgical procedure. Mean pain score (11-point numerical rating scale)
during ultrasound-guided regional anesthesia placement was the primary
outcome. Secondary outcomes were the mean pain score during surgery, heart
rate variation during ultrasound-guided regional anesthesia placement and
surgery, perioperative opioid use, anxiety (11-point numerical rating
scale where 0=no anxiety at all and 10=extremely anxious), virtual reality
immersion and presence (Igroup Presence Questionnaire), adverse events and
patient satisfaction (11-point numerical rating scale where 0=not
satisfied at all and 10=extremely satisfied). Results Mean pain scores
during ultrasound-guided regional anesthesia placement were 3.9+/-2.4 in
the control group and 3.6+/-2.4 in the virtual reality group, with a mean
difference of -0.3 (95% CI -1.2 to 0.5; p=0.22). Heart rate variation
during ultrasound-guided regional anesthesia placement and surgery was
non-significantly different. Anxiety during ultrasound-guided regional
anesthesia placement showed no significant difference; however, it was
significantly different during surgery (control: 1.5 (0.0, 4.0) vs virtual
reality: 0.0 (0.0, 2.0), p<0.01). Virtual reality immersion showed a total
mean score of 4.2+/-0.9. Seven patients (11.9%) suffered from adverse
virtual reality effects. Patient satisfaction during surgery and
perioperative opioid use showed no significant difference. Satisfaction
with virtual reality was high: 9.0 (8.0, 10.0). Copyright ©
American Society of Regional Anesthesia & Pain Medicine 2025.

<53>
Accession Number
2034792526
Title
Combination of Suture-Plug Vascular Closure Devices Versus Suture-Only
Devices Following Transcatheter Aortic Valve Implantation: A Systematic
Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2025.
Date of Publication: 2025.
Author
Haddad S.; Bashour G.; Mamas M.A.
Institution
(Haddad, Bashour) Faculty of Medicine, Tishreen University, Latakia,
Syrian Arab Republic
(Haddad, Bashour) Cancer Research Center, Tishreen University, Latakia,
Syrian Arab Republic
(Mamas) Keele Cardiovascular Research Group, Keele University, Keele,
United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is an effective
and safe intervention for severe symptomatic aortic stenosis regardless of
surgical risk. Vascular complications following TAVI are considered among
the most common and serious complications, with a higher risk of
mortality. Aim(s): We aimed to perform a systematic review and
meta-analysis to evaluate the safety and efficacy of the combination of
suture-collagen plug vascular closure devices (VCDs) compared with
suture-only devices. Method(s): We have systematically searched the
literature from inception until January 4, 2025, for cohort studies and
clinical trials comparing the combination of suture-collagen plug vascular
closure devices (VCDs) versus suture-only VCDs. Result(s): A total of
2064 patients across six studies were included in the analysis. All
studies compared dual Perclose ProGlide versus 1 Perclose ProGlide + 1
Angio-Seal, except one study that used either one Prostar or dual ProGlide
in the suture group. The combination group of suture-plug VCDs was
associated with a statistically significant reduction of VCDs failure (RR
= 0.14, CI 95% [0.09-0.23], p < 0.0001, I2 = 58.6938%),
bleeding complications (RR = 0.35, CI95% [0.24-0.53], p < 0.0001, (Formula
presented.) 0.0%), major vascular complications (RR = 0.42, CI 95% [0.28,
0.63], p < 0.0001, I2 = 50.4%), and minor vascular
complications (RR = 0.54, CI 95% [0.43, 0.66], p < 0.0001, I2 =
0%). On the other hand, all-cause mortality did not have a statistically
significant difference between the two groups (RR = 0.54, CI 95% [0.28,
1.05], p = 0.0709, I2 = 0%). Conclusion(s): In patients
undergoing TAVI, the combination strategy of suture-plug VCDs is superior
to suture-only devices regarding major and minor vascular complications,
bleeding complications, and VCD failure. The significantly higher VCD
failure of the suture-only group observed in our study led to the use of
additional closure devices to secure hemostasis, raising concerns about a
higher risk of peripheral ischemia. Copyright © 2025 Wiley
Periodicals LLC.

<54>
Accession Number
2034253482
Title
Percutaneous coronary intervention versus coronary artery bypass grafting
for left main disease according to age: A meta-analysis.
Source
Journal of Thoracic and Cardiovascular Surgery. 170(1) (pp 232-243.e21),
2025. Date of Publication: 01 Jul 2025.
Author
De Filippo O.; Di Franco A.; Improta R.; Di Pietro G.; Leone A.; Pecoraro
M.; Meynet P.; Carbone M.L.; Di Lorenzo E.; Bruno F.; Demetres M.; Carmeci
A.; Conrotto F.; Mancone M.; De Ferrari G.M.; Gaudino M.; D'Ascenzo F.
Institution
(De Filippo, Pecoraro, Meynet, Carbone, Bruno, Carmeci, Conrotto, De
Ferrari, D'Ascenzo) Division of Cardiology, Cardiovascular and Thoracic
Department, AOU Citta della Salute e della Scienza di Torino and
Department of Medical Sciences, University of Turin, Turin, Italy
(Di Franco, Gaudino) Department of Cardiothoracic Surgery, Weill Cornell
Medicine, New York, NY, United States
(Improta, Di Pietro, Mancone) Department of Clinical, Internal,
Anesthesiological and Cardiovascular Sciences, Umberto I Hospital, La
Sapienza University of Rome, Rome, Italy
(Leone, Di Lorenzo) Division of Cardiology, SG Moscati Hospital, Avellino,
Italy
(Leone) Department of Advanced Biomedical Sciences, University of Naples
Federico II, Naples, Italy
(Demetres) Samuel J. Wood Library and C.V. Starr Biomedical Information
Center, Weill Cornell Medicine, New York, NY, United States
Publisher
Elsevier Inc.

<55>
Accession Number
2033725662
Title
Comparative outcomes video-assisted thoracic surgery versus open thoracic
surgery in pulmonary echinococcosis: a systematic review and
meta-analysis.
Source
General Thoracic and Cardiovascular Surgery. 73(7) (pp 453-460), 2025.
Date of Publication: 01 Jul 2025.
Author
Salvador I.C.M.C.; da Nobrega Oliveira R.E.N.; de Almeida Silva I.; Torres
L.A.F.; Camarotti M.T.; Passos F.S.; Mariani A.W.
Institution
(Salvador, de Almeida Silva) University Anhembi Morumbi, Street Francisca
Julia, 563, North Zone, SP, Sao Paulo, Brazil
(da Nobrega Oliveira) Department of Thoracic Surgery, Barretos Cancer
Hospital, Barretos, Brazil
(Torres) Hospital Universitario Onofre Lopes, RN, Natal, Brazil
(Camarotti) Pernambuco's Health College, PE, Recife, Brazil
(Passos) Department of Thoracic Surgery, INCAR Hospital, Santo Antonio de
Jesus, Brazil
(Mariani) Faculty of Medicine, Heart Institute, Hospital das Clinicas,
University of Sao Paulo (HCFMUSP), SP, Sao Paulo, Brazil
Publisher
Springer
Abstract
Aim: This meta-analysis aimed to evaluate and compare the outcomes of
video-assisted thoracic surgery (VATS) and open thoracic surgery (OT) in
the management of pulmonary echinococcosis. Method(s): We conducted a
comprehensive search of PubMed, Embase, and Cochrane databases for studies
comparing VATS and OT. Odds ratios (ORs) for binary outcomes and mean
differences (MDs) for continuous variables were calculated with 95%
confidence intervals (CIs) using the DerSimonian and Laird random-effects
model. Heterogeneity was assessed using I2 statistics.
 Result(s): Seven studies involving 2292 patients were included. VATS
demonstrated significant advantages over OT, with reductions in
intraoperative blood loss (MD - 81.65 mL, 95% CI - 129.90 to - 33.40),
duration of thoracic drainage (MD - 2.29 days, 95% CI - 3.61 to - 0.98),
operative time (MD - 45.73 min, 95% CI - 68.41 to - 23.05), narcotic use
(MD -3.98 days, 95% CI - 6.21 to - 1.75), length of hospital stay (MD -
3.66 days, 95% CI - 5.66 to - 1.67), postoperative drainage volume (MD -
124.77 mL, 95% CI - 206.27 to - 43.27), and visual analogic score pain at
24 h after surgery (MD - 2.05 points, 95% CI - 2.40 to - 1.70). However,
VATS was associated with a higher incidence of atelectasis (OR 3.27, 95%
CI 1.03-10.35). No significant differences were observed in other
complications, such as bronchopulmonary fistula, surgical wound infection,
prolonged air leak, or failure of lung expansion. Conclusion(s): VATS
was associated with perioperative benefits, including reduced recovery
times and resource utilization. Nonetheless, the higher risk of
atelectasis suggests OT may remain favorable in complex cases requiring
broader surgical access. Tailoring the surgical approach to the patient's
needs remains crucial. Trial registry: International Prospective Register
of Systematic Reviews; N: CRD42025630187; URL:
https://www.crd.york.ac.uk/prospero/. Copyright © The Author(s),
under exclusive licence to The Japanese Association for Thoracic Surgery
2025.

<56>
Accession Number
2034583145
Title
Chronic total occlusions and coronary artery bypass grafting outcomes.
Source
Journal of Thoracic and Cardiovascular Surgery. 170(1) (pp 216-227.e3),
2025. Date of Publication: 01 Jul 2025.
Author
Gikandi A.; Stock E.M.; Dematt E.; Quin J.; Hirji S.; Biswas K.; Zenati
M.A.
Institution
(Gikandi, Quin, Hirji, Zenati) Division of Cardiac Surgery, Veterans
Affairs (VA) Boston Healthcare System, Harvard Medical School, Boston,
Mass, United States
(Gikandi, Hirji, Zenati) Division of Cardiac Surgery, Brigham and Women's
Hospital, Harvard Medical School, Boston, Mass, United States
(Stock, Dematt, Biswas) VA Cooperative Studies Program Coordinating
Center, Office of Research and Development, U.S. Department of Veterans
Affairs, Perry Point, MD, United States
Publisher
Elsevier Inc.
Abstract
Objective: To investigate the association between the presence and
grafting of chronic total occlusions (CTOs) and coronary artery bypass
grafting (CABG) outcomes. Method(s): This was a post hoc analysis of
the Randomized Endograft vs Open Prospective (REGROUP) trial, which
randomized veterans undergoing isolated on-pump CABG to endoscopic versus
open vein harvest (2014-2017). Patients were stratified on the basis of
the presence of at least 1 CTO vessel (a 100% occluded coronary lesion for
greater than or equal to 3 months) and according to whether all CTO
vessels were bypassed. Rates of major cardiac adverse events (MACE) were
compared. Result(s): At least 1 CTO was present in 453 of 1149
patients (39.4%). Over a median follow-up of 4.7 years (interquartile
range, 3.84-5.45), MACE rates were 23.4% versus 22.2% for the CTO versus
no CTO group, respectively (adjusted hazard ratio [aHR], 0.92; 95%
confidence interval [CI], 0.70-1.20). MACE rates for patients with
complete CTO grafting versus not were 23.1% versus 25.0%, respectively
(aHR, 0.95; 95% CI, 0.57-1.57). In patients with right coronary dominance
undergoing left anterior descending artery grafting, bypassing a right
coronary artery CTO was associated with significantly lower rates of
all-cause mortality (aHR, 0.38; 95% CI, 0.17-0.83). Conclusion(s): In
this REGROUP trial subanalysis, neither CTO presence or complete grafting
of CTO vessels was associated with significantly different rates of MACE.
However, the finding of possible survival benefit among a subgroup of
patients undergoing grafting of a dominant RCA CTO vessel alongside left
anterior descending artery grafting warrants additional
study. Copyright © 2024 The American Association for Thoracic
Surgery

<57>
[Use Link to view the full text]
Accession Number
2038971724
Title
Evaluation of Bioprosthetic Valve Dysfunction in the SMART Randomized
Clinical Trial.
Source
Circulation: Cardiovascular Interventions. (no pagination), 2025. Article
Number: e015202. Date of Publication: 2025.
Author
Herrmann H.C.; Blackman D.J.; Attizzani G.F.; Abdel-Wahab M.; Batchelor
W.B.; Gillam L.D.; Rogers T.; Oh J.K.; Althouse A.D.; Mehran R.; Tchetche
D.
Institution
(Herrmann) Perelman School of Medicine, University of Pennsylvania,
Philadelphia, United States
(Blackman) Leeds Teaching Hospitals, United Kingdom
(Attizzani) Harrington Heart and Vascular Institute, University Hospitals
Cleveland Medical Center, OH, United States
(Abdel-Wahab) Heart Center Leipzig, University of Leipzig, Germany
(Batchelor) Inova Schar Heart and Vascular, Falls Church, VA, United
States
(Gillam) Morristown Medical Center/Atlantic Health System, NJ, United
States
(Rogers) MedStar Washington Hospital Center, DC, United States
(Oh) Echocardiography Core Laboratory, Mayo Clinic, Rochester, MN, United
States
(Althouse) Medtronic, Minneapolis, MN, United States
(Mehran) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Tchetche) Clinique Pasteur, Toulouse, France
Publisher
Lippincott Williams and Wilkins

<58>
Accession Number
2035120994
Title
Late follow-up for a randomized trial of surgical treatment of tricuspid
valve regurgitation in patients undergoing left ventricular assist device
implantation.
Source
Journal of Thoracic and Cardiovascular Surgery. 170(1) (pp 244-253.e3),
2025. Date of Publication: 01 Jul 2025.
Author
Mendiola Pla M.; Russell S.D.; Milano C.A.; Chiang Y.; Kang L.; Poehlein
E.; Green C.L.; Benedetti F.; Billard H.; Bryner B.S.; Schroder J.N.;
Daneshmand M.A.; Nicoara A.; DeVore A.D.; Patel C.B.; Bishawi M.
Institution
(Mendiola Pla, Milano, Kang, Benedetti, Billard, Schroder) Division of
Cardiothoracic Surgery, Duke University Medical Center, Durham, NC, United
States
(Russell, DeVore, Patel) Division of Cardiology, Duke University Medical
Center, Durham, NC, United States
(Chiang) Division of Cardiovascular and Thoracic Surgery, Aurora St Luke's
Medical Center, Milwaukee, Wis, United States
(Poehlein, Green) Department of Biostatistics and Bioinformatics, Duke
University School of Medicine, Durham, NC, United States
(Bryner) Division of Cardiothoracic Surgery, Northwestern University
Feinberg School of Medicine, Chicago, Ill, United States
(Daneshmand, Bishawi) Division of Cardiothoracic Surgery, Emory
University, Atlanta, GA, United States
(Nicoara) Department of Anesthesiology, Duke University Medical Center,
Durham, NC, United States
Publisher
Elsevier Inc.
Abstract
Background: We previously reported that concurrent tricuspid valve surgery
(TVS) was not associated with a lower incidence of early right heart
failure (RHF) in patients undergoing durable left ventricular assist
device (LVAD) implantation. This follow-up analysis aimed to further
define the clinical impact of concurrent TVS after 2 months of follow-up.
 Method(s): Patients with moderate or severe tricuspid regurgitation
(TR) on preoperative echocardiography (n = 71) were randomized to LVAD
implantation either alone (no TVS group; n = 34) or with concurrent TVS
(TVS group; n = 37). Randomization was stratified by preoperative right
ventricular dysfunction. The patients were followed for at least 12 months
after surgery. The incidence of RHF was determined by an adjudication
committee using Interagency Registry for Mechanically Assisted Circulatory
Support criteria. Functional studies and repeat echocardiography were
performed at 12 months. Result(s): Demographics were similar in the 2
study arms. At 12 months, the rate of moderate or severe RHF was 50.0% in
the no TVS arm versus 51.4% in the TVS arm. No patients developed RHF
between 6 and 12 months following the procedure. Death from RHF was 5.4%
in the TVS arm versus 8.8% in the no TVS arm. At 12 months, there was no
significant difference in TR severity between the 2 arms, owing to
improvement in TR severity in the no TVS arm. Cardiopulmonary exercise
testing at 12+ months revealed no significant between-group difference in
peak oxygen consumption. Conclusion(s): In patients with significant
preimplantation TR, the severity of TR improved over time in the no TVS
arm with LVAD implantation alone. By 12 months, there was no significant
difference in TR severity between the 2 arms. This may account for the
lack of difference in late clinical or functional
parameters. Copyright © 2024 The American Association for
Thoracic Surgery

<59>
Accession Number
2038972068
Title
Differential cardiovascular impact of omega-3 fatty acid in patients at
high cardiovascular risk in Asians versus non-Asians: Sub-analysis of the
strength randomized clinical trial.
Source
Atherosclerosis. (no pagination), 2025. Article Number: 120228. Date of
Publication: 2025.
Author
Wang T.K.M.; Nicholls S.J.; St John J.; Wolski K.; Nissen S.E.
Institution
(Wang, St John, Wolski, Nissen) C5 Research, Department of Cardiovascular
Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic,
Cleveland, OH, United States
(Nicholls) Monash Cardiovascular Research Centre, Melbourne, VIC,
Australia
Publisher
Elsevier Ireland Ltd
Abstract
Background/Aims: Racial differences in lipid and cardiovascular risk
profiles are well-established, including for Asians. We compared
cardiovascular treatment effects of omega-3 carboxylic acid (CA) between
Asians and non-Asians in this post-hoc analysis of the STRENGTH trial.
 Method(s): The STRENGTH trial was a double-blinded randomized
controlled trial of 13,078 high cardiovascular risk patients enrolled at
675 global centers. Efficacy and interactions of omega-3 CA for Asians (n
= 1355) and non-Asians (n = 11,723) were assessed. The primary endpoint is
a 5-point composite of cardiovascular death, non-fatal myocardial
infarction, non-fatal stroke, coronary revascularization, and unstable
angina hospitalizations. Result(s): In Asians, omega-3 CA was
associated with significantly reduction in the primary endpoint during 3.6
+/- 0.7 years follow-up with 81/698 (Kaplan-Meier estimate (KME): 14.8 %)
events in the omega-3 CA group, 103/657 (KME: 20.4 %) events in the corn
oil group, hazard ratio (HR) 0.72, 95 %CI 0.54-0.96, p = 0.03. In
non-Asians, there was not a significant difference in primary endpoint
rates, 704/5841 (KME: 15.6 %) events in the omega-3 CA group, 692/5882
(KME: 15.9 %) events in the corn oil group, HR 1.03 95 %CI 0.93-1.14, p =
0.60. There were significant interactions between race (Asian vs
non-Asian) and treatment group for the primary endpoint (p = 0.02) and
non-fatal stroke (p = 0.02). Conclusion(s): In this exploratory
analysis from the neutral STRENGTH trial, omega-3 CA was associated with
significant reduction in the primary endpoint in Asians but not in
non-Asian patients with high cardiovascular risk. Further, ideally
randomized, research is necessary to assess these hypothesis-generating
findings and elucidate potential mechanisms for beneficial effects of
omega-3 CA in Asians. Copyright © 2025 The Authors

<60>
Accession Number
2039067152
Title
The cardiorespiratory fitness gap.
Source
Trends in Cardiovascular Medicine. (no pagination), 2025. Date of
Publication: 2025.
Author
Cifra B.; Hamilton R.M.
Institution
(Cifra, Hamilton) Division of Cardiology, Labatt Family Heart Center The
Hospital for Sick Children and Department of Pediatrics, University of
Toronto, 555 University Ave Rm 1725D Atrium, Toronto, ON, Canada
Publisher
Elsevier Inc.

<61>
Accession Number
2034779321
Title
Efficiency and safety of double-lumen bronchial tube and bronchial blocker
for one-lung ventilation in patients with thoracic surgery: a
meta-analysis.
Source
BMC Anesthesiology. 25(1) (no pagination), 2025. Article Number: 281. Date
of Publication: 01 Dec 2025.
Author
Wu Y.; Liu Y.; Ruan H.; Zhang Z.; Yang J.; Li N.; Wang G.; Wang X.
Institution
(Wu, Liu, Zhang, Yang, Li, Wang) First Hospital of Lanzhou University,
Lanzhou, China
(Wu, Ruan, Wang) Research Institution for "Ren" Doctors, China Medical
University, Shenyang, China
(Liu, Zhang, Yang, Li, Wang) The First School of Clinical Medicine,
Lanzhou University, Lanzhou, China
(Wang) CMU Center for Health Development Research, School of Health
Management, China Medical University, Shenyang, China
Publisher
BioMed Central Ltd
Abstract
Objectives: To compare the efficiency and safety of double-lumen bronchial
tube (DLBT) and bronchial blocker (BB) for one-lung ventilation (OLV) in
patients with thoracic surgery. Method(s): A systematic search was
conducted across Chinese databases and English databases from the
inception of the databases until December 31, 2024. Two researchers
independently screened the literature and extracted data. A meta-analysis
was then performed using Review Manager 5 and Stata 18.0 software. The
quality of the studies was assessed using the Cochrane bias risk
assessment tool, and a summary of findings (SoF) table was generated using
GRADEprofiler Version 3.6.1. Result(s): A total of 39 RCTs were
included, comprising 1360 patients in the BB group and 1349 patients in
the DLBT group. The excellent rate of lung collapse quality in the BB
group was 0.94 times that in the DLBT group [I2 = 32%, P =
0.07, fixed-effects; RR = 0.94; 95% CI (0.90, 0.99); P = 0.01]. There was
no significant difference in intubation time [I2 = 97%, P <
0.00001; SMD = -0.51; 95% CI (-1.17, 0.14); P = 0.12], the success rate of
first-attempt intubation [I2 = 79%, P < 0.00001; RR = 1.04; 95%
CI (0.93, 1.15); P = 0.51] or in the incidence of
malposition[I2 = 50%, P = 0.01; RR = 1.36; 95% CI (0.95, 1.96);
P = 0.10)] between the two groups. However, there was a significant
difference in positioning time, with the BB group showing shorter
positioning times compared to the DLBT group [I2 = 98%, P <
0.00001; SMD = -0.85; 95% CI (-1.50, -0.21); P = 0.004]. Compared to the
DLBT group, the BB group was associated with a reduced incidence of
hoarseness, sore throat, tracheal mucosal injury, hypoxemia, and
pneumonia. Conclusion(s): The DLBT group demonstrated certain
advantages in terms of lung collapse time and quality of lung collapse.
However, BB demonstrate significantly shorter positioning time compared to
DLBT, and it is also associated with lower risks of multiple
complications, including hoarseness, sore throat, tracheal injury,
hypoxemia, and pneumonia, highlighting its safety advantage in
postoperative care. Copyright © The Author(s) 2025.

<62>
Accession Number
2037539974
Title
Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery
Bypass Graft Surgery.
Source
Annals of Thoracic Surgery. 120(1) (pp 167-176), 2025. Date of
Publication: 01 Jul 2025.
Author
Patel S.K.; Badross M.S.; Dhingra N.K.; Moroney M.; Casey J.H.; Ali Hassan
S.M.; Khan T.S.; Hess D.A.; Koschinsky M.L.; Teoh H.; Verma S.
Institution
(Patel, Dhingra, Ali Hassan, Verma) Temerty Faculty of Medicine,
University of Toronto, Toronto, ON, Canada
(Badross) UCD School of Medicine, University College Dublin, Dublin,
Ireland
(Dhingra, Ali Hassan, Teoh, Verma) Division of Cardiac Surgery, St.
Michael's Hospital of Unity Health Toronto, Li Ka Shing Knowledge
Institute, Toronto, ON, Canada
(Dhingra, Ali Hassan, Verma) Department of Surgery, University of Toronto,
Toronto, ON, Canada
(Moroney, Casey) School of Medicine, Royal College of Surgeons in Ireland,
Dublin, Ireland
(Khan) Division of Endocrinology and Metabolism, St. Joseph's Healthcare
Centre, London, ON, Canada
(Khan) Department of Medicine, Western University, London, ON, Canada
(Hess, Koschinsky) Department of Physiology and Pharmacology, Western
University, London, ON, Canada
(Hess, Koschinsky) Robarts Research Institute, London, ON, Canada
(Hess, Verma) Department of Pharmacology and Toxicology, University of
Toronto, Toronto, ON, Canada
(Teoh) Division of Endocrinology and Metabolism, St. Michael's Hospital of
Unity Health Toronto, Li Ka Shing Knowledge Institute, Toronto, ON, Canada
Publisher
Elsevier Inc.
Abstract
Background: Coronary artery bypass grafting (CABG) remains a cornerstone
in the management of coronary artery disease (CAD). In nonurgent surgical
revascularization cases, preoperative optimization of modifiable risk
factors can improve outcomes. There is increasing interest in the
relationship between lipoprotein(a) levels and the risk for ischemic
cardiovascular disease, particularly how CABG outcomes are in turn
affected. This review highlights the role of lipoprotein(a) in the
pathogenesis of CAD and CABG outcomes and discusses future directions for
its optimal management in the perioperative period. Method(s): The
PubMed/MEDLINE database was reviewed until March 2024 to capture
publications that evaluated and/or described the relationship between
lipoprotein(a) and CABG surgery or CAD outcomes. Result(s): The
available literature supports lipoprotein(a) as a causal and independent
risk factor for the pathogenesis of CAD. Elevated lipoprotein(a) levels
are associated with an increased risk of adverse post-CABG outcomes,
including graft occlusion incidence and major adverse cardiovascular
events. Genetic variations influencing lipoprotein(a) levels play a role
in disease progression and surgical outcomes. Several therapies aimed at
reducing lipoprotein(a) levels, currently in phase III clinical trials,
show promise for improving the prognosis after CABG. Conclusion(s):
Among individuals undergoing surgical revascularization for CAD,
lipoprotein(a) levels may help define risk and inform best practices for
perioperative management. We advocate for the routine measurement of
lipoprotein(a) in all patients undergoing CABG. Emerging
lipoprotein(a)-lowering agents show promise for secondary prevention of
cardiac events, although dedicated analyses in cardiac surgical subcohorts
will be important to evaluate their role in improving CABG
outcomes. Copyright © 2025 The Authors

<63>
Accession Number
2037912913
Title
Patient Selection for Surgery vs Surveillance in Moderately Dilated
Ascending Aorta: Insights From Treatment in Thoracic Aortic Aneurysm:
Surgery versus Surveillance (TITAN:SvS), an International Prospective
Trial.
Source
Annals of Thoracic Surgery. 120(1) (pp 25-32), 2025. Date of Publication:
01 Jul 2025.
Author
Makarem A.; Appoo J.J.; Boodhwani M.; Guo M.H.; Brownlee S.; Demers P.;
Patel H.J.; Hughes G.C.; Dagenais F.; Chu M.W.A.; Ouzounian M.; Grau J.B.;
Bozinovski J.; Pozeg Z.; Tseng E.; Atoui R.; Jassar A.S.
Institution
(Makarem, Brownlee, Jassar) Division of Cardiac Surgery, Massachusetts
General Hospital and Harvard Medical School, Boston, MA, United States
(Appoo) Division of Cardiac Surgery, Libin Cardiovascular Institute,
Calgary, AB, Canada
(Boodhwani, Guo) Division of Cardiac Surgery, University of Ottawa Heart
Institute, Ottawa, ON, Canada
(Demers) Division of Cardiac Surgery, University of Montreal, Montreal,
QC, Canada
(Patel) Division of Cardiac Surgery, University of Michigan Health, Ann
Arbor, MI, United States
(Hughes) Division of Cardiac Surgery, Duke University, Durham, NC, United
States
(Dagenais) Division of Cardiac Surgery, Laval University, Quebec City, QC,
Canada
(Chu) Division of Cardiac Surgery, London Health Centre, London, ON,
Canada
(Ouzounian) Division of Cardiac Surgery, Toronto General Hospital,
Toronto, ON, Canada
(Grau) Division of Cardiac Surgery, Valley Health System, Ridgewood, NJ,
United States
(Bozinovski) Division of Cardiac Surgery, Ohio State University Wexner
Medical Center, Columbus, OH, United States
(Pozeg) Division of Cardiac Surgery, New Brunswick Heart Centre, Saint
John, NB, Canada
(Tseng) Division of Cardiac Surgery, University of California at San
Francisco Medical Center, San Francisco, CA, United States
(Atoui) Division of Cardiac Surgery, Health Sciences North, Sudbury, ON,
Canada
Publisher
Elsevier Inc.
Abstract
Background: Guidelines for treating ascending thoracic aortic aneurysms
(ATAA) are largely based on single-center studies. To understand factors
influencing patient selection for surgery vs surveillance, patient and
aneurysm characteristics were compared for patients in the randomized and
registry arms of a large prospective, multicenter, multinational trial.
 Method(s): TITAN:SvS (Treatment in Thoracic Aortic aNeurysm: Surgery
versus Surveillance) is a large prospective multicenter study of patients
with ATAA between 5.0 and 5.4 cm, randomizing patients 1:1 to initial
surgery vs surveillance. Nonrandomized patients are enrolled into a
registry where results of operative or surveillance strategy can be
monitored prospectively. Between 2018 and 2023, 615 patients were enrolled
at 22 sites in the United States and Canada. Demographic and aneurysm
characteristics were compared between randomized and registry arms.
 Result(s): Compared with randomized and operative registry groups,
patients in the surveillance registry were older with more comorbidities.
No significant differences were observed in maximal ascending aortic
diameter (5.1 cm [interquartile range, 5.0-5.2 cm] vs 5.1 cm
[interquartile range, 4.9-5.2 cm] P =.2) or other aneurysm
characteristics. Despite similar numbers of enrolling centers in the
United States (n = 11) and Canada (n = 12), Canadian patients were more
likely to be randomized (58% vs 7%, P <.01) and less likely to be enrolled
in the operative (9% vs 42%, P <.01) or surveillance registry (34% vs
51%). Conclusion(s): Enrollment data for TITAN:SvS suggest that
patient and geographic characteristics, rather than aortic size, influence
decision-making regarding the initial treatment strategy for ATAAs. These
findings highlight the need for caution when generalizing outcomes from
operative registries, because sicker patients may be
excluded. Copyright © 2025 The Authors

<64>
Accession Number
2039049645
Title
The impact of recurrent mitral regurgitation after surgical or
transcatheter mitral valve repair: a comprehensive review and a
meta-analysis.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 40(6) (no
pagination), 2025. Article Number: ivaf109. Date of Publication: 01 Jun
2025.
Author
Yu C.; Rad A.A.; He H.; Yang Y.; Maessen J.G.; Nia P.S.
Institution
(Yu, Rad, He, Yang, Maessen, Nia) Department of Cardiothoracic Surgery,
Maastricht University Medical Centre, Maastricht, Netherlands
(Rad) Medical Sciences Division, University of Oxford, Oxford, United
Kingdom
Publisher
Oxford University Press
Abstract
BACKGROUND: Recurrent mitral regurgitation (MR) is typically defined as MR
that is moderate or severe on follow-up echocardiography after the
intervention. This meta-analysis summarizes the results of all available
studies on the impact of recurrent MR on clinical outcomes after the
intervention. METHOD(S): Medline, EMBASE, PubMed and Web of Science
were searched from January 2000 to August 2024 for original studies
reporting outcomes about the clinical impact of recurrent MR. Five
clinical outcomes were analysed: reoperation, cardiovascular deaths,
readmission, heart failure and New York Heart Association (NYHA)
functional classification. The summary odds ratio (OR) with the 95%
confidence interval (CI) was used to assess the risk of clinical outcomes.
 RESULT(S): A total of 22 studies were included in the final analysis,
involving 5,804 patients, of which 960 had recurrent MR. The overall
pooled incidence of recurrent MR is 16.54%. Secondary or primary patients
with MR with recurrent MR after an intervention had higher rates of
reoperation [(OR = 6.25, 95% CI, 2.95-14.41; P < 0.001) or (OR = 22.54,
95% CI, 14.96-33.98; P < 0.001)]or of cardiovascular death [(OR = 5.26,
95% CI, 2.35-11.77; P < 0.001) or (OR = 1.68, 95% CI, 1.32-2.14; P <
0.001)]. The rates were also high for readmission (OR = 3.95, 95% CI,
2.56-6.10; P < 0.001), heart failure incidence (OR = 2.87, 95% CI,
1.75-5.11; P < 0.001) and the number of NYHA functional class III/IV (OR =
5.40, 95% CI, 3.01-9.70; P < 0.001) for recurrent MR of secondary MR.
However, no significant association was found between recurrent MR of
primary MR and the incidence of NYHA functional class III/IV (OR = 1.02,
95% CI, 0.47-2.22; P = 0.96). CONCLUSION(S): Recurrent MR is
associated with higher rates of reoperations, readmissions, cardiovascular
deaths, incidences of heart failure and NYHA functional class III/IV
numbers. However, recurrent MR of primary MR is not correlated with NYHA
functional class III/IV. Copyright © The Author(s) 2025.
Published by Oxford University Press on behalf of the European Association
for Cardio-Thoracic Surgery.

<65>
Accession Number
2033049036
Title
Comparison of Cryoballoon vs. Pulsed Field Ablation in Patients with
Symptomatic Paroxysmal Atrial Fibrillation (SINGLE SHOT CHAMPION): Study
protocol for a randomized controlled trial.
Source
Heart Rhythm O2. 5(7) (pp 460-467), 2024. Date of Publication: 01 Jul
2024.
Author
Maurhofer J.; Kueffer T.; Knecht S.; Thalmann G.; Badertscher P.;
Kozhuharov N.; Krisai P.; Jufer C.; Iqbal S.U.R.; Heg D.; Servatius H.;
Tanner H.; Kuhne M.; Roten L.; Sticherling C.; Reichlin T.
Institution
(Maurhofer, Kueffer, Thalmann, Kozhuharov, Jufer, Iqbal, Servatius,
Tanner, Roten, Reichlin) Department of Cardiology, Inselspital -
University Hospital Bern, University of Bern, Bern, Switzerland
(Knecht, Badertscher, Krisai, Kuhne, Sticherling) Department of
Cardiology, University Hospital Basel, University of Basel, Basel,
Switzerland
(Heg) Department of Clinical Research, University of Bern, Bern,
Switzerland
Publisher
Elsevier B.V.
Abstract
Background: Single-shot devices are increasingly used for pulmonary vein
isolation (PVI) in atrial fibrillation (AF). The Arctic Front cryoballoon
is the most frequently used single-shot technology. A recently developed
novel pulsed field ablation (PFA) device (FARAPULSE) has been introduced
with the aim to improve procedural safety and efficacy. Objective(s):
This study will compare the novel FARAPULSE PFA device and the Arctic
Front cryoballoon for first PVI in patients with symptomatic paroxysmal
AF. Method(s): SINGLE SHOT CHAMPION is a multicenter, randomized
controlled trial with blinded endpoint adjudication by an independent
clinical events committee. Overall, 210 patients with paroxysmal AF
undergoing their PVI are randomized 1:1 between PFA and cryoballoon
ablation. Continuous rhythm monitoring with an implantable cardiac monitor
is performed in all patients. Result(s): The primary endpoint is time
to first recurrence of any atrial tachyarrhythmia (AF and/or organized
atrial tachyarrhythmia) lasting >=120 seconds and identified by the
implantable cardiac monitor within 91 and 365 days postablation. The
composite procedural safety endpoint includes cardiac tamponade requiring
drainage, persistent phrenic nerve palsy, vascular complications requiring
intervention, stroke/transient ischemic attack, atrioesophageal fistula,
and death occurring during or up to 30 days after the procedure. Key
secondary endpoints include (1) increase in high-sensitivity troponin on
day 1 postablation, (2) analysis of postablation 3-dimensional
electroanatomic mapping (first 25 patients per study group), (3) AF
burden, and (4) quality-of-life changes. Conclusion(s): SINGLE SHOT
CHAMPION will evaluate the efficacy and safety of PVI using the novel
FARAPULSE PFA for patients with symptomatic paroxysmal AF. Copyright
© 2024 Heart Rhythm Society

<66>
Accession Number
647645918
Title
The Effect of Breathing Exercise With Incentive Spirometer on Pain,
Anxiety, Comfort, and Physiological Parameters Before and After Cardiac
Surgery: A Randomized Controlled Experimental Study.
Source
Journal of perianesthesia nursing : official journal of the American
Society of PeriAnesthesia Nurses. (no pagination), 2025. Date of
Publication: 09 Jun 2025.
Author
Ciftci H.; Korkut S.; Karaca S.
Institution
(Ciftci) Cardiac Surgery Operating Room, Health Sciences University Adana
City Training and Research Hospital, Adana, Turkey
(Korkut) Department of Nursing, Faculty of Health Sciences, Erciyes
University, Kayseri, Turkey
(Karaca) Cardiovascular Surgery Department, Adana City Training and
Research Hospital, Adana, Turkey
Abstract
PURPOSE: This study was conducted to investigate the effect of breathing
exercise with incentive spirometer on pain, anxiety, comfort, and
physiological parameters in cardiac surgery patients before and after
surgery. DESIGN: The research was conducted as a single-center,
prospective, randomized controlled experimental study. METHOD(S):
Patients in the intervention I group had breathing exercises performed, in
addition to the routine practices of the clinic for 5 days after surgery.
Patients in intervention II group had breathing exercises in addition to
routine practices for 5 days before surgery and 5 days after surgery. In
the control group, only the routine practice of the clinic was performed.
FINDINGS: On postoperative days 1 and 5, the pain and anxiety levels of
the intervention I and II groups were significantly lower, and the comfort
level was significantly higher than the control group. On the post-op
first day, partial oxygen pressure values of the patients in the
intervention II group were significantly higher than the others. The heart
rate of the individuals in the intervention I group on the first post-op
day was significantly lower than the other two groups. Post-op days 1 and
5, SaO2 values were significantly higher in the intervention groups
compared with the control group. CONCLUSION(S): Breathing exercises
performed with incentive spirometer before and after the operation
decreased the pain and anxiety levels of the patients and increased their
comfort. However, it was determined that this application did not create a
significant difference in vital signs (except heart rate), pulmonary
function test values (except SaO2), and arterial blood gas values (except
partial oxygen pressure). Copyright © 2025 The American Society
of PeriAnesthesia Nurses. Published by Elsevier Inc. All rights reserved.

<67>
Accession Number
2034975667
Title
Cardiovascular Outcomes of Perioperative Sodium-Glucose Transporter 2
Inhibition in Cardiac Surgery Patients: An Open-Label Randomized Pilot
Study.
Source
Acta Anaesthesiologica Scandinavica. 69(6) (no pagination), 2025. Article
Number: e70075. Date of Publication: 01 Jul 2025.
Author
Snel L.I.P.; Oosterom-Eijmael M.J.P.; Lankadeva Y.R.; Plummer M.P.;
Preckel B.; Zuurbier C.J.; Hermanides J.; van Raalte D.H.; Hulst A.H.
Institution
(Snel, Oosterom-Eijmael, Preckel, Hermanides, Hulst) Department of
Anesthesiology, Amsterdam University Medical Center, Amsterdam,
Netherlands
(Snel, Oosterom-Eijmael, van Raalte) Department of Endocrinology,
Amsterdam University Medical Center, Amsterdam, Netherlands
(Snel, Oosterom-Eijmael, van Raalte, Hulst) Amsterdam Cardiovascular
Sciences Research Institute, Amsterdam, Netherlands
(Oosterom-Eijmael, Hulst) Amsterdam Gastroenterology Endocrinology
Metabolism Research Institute, Amsterdam, Netherlands
(Lankadeva) Preclinical Critical Care Unit, Florey Institute of
Neuroscience and Mental Health, The University of Melbourne, Melbourne,
VIC, Australia
(Lankadeva) Department of Critical Care, Melbourne Medical School, The
University of Melbourne, Melbourne, VIC, Australia
(Lankadeva) Department of Anesthesia, Austin Health, Melbourne, VIC,
Australia
(Plummer) Intensive Care Unit, Royal Adelaide Hospital, Adelaide, SA,
Australia
(Plummer) School of Medicine, University of Adelaide, Adelaide, SA,
Australia
(Preckel, Hermanides) Amsterdam Public Health Research Institute, Quality
of Care, Amsterdam, Netherlands
(Zuurbier) Laboratory of Experimental Intensive Care and Anesthesiology,
Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Publisher
John Wiley and Sons Inc
Abstract
Background: Previous studies have shown cardiovascular benefits of SGLT2
inhibitors. The aim of this study was to evaluate the cardiovascular
effects of perioperative SGLT2 inhibition in patients undergoing cardiac
surgery. Method(s): In this open-label pilot study, adult patients
undergoing cardiac surgery were randomized to receive a daily dose of
empagliflozin (10 mg; oral) 3 days before surgery until 2 days after
surgery, or standard of care. Blood pressure, heart rate, postoperative
diuresis, intravenous fluid administration, fluid balance, and vasoactive
support were compared between groups during the first 24 postoperative
hours. Result(s): About 55 patients (sex: 73% male, age: 66 +/- 10
years, BMI: 28 +/- 4 kg/m2, empagliflozin n = 25, control n =
30) were included in this study and analyzed according to the
intention-to-treat principle. Empagliflozin was associated with increased
diuresis, mean difference 549 mL (95% CI 258-839, p < 0.001), and less
positive fluid balance postoperatively, mean difference -1217 mL (95% CI
-2373- -61, p = 0.039). Empagliflozin did not increase the amount of
intravenous fluid administered. In the empagliflozin group, norepinephrine
was infused for 11.8 +/- 11.5 h compared to 19.3 +/- 19.3 h in the control
group (p = 0.080). No significant between-group differences were observed
in postoperative blood pressure and heart rate. Conclusion(s):
Perioperative SGLT2 inhibition was associated with increased diuresis and
lesser fluid accumulation without an increase in vasopressor requirement.
These data warrant validation and further evaluation in a larger-scale,
double-blind, placebo-controlled trial. Editorial Comment: In this
sub-study of the randomized MERCURI-2 trial of perioperative empagliflozin
for nondiabetics in cardiac surgery, the authors describe the hemodynamic
outcomes and fluid status of the patients. The authors noted a higher
urine output and a more negative fluid balance in the intervention group
compared to the placebo group. An interesting observation is the trend
towards lower noradrenaline usage, although this cannot be concluded with
confidence based on this data. The findings support considering and
further studying the use of these medications for patients with
cardiovascular disease undergoing surgery. Trial Registration:
https://onderzoekmetmensen.nl/en/trial/26563 Identifier:
NL9561. Copyright © 2025 The Author(s). Acta Anaesthesiologica
Scandinavica published by John Wiley & Sons Ltd on behalf of Acta
Anaesthesiologica Scandinavica Foundation.

<68>
Accession Number
2036693173
Title
Transcutaneous Electrical Acupoint Stimulation (TEAS) Facilitates
Postoperative Recovery in Day Lung Cancer Surgery: A Randomized Controlled
Trial.
Source
Journal of Pain Research. 18 (pp 3017-3026), 2025. Date of Publication:
2025.
Author
Wu S.; Lou J.; Zou H.; Wang W.; Zhang Y.; Xu Y.; Hou X.; Wu J.
Institution
(Wu, Wang, Zhang, Wu) Department of Anesthesiology, Shanghai Chest
Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai,
China
(Lou, Hou) President's Office, Shanghai Chest Hospital, Shanghai Jiao Tong
University, School of Medicine, Shanghai, China
(Zou) Department of Science and Education, Shanghai Chest Hospital,
Shanghai Jiao Tong University School of Medicine, Shanghai, China
(Xu) Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital,
Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Publisher
Dove Medical Press Ltd
Abstract
Background: Day thoracic surgery requires effective analgesia and a rapid
recovery. This study evaluated whether Transcutaneous Electrical Acupoint
Stimulation (TEAS) reduces postoperative pain and analgesic use in lung
cancer surgery. Method(s): In this randomized, sham-controlled trial
at a tertiary hospital in Shanghai, 100 patients (18-70 years old, ASA
I-II) who underwent day lung cancer surgery (video-assisted thoracoscopic
pulmonary wedge resection) were enrolled. Participants were randomized to
receive either TEAS or sham TEAS in the Post-Anesthesia Care Unit. The
TEAS group received 30 minutes of stimulation at Hegu (LI4) and Neiguan
(PC6), whereas the sham group received electrode placement without
stimulation. Primary outcome was pain intensity 24 h after surgery,
measured using the visual analog scale (VAS). Secondary outcomes were VAS
scores at 1 h and 12 h post-surgery, analgesic consumption, incidence of
moderate-to-severe pain (VAS score >4), incidence of postoperative nausea
and vomiting (PONV), Quality of Recovery (QoR-15) scores, and safety
events. Result(s): The TEAS group had significantly lower VAS scores
at 1 hour (0.94 vs 1.84, p = 0.006), 12 hours (2.00 vs 5.40, p < 0.001),
and 24 hours (1.72 vs 4.02, p < 0.001). The incidence of
moderate-to-severe pain within 12 hours was reduced (12.0% vs 74.0%, p <
0.001). Analgesic consumption was lower in the TEAS group. The QoR-15
scores at 24 h were higher in the TEAS group (130.8 vs 115.9, p < 0.001).
No significant differences were observed in PONV, length of hospital stay,
or adverse events. Conclusion(s): TEAS reduces postoperative pain and
analgesic use, improves the recovery quality in lung cancer surgery, and
supports its integration into ERAS protocols. Trial Registration:
ChiCTR2200066600.
https://www.chictr.org.cn/showproj.html?proj=187035. Copyright ©
2025 Wu et al.

<69>
[Use Link to view the full text]
Accession Number
2039191018
Title
Comparison of TAVR with SAVR on clinical outcomes in patients with aortic
stenosis: A systematic review and meta-analysis.
Source
Annals of Medicine and Surgery. (no pagination), 2025. Date of
Publication: 2025.
Author
Khan K.G.; Garcia I.; Rodriguez A.; Wright W.; Shahid H.; Alrashed A.;
Pornchai A.; Manoj M.P.; Fagbamila O.; Mylavarapu M.
Institution
(Khan) Department of Internal Medicine, Baqai Medical University, Karachi,
Pakistan
(Garcia) Department of Internal Medicine, St. George's University, Grenada
(Rodriguez) Department of Internal Medicine, Universidad de Los Andes,
Merida, Venezuela
(Wright) Department of Internal Medicine, Texila American University,
Georgetown, Guyana
(Shahid) Department of Internal Medicine, Bahcesehir University, Istanbul,
Turkey
(Alrashed) Department of Internal Medicine, Imperial College London,
London, United Kingdom
(Pornchai) Department of Internal Medicine, University of Pittsburg
Medical Center, PA, United States
(Manoj) Department of General Medicine, Government Medical College,
Kerala, India
(Fagbamila) Saint James School of Medicine, Arnos Vale, Saint Vincent and
the Grenadines
(Mylavarapu) Department of Public Health, Adelphi University, NY, United
States
Publisher
Lippincott Williams and Wilkins
Abstract
Introduction: The advances and studies carried out in the area have shown
that patients with aortic stenosis (AS) undergoing surgical valve
replacement (SAVR) did not have encouraging outcomes. This study aims to
compare the different risk factors in patients with AS undergoing
transcatheter aortic valve replacement (TAVR) vs. SAVR, respectively, to
offer options and more favorable results based on the results obtained in
patients with these conditions. Method(s): The study was in
accordance with the PRISMA guidelines. Studies comparing outcomes of
surgical and transaortic catheter valve replacements in adults were
included. Descriptive statistics, binary random effects, and continuous
random effects were used. I2 statistics were used to assess for
heterogeneity. A P-value <=0.05 was considered statistically significant.
 Result(s): In total, eight studies with 18 671 patients were included
in our study. All-cause mortality (2.48% vs. 3.03%), major bleeding
(11.25% vs. 31.05%), and atrial fibrillation (2.39% vs. 50.42%) were lower
in TAVR compared to SAVR. Furthermore, odds of all-cause mortality (odds
ratio [OR]: 0.79; 95% CI: 0.63-1.00; P = 0.05), stroke (OR: 0.71; 95% CI:
0.58-0.87; P = 0.0008), and acute kidney injury (AKI) (OR: 0.38; 95% CI:
0.29-0.49; P < 0.00001) were lower in the TAVR group compared to the SAVR
group. Conclusion(s): TAVR is superior to SAVR and significantly
reduces the risks associated with all-cause mortality, stroke, AKI, and
other clinical outcomes. Furthermore, additional research is regarding the
long-term effects of transcatheter aortic valve replacement. Copyright
© 2025 The Authors.

<70>
Accession Number
647645303
Title
Transcatheter Aortic Valve Replacement for Patients with Moderate Aortic
Stenosis - a Propensity Matched Analysis: TAVR vs clinical surveillance
for moderate AS.
Source
The American journal of cardiology. (no pagination), 2025. Date of
Publication: 06 Jun 2025.
Author
Adrichem R.; Yang C.; Geleijnse M.L.; van den Dorpel M.M.P.; Cummins P.A.;
Kardys I.; Daemen J.; Nuis R.-J.; Van Mieghem N.M.
Institution
(Adrichem, Yang, Geleijnse, van den Dorpel, Cummins, Kardys, Daemen, Nuis)
Department of cardiology, Thoraxcenter, Cardiovascular Institute, Erasmus
University Medical Center, Rotterdam, Netherlands
(Van Mieghem) Department of cardiology, Thoraxcenter, Cardiovascular
Institute, Erasmus University Medical Center, Rotterdam, Netherlands
Abstract
Moderate aortic stenosis (AS) has been linked to impaired long-term
survival. Whether transcatheter aortic valve replacement (TAVR) may
improve clinical outcome of moderate AS is unknown. We aimed to
investigate the potential clinical benefits of TAVR for patients with
moderate AS irrespective of LVEF. We used univariable and multivariable
Cox regression models to find predictors for mortality and a composite of
mortality and heart failure hospitalizations. We also performed a
propensity score-matched comparison of outcomes between patients with
moderate AS who underwent TAVR, and those with clinical surveillance with
surgical aortic valve replacement or TAVR only upon progression to severe
AS. We identified 115 patients with moderate AS who underwent TAVR and 220
patients with moderate AS who underwent clinical surveillance. TAVR
patients were older, had more comorbidities and were more symptomatic than
the clinical surveillance patients. TAVR was associated with lower
all-cause mortality (multivariable adjusted HR: 0.51, 95%CI: 0.35-0.76)
and reduced incidence of the composite endpoint of all-cause mortality and
heart failure hospitalizations (adjusted HR: 0.53, 95%CI: 0.36-0.77).
These results were reinforced in our propensity score matched analysis
(unadjusted matched HR: 0.50, 95% CI: 0.33-0.75). In conclusion, TAVR may
improve clinical outcome in patients with moderate AS. Our findings
justify randomized controlled trials that evaluate TAVR in patients with
moderate AS. Copyright © 2025. Published by Elsevier Inc.

<71>
Accession Number
2034984279
Title
Outcomes of heart surgery in neonates with trisomy 13 and 18: a systematic
review with metanalysis.
Source
European Journal of Pediatrics. 184(7) (no pagination), 2025. Article
Number: 430. Date of Publication: 01 Jul 2025.
Author
de Sa Bittencourt Camara Bastos C.; Vale da Cruz L.; Hirano Arruda Moraes
L.; Jornada Krebs V.L.; de Carvalho W.B.
Institution
(de Sa Bittencourt Camara Bastos, Vale da Cruz, Jornada Krebs, de
Carvalho) Department of Pediatrics, Faculty of Medicine of the University
of Sao Paulo, Instituto da Crianca e do Adolescente do Hospital das
Clinicas, Av. Dr. Eneas de Carvalho Aguiar, 647, Sao Paulo, Sao Paulo,
Brazil
(Hirano Arruda Moraes) Neonatal Section, Pediatric Division, University
Hospital of the University of Sao Paulo, Sao Paulo, Brazil
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
This systematic review and meta-analysis aimed to evaluate the clinical
outcomes of cardiac surgery in neonates with trisomy 13 (T13) or trisomy
18 (T18) compared to those managed with palliative care. A literature
search was conducted in PubMed and EMBASE, following PRISMA guidelines,
and included five retrospective cohort studies (1627 patients). Outcomes
analyzed included in-hospital mortality, survival at 12 months, length of
stay (LOS), hospital discharge rates, and the need for mechanical
ventilation. The meta-analysis showed that cardiac surgery significantly
reduced the odds of in-hospital mortality (OR 0.12, CI 95% 0.03-0.42, p <
0.01), increased survival at 12 months (OR 19.77, CI 95% 5.12-76.36, p <
0.01), and improved discharge rates (OR 12.53, CI 95% 3.63-43.22, p <
0.01). However, limited data were available on quality of life and
mechanical ventilation duration. Conclusion(s): Despite the positive
impact of cardiac surgery on survival and discharge rates, the evidence
remains low quality, as the included studies were primarily retrospective
cohorts with moderate risk of bias. The findings highlight the importance
of involving families in the decision-making process, given their
differing perspectives on quality of life. Further high-quality studies,
such as randomized controlled trials, are needed to provide stronger
evidence on this topic. Copyright © The Author(s), under
exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature
2025.

<72>
Accession Number
2039205871
Title
Randomized Trials in Cardiac Surgery: Why and How.
Source
European Journal of Cardio-thoracic Surgery. 67(6) (no pagination), 2025.
Article Number: ezaf164. Date of Publication: 01 Jun 2025.
Author
Gaudino M.; Siepe M.; Murphy G.J.; Williams B.; Sandner S.; Gregg A.C.;
Moskowitz A.J.; Falk V.; Gelijns A.C.
Institution
(Gaudino, Gregg) Department of Cardiothoracic Surgery, Weill Cornell
Medicine, New York, NY, United States
(Siepe, Falk) Department of Cardiac Surgery, University of Bern,
University Hospital Bern, Bern, Switzerland
(Murphy) Department of Cardiovascular Sciences, NIHR Leicester Biomedical
Research Unit in Cardiovascular Medicine, University of Leicester,
Leicester, United Kingdom
(Williams) On Behalf of the Global Cardiovascular Research Funders Forum
(Sandner) Department of Cardiac Surgery, Medical University of Vienna,
Vienna, Austria
(Moskowitz, Gelijns) Department of Population Health Science and Policy,
Icahn School of Medicine at Mount Sinai, New York, NY, United States
(Falk) Deutsches Zentrum fur Herz-Kreislauf-Forschung (DZHK), Partner Site
Berlin, Berlin, Germany
(Falk) Department of Health Sciences and Technology, Eidgenossische
Technische Hochschule Zurich, Zurich, Switzerland
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES Randomized clinical trials (RCTs) are the gold standard for
comparative effectiveness. However, they face unique challenges in cardiac
surgery. The objective of this work is to summarize the challenges of RCTs
in cardiac surgery, describe efforts employed in recent years to mitigate
these impediments and outline the future opportunities for increased RCT
adoption in the specialty. METHODS This review was conducted as an expert
analysis on the existing state of RCTs in cardiac surgery based on expert
discussion at a dedicated session during the 2024 Annual Meeting of the
European Association for Cardio-Thoracic Surgery (EACTS). Different
trial-support infrastructures, such as the Randomized Comparison of the
Clinical Outcomes of Single versus Multiple Arterial Grafts (ROMA)
Network, the Cardiothoracic Surgical Trials Network (CTSN), the Global
Cardiovascular Research Funders Forum (GCRFF) and the UK Model, and their
respective mechanisms for overcoming RCT barriers were described in
detailed. Models were selected due to specific author involvement and
knowledge. Future directions were postulated based on current trends.
RESULTS Despite heterogeneous structures, the described models largely
aimed to increased cardiac RCTs through improved trial participation,
either via increased trainees, expanded stakeholders or focused patient
recruitment, facilitating funding and fostering wider collaboration.
CONCLUSIONS RCTs are a key component for clinical advancement yet have
been underutilized in cardiac surgery. Recent endeavours have reduced the
multifactorial barriers associated with cardiac surgery RCTs and
intentional future efforts are necessary for continued cardiac
advancement. Copyright © 2025 The Author(s). Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved. For commercial re-use, please contact
reprints@oup.com for reprints and translation rights for reprints. All
other permissions can be obtained through our RightsLink service via the
Permissions link on the article page on our site - for further information
please contact journals.permissions@oup.com.

<73>
Accession Number
647642849
Title
Time to rethink the prioritization of IABP patients in heart allocation
systems worldwide?.
Source
The Journal of heart and lung transplantation : the official publication
of the International Society for Heart Transplantation. (no pagination),
2025. Date of Publication: 06 Jun 2025.
Author
Delmas C.; Vandenbriele C.; Baudry G.
Institution
(Delmas) Intensive Cardiac Care Unit, University Hospital of Toulouse,
Toulouse, France; Universite Paul Sabatier - Toulouse III, Toulouse,
France; Recherche et Enseignement en Insuffisance Cardiaque Avancee,
Transplantation et Assistance (REICATRA), Institut Saint Jacques,
Toulouse, France
(Vandenbriele) Heart Center Aalst, Aalst, Belgium; Adult Intensive Care,
Royal Brompton and Harefield Hospitals, Guy's & St Thomas' NHS Foundation
Trust, London, UK; Department of Surgery and Cancer, Faculty of medicine,
Imperial College London, UK
(Baudry) Recherche et Enseignement en Insuffisance Cardiaque Avancee,
Transplantation et Assistance (REICATRA), Institut Saint Jacques,
Toulouse, France; Universite de Lorraine, INSERM, Centre d'Investigation
Clinique Plurithematique 1433, Inserm U1116, CHRU de Nancy and F-CRIN,
INI-CRCT, Nancy, France
Abstract
The intra-aortic balloon pump (IABP) remains widely used in clinical
practice despite increasing evidence questioning its efficacy and safety.
Designed as a simple temporary mechanical circulatory support device, IABP
might offer benefits such as afterload reduction, cardiac output
enhancement, and coronary perfusion improvement. However, large randomized
controlled trials such as IABP-SHOCK II and CRISP MI have failed to
demonstrate a survival benefit in acute myocardial infarction related
cardiogenic shock. The ALTSHOCK2 study recently failed to show a clinical
advantage of IABP-therapy in patients with heart failure-related
cardiogenic shock. The use of IABP as a bridge to transplantation is
particularly common in countries where national allocation systems
prioritize patients on IABP support. The results of the recent
ALTSHOCK2-trial question the justification for its continued inclusion in
prioritization models. Hence, we examine the physiological effects of
IABP, its application in shock states and low cardiac-output syndrome, and
its role in transplantation allocation policies worldwide. In line with
the present data, we call for a reevaluation of its role in clinical
practice and transplant allocation to align with strong clinical
evidence. Copyright © 2025. Published by Elsevier Inc.

<74>
Accession Number
2034981588
Title
Tirzepatide for reduction of morbidity and mortality in adults with
obesity: rationale and design of the SURMOUNT-MMO trial.
Source
Obesity. (no pagination), 2025. Date of Publication: 2025.
Author
Lam C.S.P.; Rodriguez A.; Aminian A.; Ferrannini E.; Heerspink H.J.L.;
Jastreboff A.M.; Laffin L.J.; Pandey A.; Ray K.K.; Ridker P.M.; Sanyal
A.J.; Yki-Jarvinen H.; Mason D.; Strzelecki M.; Bartee A.K.; Cui C.; Hurt
K.; Linetzky B.; Bunck M.C.; Nissen S.E.
Institution
(Lam) Cardiovascular and Metabolic Disorders Programme, Duke-National
University of Singapore Medical School, Singapore, Singapore
(Lam) National Heart Centre Singapore, Singapore, Singapore
(Rodriguez, Bartee, Cui, Hurt, Linetzky, Bunck) Eli Lilly and Company,
Indianapolis, IN, United States
(Aminian) Bariatric and Metabolic Institute, Department of General
Surgery, Cleveland Clinic, Cleveland, OH, United States
(Ferrannini) Endocrinology and Metabolic Diseases, CNR Institute of
Clinical Physiology, Pisa, Italy
(Heerspink) Department of Clinical Pharmacy and Pharmacology, University
of Groningen, University Medical Center Groningen, Groningen, Netherlands
(Heerspink) The George Institute for Global Health, Sydney, NSW, Australia
(Jastreboff) Department of Medicine (Endocrinology and Metabolism) and
Pediatrics (Pediatric Endocrinology), Yale University School of Medicine,
New Haven, CT, United States
(Laffin) Section of Preventive Cardiology and Rehabilitation, Department
of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH,
United States
(Pandey) Division of Cardiology, Department of Internal Medicine,
University of Texas Southwestern Medical Center, Dallas, TX, United States
(Ray) Department of Primary Care and Public Health, Imperial College
London, London, United Kingdom
(Ridker) Divisions of Cardiovascular Medicine and Preventive Medicine,
Brigham & Women's Hospital, Harvard Medical School, Boston, MA, United
States
(Sanyal) Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
and Division of Gastroenterology, Hepatology and Nutrition, Virginia
Commonwealth University School of Medicine, Richmond, VA, United States
(Yki-Jarvinen) Department of Medicine, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland
(Yki-Jarvinen) Minerva Foundation Institute for Medical Research,
Helsinki, Finland
(Mason, Strzelecki) Cleveland Clinic Coordinating Center for Clinical
Research, Cleveland, OH, United States
(Nissen) Cleveland Clinic Coordinating Center for Clinical Research,
Cardiology/Clinical Trials, Cleveland, OH, United States
Publisher
John Wiley and Sons Inc
Abstract
Objective: Obesity is a major cause of morbidity and mortality worldwide.
Tirzepatide is a glucose-dependent insulinotropic polypeptide receptor and
glucagon-like peptide-1 receptor agonist providing substantial weight
reduction and metabolic benefits both in type 2 diabetes and obesity. We
hypothesized that tirzepatide can improve morbidity and mortality in
adults with obesity or overweight but without diabetes. Method(s):
SURMOUNT-MMO is a randomized, double-blind, event-driven trial to
investigate the impact on morbidity and mortality with once-weekly
tirzepatide compared with placebo in adults living with obesity, without
diabetes, and with, or at risk of, cardiovascular disease. The primary
endpoint is time to first occurrence of a five-component composite outcome
of nonfatal myocardial infarction, nonfatal stroke, coronary
revascularization, heart failure events, or death from any cause.
 Result(s): The trial will enroll ~15,000 participants aged >=40 from
664 sites across 27 countries with BMI >=27.0 kg/m2 and either
established cardiovascular disease or multiple cardiovascular risk
factors. Conclusion(s): SURMOUNT-MMO will provide evidence of the
clinical benefits of tirzepatide on multiple outcomes among individuals
with overweight or obesity but without diabetes. This is the first outcome
trial of an incretin medication that assesses both primary and secondary
cardiovascular disease prevention. Copyright © 2025 The Obesity
Society.

<75>
Accession Number
647644737
Title
IN-HOSPITAL OUTCOMES AFTER EMERGENCY OR PROPHYLACTIC VENOARTERIAL
EXTRACORPOREAL MEMBRANE OXYGENATION DURING TRANSCATHETER AORTIC VALVE
IMPLANTATION: A COMPREHENSIVE REVIEW OF THE LITERATURE.
Source
European Heart Journal, Supplement. Conference: 50th Congress of the
Italian Association of Hospital Cardiologists, ANMCO. Rimini Italy.
21(Supplement E) (pp E52), 2019. Date of Publication: 01 May 2019.
Author
Romano G.; Raffa G.; Gandolfo C.; Pilato M.
Institution
(Romano, Raffa, Gandolfo, Pilato) IRCCS - ISMETT, PALERMO; IRCCSS -
ISMETT, PALERMO; IRCCS - ISMETT, PALERMO
Publisher
Oxford University Press
Abstract
Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) has been used
to deal with life-threatening complications as well as back-up or active
cardiovascular support during high-risk procedures in patients undergoing
transcatheter aortic valve implantation (TAVI). PubMed and Medline
electronic databases were searched in order to identify studies with
emergency or prophylactic V-A ECMO application in association with TAVI
procedures. From November 2012 to November 2017, 14 relevant studies were
identified that included 5,115 TAVI patients of whom 102 (2%) required
ECMO (22 prophylactically, 66 as an emergency and 14 without a reported
indication). The reason for emergency V-A ECMO institution was detailed in
64 patients: left ventricle free wall rupture (n=14), haemodynamic
instability (n=12), ventricular arrhythmias (n=7), aortic annulus rupture
(n=6), coronary obstruction (n=6), low left ventricular output (ejection
fraction<35%) (n=5), uncontrollable bleeding (n=5), severe aortic
regurgitation (n=4), prosthesis embolisation (n=3), aortic dissection
(n=1) and respiratory failure (n=1). Femoral arterial and vein cannulation
was the most common access technique for V-A ECMO institution. Major
bleeding (n=7) and vascular access complications (n=7) were reported after
ECMO institution. The overall in-hospital survival was 73% (61% in the
emergency vs 100% in the prophylactic group). V-A ECMO support should be
available at any centre performing TAVI and provides effective mechanical
circulatory support in an emergency setting. We present an algorithm to
aid decisions about prophylactic circulatory assistance with ECMO and it
should form part of the heart team discussion before a TAVI procedure is
undertaken.

<76>
Accession Number
647628209
Title
Prognostic Impact of Prior Percutaneous Coronary Interventions in Patients
Undergoing Coronary Artery Bypass Grafting-A Systematic Review and
Meta-analysis.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Kirov H.; Caldonazo T.; Woehlecke H.; Fischer J.; Runkel A.; Mukharyamov
M.; Doenst T.
Institution
(Kirov, Caldonazo, Woehlecke, Fischer, Runkel, Mukharyamov, Doenst) Jena
University Hospital, Jena, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: There is controversy on the effect of percutaneous coronary
intervention (PCI) on outcomes of patients undergoing coronary artery
bypass grafting (CABG). We meta-analytically assessed the prognostic
impact of prior PCI in patients with coronary artery disease (CAD) who
underwent CABG. Method(s): We performed a systematic review and
meta-analysis of studies comparing patients who underwent CABG and had
prior PCI in the past with patients who underwent CABG as primary
treatment of CAD. Three databases were assessed. The study selection and
data extraction were performed by two independent investigators and
checked by a senior author. The primary endpoint was perioperative
mortality. The secondary outcomes were perioperative myocardial infarction
(MI), neurological events (NE), bleeding, acute renal failure (ARF), and
hospital length of stay (LOS). The overall odds ratio (OR) and standard
mean difference (SMD), as well as the 95% confidence interval (CI) were
calculated using random-effects model. Result(s): After screening of
all records found through the systematic search, 18 studies met the
criteria for inclusion in the final analysis. Risk of perioperative
mortality in patients undergoing direct CABG was lower than in those with
prior PCI (OR: 0.86, 95% CI, 0.77-0.97, p = 0.02). There was no
significant difference between the groups regarding perioperative MI (OR:
0.83, 0.62-1.13, p = 0.24), NE (OR: 0.97, 0.81-1.15, p = 0.71), bleeding
(OR: 0.79, 0.60-1.05, p = 0.10), ARF (OR: 0.83, 0.59-1.16, p = 0.27), and
hospital LOS (SMD: 0.26, -0.18 to 0.70, p = 0.24). Conclusion(s):
CABG in patients with prior PCI appears to be associated with higher rates
of perioperative mortality when compared with patients who underwent CABG
as primary treatment of CAD.

<77>
Accession Number
2039204346
Title
TAVI Through the Years: A Systematic Review of Progress.
Source
Journal of Pharmacy and Bioallied Sciences. 17 (pp S1115-S1123), 2025.
Date of Publication: 01 Jun 2025.
Author
Ahmad S.; Prabhu M.M.; Bhat R.; Hasan A.; Ahmad A.; Ahmad R.
Institution
(Ahmad, Prabhu, Bhat) Department of General Medicine, Kasturba Medical
College, Manipal Academy of Higher Education, Karnataka, Manipal, India
(Hasan) Department of Cardiology, Jawaharlal Nehru Medical College and
Hospital, Uttar Pradesh, Aligarh, India
(Ahmad) Department of Medicine, Emirates Health Services, Ras Al Khaimah,
United Arab Emirates
(Ahmad) Department of Medicine, RAK Medical and Health Sciences
University, Ras Al Khaimah, United Arab Emirates
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Transcatheter Aortic Valve Implantation (TAVI) has evolved
over the years and now is being used in the management of patients with
symptomatic severe aortic stenosis (AS) in categories of high,
intermediate, and even low operative risk. Previously TAVI was used as an
option only in inoperable or high operative risk elderly patients. Our
systematic review gives an idea of how TAVI has evolved in use over the
last ten years. Material(s) and Method(s): A comprehensive literature
search was conducted across electronic databases, including MEDLINE,
Embase, Web of Science, Scopus, and the Cochrane Library. This research
used keywords such as 'TAVI,' 'AF,' 'PPI,' 'aortic regurgitation,' and
Surgical Aortic Valve Replacement (SAVR) and included only those studies
that were published in English between January 2014 and December 2024. The
intervention is TAVI. Extracted data included study design, sample size,
participant demographics, details of the intervention, control conditions,
and outcome metrics. Outcomes noted were stroke, cardiovascular outcomes,
procedural complications, cerebrovascular incidents, vascular outcomes,
bleeding, length of hospital stay, and mortality. Sensitivity analyses
were conducted, excluding studies with significant bias or small sample
sizes (fewer than 10 participants). Based on the study findings, TAVI
demonstrates significant advantages in terms of shorter hospital stays,
reduced bleeding, and non inferiority to SAVR in short-term mortality
outcomes. However, TAVI is associated with higher rates of paravalvular
leaks, conduction disturbances requiring Permanent Pacemaker Implantation,
and mild-to-moderate Aortic Regurgitation. SAVR patients had higher
incidences of New-Onset Atrial Fibrillation and procedural bleeding.
Long-term survival and freedom from reintervention were slightly better in
SAVR patients in certain studies, although not universally significant.
Both procedures showed comparable rates of stroke and Myocardial
Infarction in most studies, emphasizing the need to tailor treatment based
on individual patient profiles. In our systematic review of TAVI we have
covered the application of TAVI in different patients with varying
anatomical and clinical phenotypes. Result(s): TAVI has been
successful in the treatment of symptomatic severe AS and the recent
advances in radiological imaging have created a path to explore different
anatomical variations. Various trials have already established TAVI as a
viable treatment in elderly patients with high and intermediate operative
risk, while certain studies also advocated the use of TAVI in patients
with low risk. Conclusion(s): The expansion of TAVI to manage
patients in other horizons involving younger patients with asymptomatic
severe AS, and long-term outcomes of valve durability and moderate AS in
combination with cardiac failure bicuspid aortic valve stenosis and pure
native aortic regurgitation are however still under
research. Copyright © 2025 Journal of Pharmacy and Bioallied
Sciences.

<78>
Accession Number
2039272458
Title
Comparison of Myocardial Protective Effect of Sevoflurane Versus Propofol
in Patients Undergoing Mitral Valve Replacement Surgery.
Source
International Journal of Current Pharmaceutical Review and Research. 17(4)
(pp 954-959), 2025. Date of Publication: 2025.
Author
Meena R.; Sachin; Meena S.; Vijay M.; Garg A.; Rasha M.
Institution
(Meena) Department of Anaesthesia, SMS Medical College, Jaipur, India
(Sachin, Vijay, Rasha) Department of Anaesthesia, SMS Medical College,
Jaipur, India
(Meena) Department of Emergency Medicine, SMS Medical College, Jaipur,
India
(Garg) Department of Anaesthesia, SMS Medical College, Jaipur, India
Publisher
Dr. Yashwant Research Labs Pvt. Ltd.
Abstract
Background and Aims: Cardiac surgical procedures unavoidably produce
myocardial cell injury. This study was plannedto compare myocardial
protective effect of sevoflurane versus propofol in terms of comparing the
plasma cardiac troponin-I (cTnI) and creatine kinase isozyme (CK-MB) level
as the primary markers of myocardial cell injury in patients undergoing
heart valve replacement surgery. Material(s) and Method(s): This
hospital based Prospective, Randomized, Interventional study included 70
eligible cases of age 30-65 years divided equally into two groups. In
group A Sevoflurane and in group B, Propofol was used for maintaining
anaesthesia. Cardiac Troponin I, CK MB were determined before induction,
3hours,6 hours after aortic unclamping, 24hrs and 48hours after surgery.
As secondary objective hemodynamic parameters were also recorded at
different intervals. Result(s): Cardiac Troponin I and CK MB levels
were lower in sevoflurane group at all time intervals after aortic
unclamping with statistically significant lower values at 3hr and 6hr of
aortic unclamping compared to propofol group. Hemodynamic parameters,
Automatic heartbeat recovery, Mechanical ventilation duration and ICU stay
duration in both groups were comparable. Conclusion(s):
Administration of sevoflurane during cardiac surgery can produce better
myocardial protection in comparison of intravenous infusion of
propofol. Copyright © 2025 Dr. Yashwant Research Labs Pvt. Ltd..
All rights reserved.

<79>
Accession Number
647626472
Title
A prospective randomized study that compares three different dressings for
the prevention of surgical site infections following major heart surgery.
Source
Scientific reports. 15(1) (pp 19960), 2025. Date of Publication: 06 Jun
2025.
Author
Perez-Granda M.J.; Cuerpo G.; Barrio J.M.; Valerio M.; Munoz P.; Pinto
AG.; Valencia D.E.; Vicario F.S.; Bouza E.
Institution
(Perez-Granda) Clinical Microbiology and Infectious Diseases Department,
Hospital General Universitario Gregorio Maranon, Madrid, Spain
(Perez-Granda) CIBER de Enfermedades Respiratorias-CIBERES (CB06/06/0058),
Madrid, Spain
(Perez-Granda) Department of Nursing, School of Nursing, Physiotherapy and
Podiatry, Universidad Complutense de Madrid, Madrid, Spain
(Perez-Granda) Department of Cardiac Surgery, Hospital General
Universitario Gregorio Maranon, Madrid, Spain
(Cuerpo, Pinto, Valencia, Vicario) Department of Cardiac Surgery, Hospital
General Universitario Gregorio Maranon, Madrid, Spain
(Barrio, Valerio, Munoz, Bouza) CIBER de Enfermedades
Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain
(Barrio) Department of Anesthesiology, Hospital General Universitario
Gregorio Maranon, Madrid, Spain
(Valerio, Munoz) Clinical Microbiology and Infectious Diseases Department,
Hospital General Universitario Gregorio Maranon, Madrid, Spain
(Munoz, Pinto, Bouza) Medicine Department, School of Medicine, Universidad
Complutense de Madrid, Madrid, Spain
(Bouza) Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM),
Madrid, Spain
Abstract
Surgical site infection (SSI) is among the most common complication of
major heart surgery patients with incidences ranging from 0.5 to 16.5%.
Our aim was to compare the incidence, etiology and prognosis of surgical
wound infection in three groups of patients with three different type of
wound dressing used in a large cohort of patients undergoing cardiac
surgery requiring median sternotomy (MHS). This was a randomized,
prospective clinical study conducted in 900 adults undergoing MHS at our
center from October 10, 2019 to February 22, 2022. Before surgical
closure, patients were randomized to 3 different wound dressing groups
(300 patients per group): A) conventional gauze (Mepore), B) Absorbent:
polyurethane foam (Mepilex), or C) Vacuum-negative-pressure therapy (NPWT)
wound dressing (PICO, Smith & Nephew S.A.). Overall, 900 patients were
randomized as follows: 300 patients in each group received conventional,
absorbent or vacuum wound dressing respectively. Rates of SSI in groups A,
B and C were respectively 2.3%, 3% and 3% for superficial SSI (sSSI) (p =
0.848) and 2%, 2% and 0.7% for postsurgical mediastinitis (PSM) (p =
0.313). Mortality in the whole group was 4.4% there being no significant
differences between the three groups (4.7%, 5.7% and 3% respectively; p =
0.277). The NPWT system was better at preventing PSM than the other
dressings only in the subgroup of patients undergoing coronary artery
bypass graft surgery (CABG) with mammary artery grafts. We have not been
able to demonstrate significant differences in the incidence of SSI in the
whole series with any of the different dressings. The newer, more
expensive, NPWT dressing were more effective only at preventing
Post-Surgical Mediastinitis in patients undergoing CABG with internal
mammary artery grafts. ClinicalTrials.gov identifier (NCT number):
NCT03905213. Copyright © 2025. The Author(s).

<80>
Accession Number
2034983394
Title
Cardiovascular and Non-Cardiovascular Complications of Transcatheter
Aortic Valve Implantation.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2025.
Date of Publication: 2025.
Author
Padilla-Serrano A.; Pozo J.I.G.; Lorente E.C.; Cruz A.C.
Institution
(Padilla-Serrano, Pozo, Lorente, Cruz) Unidad de Cuidados Intensivos
Cardiovasculares, Servicio de Medicina Intensiva, Hospital Universitario
Virgen de las Nieves, Granada, Spain
(Padilla-Serrano, Pozo, Cruz) Grupo de investigacion PAIDI, criticallab
cts 609, Granada, Spain
(Padilla-Serrano, Lorente, Cruz) Grupo de investigacion biosanitaria
ibs.Granada, TEC23-Laboratorio para la Investigacion en Medicina Intensiva
y Educacion Medica (INTENSIVEEDUCATIONLAB, Granada, Spain
(Cruz) Profesor de Medicina, Universidad de Granada, Granada, Spain
Publisher
John Wiley and Sons Inc
Abstract
Degenerative aortic valve stenosis is becoming a more prevalent disease,
and transcatheter aortic valve implantation (TAVI) offers a treatment
option for patients who are at high surgical risk. This manuscript reviews
cardiovascular and non-cardiovascular complications associated with TAVI.
A search was conducted in PubMed, Scopus, and Web of Science using the
terms "transcatheter aortic valve implantation" and each keyword referring
to potential complications, with the Boolean operator "AND" used to allow
us to obtain documents containing two or more keywords simultaneously. The
most frequent cardiovascular complications were hemorrhage and vascular
access-related complications (2.93%-24%), new-onset left bundle branch
block (13.3%-37%), and myocardial injury (95%-100%). Among
non-cardiovascular complications, stroke and subclinical brain injury
occurred in 1.6%-5% of cases; acute kidney injury, in 11.7%; and delirium,
in 17.8%-23.7%. Described mortality ranges from 1.1% to 4.2%. This
narrative review provides a multidimensional perspective of TAVI
complications by addressing both cardiovascular and non-cardiovascular
complications. Non-cardiovascular complications, such as delirium,
negatively influence mortality. Copyright © 2025 Wiley
Periodicals LLC.

<81>
Accession Number
2039274554
Title
Etiology-specific survival and reoperation trends following surgical
mitral valve repair and replacement: A meta-analysis of reconstructed
time-to-event data.
Source
Trends in Cardiovascular Medicine. (no pagination), 2025. Date of
Publication: 2025.
Author
Al-Tawil M.; Sicouri S.; Yamashita Y.; Ramlawi B.
Institution
(Al-Tawil, Sicouri, Yamashita, Ramlawi) Department of Cardiothoracic
Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA,
United States
(Yamashita, Ramlawi) Lankenau Heart Institute, Wynnewood, PA, United
States
Publisher
Elsevier Inc.
Abstract
Current American and European guidelines recommend mitral valve repair
(MVr) over replacement (MVR) whenever feasible. However, these
recommendations are primarily based on data from patients with
degenerative mitral regurgitation (DMR), whereas evidence supporting MVr
in other etiologies, such as infective endocarditis (IE) or ischemic
mitral regurgitation (IMR), remains less conclusive. We systematically
searched for and identified studies published after 2000 that compared MVr
and MVR in patients with specific mitral valve disease etiologies,
including DMR, IE, IMR, and rheumatic heart disease (RHD). A total of 61
records (10 DMR, 21 IE, 18 IMR, and 12 RHD) of 59 studies published
between 2005 and 2024, were included. MVr consistently demonstrated
superior survival compared to MVR in DMR and IE patients. Parametric
time-varying hazard ratios revealed a sustained survival benefit of MVr in
DMR and IE, whereas in IMR and RHD, the survival advantage was
transient-lasting only up to six months and 2.7 years postoperatively,
respectively-after which survival hazards between MVr and MVR became
comparable. This was further corroborated by the results of a two-year
landmark and the propensity-matched subgroup analyses. In DMR, MVr was
associated with lower reoperation rates compared to MVR; however, in IE,
IMR, and RHD, MVr was associated with significantly higher reoperation
rates compared to MVR. Our study supports current guidelines favoring MVr
over MVR, demonstrating sustained survival benefits in DMR. In IE-specific
MR, MVr also showed consistent benefits over MVR, demonstrating that MVr
should be prioritized when feasible. However, in IMR and RHD, there was no
notable survival advantage of MVr over MVR, with higher reoperation rates
observed with MVr. These findings highlight the need for etiology-specific
and individualized surgical planning. Copyright © 2025

<82>
Accession Number
647628294
Title
ERAS in High-risk Patients: Improvement of Clinical Outcomes.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Casper J.; Krey M.; Dolata L.; Gemander C.; Sarwari H.; Yalin Y.; Pecha
S.; Chindris V.; Schulte-Uentrop L.; Girdauskas E.; Reichenspurner H.;
Petersen J.
Institution
(Casper) Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
(Krey) University Medical Center Hamburg-Eppendorf, Hamburg, Germany
(Dolata, Sarwari, Yalin) University Heart and Vascular Center Hamburg,
Hamburg, Germany
(Gemander) Uni, Hamburg, Germany
(Pecha, Schulte-Uentrop, Reichenspurner, Petersen) HamburgGermany
(Chindris) Universitatskjlinikum Hamburg-Eppendorf, Martinistrase,
Hamburg- Nord, Germany
(Girdauskas) University Heart Center, Augsburg, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Enhanced Recovery After Surgery (ERAS) uses a
multidisciplinary, evidence-based approach to improve overall outcomes and
length of stay for patients undergoing surgery. Multimorbid patients in
particular could benefit from the ERAS protocol. This study aims to show
the effects of an ERAS routine in patients undergoing high-risk surgery
according to the ERAS guidelines. Method(s): The ERAS protocol with
preoperative appointments and dedicated prehabilitation was applied to a
total of 93 patients from June 2023 to July 2024. According to the ERAS
guidelines, procedures such as root repair/replacement, ascending aortic
replacement, Ross procedure, redo procedures, and combined valve
procedures are defined as high-risk procedures. Of the 93 ERAS patients,
31 patients were considered high risk for ERAS (high risk group) compared
with 62 low-risk patients (low-risk group). Result(s): The high-risk
group was significantly younger (high-risk: 57.5 +/- 7.8 versus low-risk:
60.9 +/- 6.2; p = 0.024) and had a higher EURO-Score II (high-risk: 1.5
+/- 0.89 versus low-risk: 0.87 +/- 45; p = 0.001). Other baseline
characteristics were similar in both groups. Cardiopulmonary bypass time
(p = 0.205) and aortic cross-clamp time (high-risk: 101.9 +/- 46.2 versus
low-risk: 84.3 +/- 23.9; p = 0.088) were similar in both groups.
Extubation in the OR was possible in 35.4% of the high-risk group and 34%
of the low-risk group (p = 0.932). Reintubation was required for
postoperative bleeding in 2/31 patients (high-risk) and 2/62 (low-risk)
patients. Admission to PACU-24 instead of ICU was possible in 32% of
high-risk and 53% of low-risk patients (p = 0.056). One low-risk patient
had postoperative delirium. ICU readmission was required in 2/31
(high-risk) and 2/62 (low-risk) patients (p = 0.470). ICU stay (high-risk:
28.5 +/- 23.4 versus low-risk: 32.9 +/- 30.7; p = 0.481) and postoperative
hospital stay (high-risk: 8.6 +/- 3.8 versus low-risk: 7.2 +/- 2.9; p =
0.084) were similar in both groups. Conclusion(s): ERAS protocols can
also be safely implanted in more complex patients such as combined valve
procedures, Ross procedures, and/or redo procedures. However, a dedicated
multi-professional team with a dedicated ERAS nurse is required to manage
these multimorbid patients within the ERAS protocol.

<83>
Accession Number
2039282365
Title
3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left
Atrial Appendage Closure in Patients With Atrial Fibrillation: Results
From the SWISS-APERO Randomized Clinical Trial.
Source
Journal of the American College of Cardiology. 86(1) (pp 3-14), 2025. Date
of Publication: 08 Jul 2025.
Author
Galea R.; De Marco F.; Aminian A.; Meneveau N.; Chalkou K.; Anselme F.;
Grani C.; Franzone A.; Vranckx P.; Fischer U.; Valgimigli M.; Raber L.
Institution
(Galea, Grani, Valgimigli, Raber) Department of Cardiology, Bern
University Hospital, University of Bern, Bern, Switzerland
(Galea) Department of Cardiology, Hospital Centre of Biel, Biel,
Switzerland
(De Marco) Department of Cardiology, Monzino Cardiology Center, Milan,
Italy
(Aminian) Department of Cardiology, Centre Hospitalier Universitaire de
Charleroi, Charleroi, Belgium
(Meneveau) Besancon University Hospital, University of Burgundy
Franche-Comte, Besancon, France
(Chalkou) Department of Clinical Research, University of Bern, Bern,
Switzerland
(Anselme) Department of Cardiology, University Hospital of Rouen, Rouen,
France
(Franzone) Department of Advanced Biomedical Sciences, University Federico
II University, Naples, Italy
(Vranckx) Department of Cardiology and Critical Care Medicine, Hartcentrum
Hasselt, Jessa Ziekenhuis, Hasselt, Belgium
(Vranckx) Faculty of Medicine and Life Sciences, Hasselt University,
Hasselt, Belgium
(Fischer) Department of Neurology, Bern University Hospital, University of
Bern, Bern, Switzerland
(Valgimigli) Cardiocentro Ticino Institute and Universita della Svizzera
Italiana (USI), Lugano, Switzerland
Publisher
Elsevier Inc.
Abstract
Background: No study thus far has compared Amulet with Watchman FLX for
clinical outcomes beyond 1 year after percutaneous left atrial appendage
closure (LAAC). Objective(s): The goal of this study was to compare
Amulet and Watchman FLX in terms of 3-year clinical outcomes.
 Method(s): In the investigator-initiated SWISS-APERO (Comparison of
Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial
Appendage Closure) trial, patients with atrial fibrillation and high
bleeding risk undergoing LAAC were randomly assigned (1:1) to receive
Amulet or Watchman/FLX across 8 centers. Study endpoint included the
composite of cardiovascular death, stroke, transient ischemic attack, or
systemic embolism at 3 years. Analyses were repeated in the as-treated
(AT) and per-protocol (PP) populations. Result(s): Of the 221
patients randomized to treatment, 220 completed LAAC and 3 patients
randomized to receive the Amulet device received the Watchman FLX device.
The follow-up rate at 3 years was 96.4% in the Amulet group and 97.3% in
the Watchman group. The composite ischemic endpoint occurred numerically
less frequently in the Amulet group compared with the Watchman group
(18.2% vs 31.0%; HR: 0.58; 95% CI: 0.33-1.03; P = 0.06). In both the AT
(17.0% vs 31.1%; HR: 0.53; 95% CI: 0.30-0.96; P = 0.035) and PP (16.2% vs
29.2%; HR: 0.54; 95% CI: 0.29-1.00; P = 0.049) populations, the composite
ischemic endpoint was significantly lower in the Amulet group compared
with the Watchman group. Conclusion(s): At 3 years after LAAC, there
was no significant difference in the ischemic risk between the Amulet and
the Watchman FLX groups. The lower occurrence of the ischemic composite
endpoint observed in the Amulet group in both the AT and PP analyses is
hypothesis generating and emphasizes the need for further studies.
(Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing
Left Atrial Appendage Closure [SWISS-APERO]; NCT03399851) Copyright
© 2025 American College of Cardiology Foundation

<84>
Accession Number
2034975293
Title
Development and validation of a novel prediction model for new-onset
atrial fibrillation after lung resection.
Source
Annals of Medicine. 57(1) (no pagination), 2025. Article Number: 2519673.
Date of Publication: 2025.
Author
Chen Y.; Hu Y.; Wang J.; Sun J.; Hu B.; Huang K.; He Z.; Liang C.; Lin Y.
Institution
(Chen, Hu, Wang, Hu, Huang, He, Liang) Department of Cardiology, Shanghai
Changzheng Hospital, Navy Medical University, Shanghai, China
(Chen, Wang, Hu, Huang, He, Liang) Shanghai Cardiovascular Institute of
Integrative Medicine, Shanghai, China
(Chen, Sun, Lin) Department of Cardiology, Fujian Medical University Union
Hospital, Fujian Heart Medical Center, Fujian Clinical Medical Research
Center for Heart and Macrovascular Diseases, Fujian Institute of Coronary
Artery Disease, Fuzhou, China
(Hu) Department of Pharmacy, Shanghai Changzheng Hospital, Navy Medical
University, China
Publisher
Taylor and Francis Ltd.
Abstract
Background: Postoperative atrial fibrillation (POAF) is the most prevalent
and potentially life-threatening arrhythmia following thoracic surgery.
This study aimed to construct and validate a predictive model for
assessing POAF risk. Method(s): A meta-analysis was conducted to rank
risk factors associated with POAF based on their respective risk ratios
(RRs). Significant risk factors identified from the meta-analyses were
incorporated into the model and assigned weights. External validation was
performed using a retrospective cohort from China. Receiver operating
characteristic (ROC) curves, calibration plots and decision curve analysis
(DCA) were employed to assess the model's predictive performance,
calibration and clinical utility. Result(s): We screened 40 cohort
studies involving 58,899 patients. We developed a risk model that
incorporated age >= 70 years (RR 2.10, 95% CI 1.34-3.30; p < 0.05), male
sex (RR 1.46, 95% CI 1.34-1.60; p < 0.05), COPD (RR 2.28, 95% CI
1.81-2.89; p < 0.05), CAD (RR 1.72, 95% CI 1.49-1.99; p < 0.05), heart
failure (RR 1.62, 95% CI 1.12-2.35; p < 0.05), pneumonectomy (RR 2.32, 95%
CI 2.01-2.67; p < 0.05) and lobectomy (RR 1.86, 95% CI 1.38-2.51; p <
0.05) and thoracotomy (RR 1.46, 95% CI 1.30-1.64; p < 0.05). Validation
was performed in an external cohort of 1546 participants, demonstrating
strong discrimination with an area under the receiver operating
characteristic curve (95% CI) of 0.89 (95% CI 0.81-0.83). The calibration
curve and DCA curve results demonstrated good concordance and
applicability. Conclusion(s): This model, built with easily
accessible clinical variables, could accurately predict the risk of POAF.
This holds promise for improving clinical decision making and guiding
early interventions. Copyright © 2025 The Author(s). Published by
Informa UK Limited, trading as Taylor & Francis Group.

<85>
Accession Number
2039203698
Title
Link Between Cardiac Allograft Vasculopathy and Metabolic Syndrome: A
Systematic Review and Meta-Analysis.
Source
Metabolic Syndrome and Related Disorders. (no pagination), 2025. Date of
Publication: 2025.
Author
Pajareya P.; Chuanchai W.; Siranart N.; Phutinart S.; Jansem P.; Basch N.;
Techasatian W.; Tokavanich N.; Prasitlumkum N.; Chokesuwattanaskul R.
Institution
(Pajareya, Chuanchai, Siranart, Phutinart, Chokesuwattanaskul) Division of
Cardiovascular Medicine, Center of Excellence in Arrhythmia Research,
Cardiac Center, Faculty of Medicine, King Chulalongkorn Memorial Hospital,
Chulalongkorn University, Bangkok, Thailand
(Jansem) Department of Psychiatry, Faculty of Medicine, Prince of Songkla
University, Songkhla, Thailand
(Basch) Faculty of Medicine, King Chulalongkorn Memorial Hospital,
Chulalongkorn University, Bangkok, Thailand
(Techasatian) Division of Cardiovascular Medicine, Louisiana State
University, Shreveport, LA, United States
(Tokavanich) Division of Cardiovascular Medicine, University of Michigan
Health, Ann Arbor, MI, United States
(Prasitlumkum) Department of Cardiovascular Medicine, Mayo Clinic,
Rochester, MN, United States
Publisher
Mary Ann Liebert Inc.
Abstract
Background: Metabolic syndrome (MetS) is increasingly prevalent globally
and is linked to inflammation in cardiac tissues. Cardiac allograft
vasculopathy (CAV) is a significant inflammatory condition and a leading
cause of graft failure after orthotopic heart transplantation (OHT). The
relationship between MetS and CAV remains poorly understood.
 Method(s): A literature search was conducted from inception to
September 2024, including studies that reported associations between MetS
or its components (obesity, hypertension, dyslipidemia, and diabetes
mellitus) and CAV. The primary endpoint was the development of CAV after
OHT. Results were presented as odds ratios (OR) or hazard ratios (HR) with
95% confidence intervals (CI), employing both random and fixed-effect
models based on heterogeneity. Result(s): A total of 16 studies
involving 3,366 patients were included. The prevalence of MetS was high
before OHT (32%, 95% CI: 24-41%, I2 = 75%) and increased after
OHT (37%, 95% CI: 18-61%, I2 = 83%). MetS was significantly
associated with CAV (OR = 1.99, 95% CI: 1.28-3.09, I2 = 36%).
Key components of MetS linked to CAV included obesity (OR = 1.54, 95% CI:
1.11-2.13, I2 = 0%) and dyslipidemia (OR = 1.87, 95% CI:
1.49-2.36, I2 = 0%). New-onset diabetes mellitus after
transplantation increases the risk of CAV with an HR of 1.71 (95% CI:
1.56-1.88, I2 = 0%). Conclusion(s): The high prevalence of
MetS both before and after OHT is associated with an increased risk of
CAV, highlighting the need for targeted interventions to manage MetS in
heart transplant recipients. Copyright 2025, Mary Ann Liebert, Inc.,
publishers.

<86>
Accession Number
647628166
Title
Survival Trends of Patients After Mitral Valve Repair for Structural
Mitral Regurgitation Compared to the General Population.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Caldonazo T.; Kirov H.; Sakhtianchi B.A.; Tasoudis P.; Fischer J.;
Mukharyamov M.; An K.R.; Doenst T.; Runkel A.
Institution
(Caldonazo, Kirov, Sakhtianchi, Fischer, Mukharyamov, Doenst, Runkel) Jena
University Hospital, Jena, Germany
(Tasoudis) University of North Carolina, Chapel Hill, United States
(An) University of Toronto, Toronto, Canada
Publisher
Georg Thieme Verlag
Abstract
Background: Surgical mitral valve repair (MVr) for structural mitral
regurgitation (MR) restores valve function. Individual studies suggest
that MVr may normalize life expectancy. We performed a systematic review
and a meta-analysis of all studies assessing the impact of MVr for
structural MR on survival. Method(s): Three databases were assessed
searching for studies with survival comparisons to the regional
age-matched general population. The primary and single endpoint was
long-term mortality. Individual patient data (IPD) were reconstructed from
the published Kaplan-Meier curves and was used to calculate overall
survival. The Cox proportional hazards regression model was used to assess
between-group differences. The hazard ratios (HR) and 95% confidence
intervals (CI) of each individual study was calculated. Landmark analysis
was performed to check the robustness of the estimated effect.
 Result(s): Four studies met the criteria for inclusion in the final
analysis. The studies' follow-up ranged from 10 to 26 years. The pooled
Kaplan-Meier curves of reconstructed IPD show that for the entire
follow-up, patients who underwent MVr had higher risk of death compared
with the general age-matched population (HR: 0.62, 95% CI: 0.53-0.72, p <
0.01). Due to violation of the HR proportions, a landmark analysis was
performed splitting the events after 6 years. There was no survival
difference between the groups until 6 years after surgery (HR: 0.83, 95%
CI, 0.68-1.03, p = 0.09). From 6 to 26 years of follow-up, curves diverged
and the MVr group demonstrated significantly higher risk of death compared
with the general age-matched population (HR: 0.45, 95% CI, 0.36-0.56, p <
0.01). The individual studies showed that the decrease in survival after 6
years was associated with an increase in return of MR and need of
reoperation. Conclusion(s): MVr for structural MR has the potential
to restore life expectancy compared with the general population. However,
this effect is limited to the first 6 years after surgery. Risk of death
thereafter correlates with the return of severe regurgitation and/or the
need for reoperation.

<87>
Accession Number
647628297
Title
Survival Trends of Patients after Coronary Artery Bypass Grafting and
Sex-specific Differences-A Meta-analysis of Reconstructed Time-to-event
Data.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Kirov H.; Caldonazo T.; Toshmatov S.; Tasoudis P.; Fischer J.; Runkel A.;
Mukharyamov M.; Doenst T.
Institution
(Kirov, Caldonazo, Toshmatov, Fischer, Runkel, Mukharyamov, Doenst) Jena
University Hospital, Jena, Germany
(Tasoudis) University of North Carolina, Chapel Hill, United States
Publisher
Georg Thieme Verlag
Abstract
Background: Randomized evidence suggest that coronary artery bypass
grafting (CABG) has the potential to improve life expectancy. Women are
considered to have worse outcomes after CABG, but they are generally
underrepresented in randomized trials. Registry data and trial
sub-analyses provide controversial results for CABG in women. We
systematically assessed the survival-improving potential of CABG in both
sexes by analyzing studies that assessed CABG outcomes compared with the
age-matched general population. Method(s): Three databases were
assessed (MEDLINE, ScienceDirect, and Cochrane Library). Primary and
single outcome was long-term all-cause mortality. Reconstruction of
time-to-event data was performed. Sex-specific data from the arms were
separately extracted. Hazard ratios (HR) and 95% confidence intervals (CI)
were calculated. Landmark analysis was performed to check the robustness
of the estimated effect. Result(s): A total of 1,352 studies were
retrieved. Eight studies encompassing 142,165 patients were included in
the analysis. For the entire 19 years observation period, patients who
underwent CABG had worse survival than the general population in both male
(HR = 1.14, 95% CI, 1.05-1.23, p = 0.002) and female patients (HR = 1.21,
95% CI, 1.01-1.47, p = 0.045). However, the curves separated only after
approximately 10 years which coincided with a violation of the
proportional of hazard ratio assumption of the analysis. Performing
landmark analyses suggest that there is no difference in life expectancy
compared with the general population in the first decade. The direct
comparison of men versus women suggests that very long-term survival was
slight better in women (HR: 1.04, 95% CI, 1.01-1.08). Conclusion(s):
Both men and women after CABG for treatment of CAD experience similar life
expectancy in the first decade compared with the general population.
Beyond 10 years, life expectancy becomes worse than the general population
and is the worst in men. It may be speculated that this difference is due
to graft occlusions.

<88>
Accession Number
2039232135
Title
Meta-analysis of erector spinae plane block efficacy in managing
postoperative pain following cardiac surgery.
Source
Current Problems in Cardiology. 50(8) (no pagination), 2025. Article
Number: 103098. Date of Publication: 01 Aug 2025.
Author
Sandeep B.; Huang X.; Jiang F.; Cheng H.; Li Y.; Xiao Z.
Institution
(Sandeep, Cheng, Li, Xiao) Department of Cardio-Thoracic Surgery, Chengdu
Second People's Hospital, Sichuan, Chengdu, China
(Huang) Department of Anesthesiology, The Third People's Hospital of
Chengdu, Sichuan, Chengdu, China
(Jiang) Department of Nursing, Pengzhou Peoples's Hospital, 255 South
Third Ring Road, Sichuan, Pengzhou City, China
Publisher
Elsevier Inc.
Abstract
Cardiac surgery is associated with significant postoperative pain,
necessitating effective multimodal analgesia to reduce opioid-related
morbidity. This systematic review and meta-analysis evaluated the
analgesic efficacy of erector spinae plane block (ESPB) in adult cardiac
surgery. Twenty-three randomized controlled trials (1,612 patients) were
included. Primary outcomes revealed no significant difference in 24-hour
postoperative coughing pain scores between ESPB and control groups (MD
0.12; 95 % CI:0.26 to 0.50; P = 0.54). However, ESPB demonstrated
significant reductions in coughing and resting pain scores at 48 h (MD
-0.60; 95 % CI:0.81to-0.38; P < 0.00001) and 72 h (MD -0.67; 95 % CI:1.02
to-0.33; P = 0.0001), alongside reduced 24-hour morphine consumption (MD
-2.04; 95 % CI:2.46 to-1.61; P < 0.00001) and shorter mechanical
ventilation duration (MD -26.53 minutes; 95 % CI:41.78 to-11.27; P =
0.0007). No differences were observed in ICU/hospital stays or
surgical/anesthesia durations. Subgroup analyses highlighted variability
in continuous versus single-shot ESPB techniques. High heterogeneity (I2
>50 %) and moderate-to-low GRADE evidence underline the need for
standardized protocols. ESPB shows promise in enhancing recovery by
reducing opioid use and late-phase pain, though further high-quality
trials are warranted. Copyright © 2025 Elsevier Inc.

<89>
Accession Number
2039226241
Title
Perioperative challenges and management strategies for non-cardiac surgery
in patients with rheumatic heart diseases: A narrative review.
Source
Journal of Anaesthesiology Clinical Pharmacology. 41(3) (pp 384-395),
2025. Date of Publication: 01 Jul 2025.
Author
Singh M.; Abraham A.; Soni S.C.; Singh S.
Institution
(Singh) Department of Anesthesiology and Critical Care Surgery, Ochsner
Medical Center, New Orleans, LA, United States
(Abraham) Department of Anesthesiology and Intensive Care and
Resuscitation, Cleveland Clinic, OH, United States
(Soni) Department of Anesthesiology and Critical Care, All India Institute
of Medical Sciences, Rajasthan, Jodhpur, India
(Singh) Department of Surgery, Division of Cardiac Surgery, Ochsner
Medical Center, New Orleans, LA, United States
Publisher
Wolters Kluwer Medknow Publications
Abstract
Rheumatic heart diseases (RHDs) impose a substantial global burden,
primarily affecting individuals under 25 years of age in low- and
medium-income countries (LMICs) and poor and marginalized groups in
high-income countries. [1-3] The underlying cause is a group A
beta-hemolytic streptococcus, which triggers an immune-mediated attack on
the heart and joints. Although acute rheumatic fever (ARF) is treatable,
its occurrence and complications remain high in impoverished areas. [4]
Variations in social structure contribute to differences in the incidence
and progression of the disease, even in affluent regions. [5]
Administering anesthesia to this patient population presents significant
challenges, particularly when early management has been inadequate due to
limited medical care and follow-up. Literature shows evidence for
anesthetic management of different types of RHDs, mostly focusing on
mitral and aortic valvulopathies. [6,7] This review synthesizes literature
from databases such as MEDLINE and PubMed searches from the year 2000 to
date, focusing on anesthesia management strategies and the challenges
posed by ARF and RHD. Specific topics covered include the diagnosis and
management of ARF, acute complications, perioperative care for patients
with RHD, and unique considerations for different valvular pathologiesWith
this review, we aim to discuss the available evidence, current World
Health Organization (WHO) and societal guidelines in the context of
perioperative medical and anesthetic management, hemodynamic challenges,
and postoperative courses. An emphasis on basic point-of-care ultrasound
(POCUS) training is made in this review as the current era of diagnostics
and therapeutics is increasingly reliant on
echocardiography. Copyright © 2025 Journal of Anaesthesiology
Clinical Pharmacology.

<90>
Accession Number
647628339
Title
54th Annual Meeting of the German Society for Thoracic and Cardiovascular
Surgery (DGTHG).
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Anonymous
Publisher
Georg Thieme Verlag
Abstract
The proceedings contain 194 papers. The topics discussed include:
video-assisted thoracoscopic surgery versus open thoracotomy for resection
of lung metastasis-a meta-analysis of reconstructed time-to-event data;
clinical impact of prosthesis - patient mismatch after surgical aortic
valve replacement: a multicenter prospective analysis; development and
hemodynamic analysis of low-pressure tubular heart valves; impact of
calcification on hemodynamic performance of tubular heart valves;
postoperative release patterns of cardiac biomarkers in patients
undergoing endoscopic mitral valve surgery with or without concomitant
cryoablation; transaxillary cut-down versus transfemoral access in TAVI;
and impact of cardio-anatomical characteristics on bleeding complications
of transapical transcatheter intervention.

<91>
Accession Number
647628148
Title
Is Negative Pressure Wound Therapy Better for Sternal Wound Healing?.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Taghiyev Z.T.; Sandoval Valderrama J.F.; Niemann B.; Roth P.; Orhan C.;
Haj M.; Grieshaber P.; Boning A.
Institution
(Taghiyev, Sandoval Valderrama, Niemann, Roth, Orhan, Haj, Grieshaber,
Boning) Department of Cardiovascular Surgery, University Hospital Giessen,
Giessen, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: The purpose of this prospective, randomized study is to
determine whether the preventive negative pressure wound therapy with
PICOTM dressing system could reduce wound complications after the standard
median sternotomy in cardiac surgery. Method(s): 256 patients
undergoing open cardiac surgery during the period July 2019 to July 2023
were prospectively randomized in two groups: 108 patients were treated
with PICOTM (Smith and Nephew Ltd, Hull, England) which was applied for 5
to 7 days, whereas 148 patients in control group received conventional
wound dressings. Primary endpoints were superficial and deep sternal wound
healing disorders, as well as the rate of sternal instability within 7,
30, and 180 days after surgery. Inverse probability of treatment weighting
(IPTW) was used to assess the impact of PICOTM on wound complications.
 Result(s): After randomization, baseline and procedural
characteristics were similar in both groups. In the PICO group the
incision was primarily closed in 102 (94.4%) patients and there were seven
cases (95.3%) of superficial dehiscence in the control group after 7 days
of treatment. The overall 30-day incidence of sternal wound healing
disorders was similar in both groups (17 [15.7%] versus 21 [14.2%], p =
0.726). 180 days after surgery, two patients in each group showed a skin
dehiscence, while two patients in the PICO group had an instable sternum.
Statistically, significantly less wound healing problems occurred in the
PICO compared with the conventional group within 7 days after surgery (OR
2.1, 95%CI [1.016 to 4.369], p = 0.045), but not on 30 and 180 days after
surgery, respectively (OR 1.0, 95%CI [0.472 to 2.247], p = 0.942 and OR
6.7, 95%CI [0.685 to 66.098], p = 0.102). Conclusion(s): The initial
superiority of the PICOTM system to prevent wound infections following
open-heart surgery could not be maintained at the 30- and 180-day
follow-up.

<92>
Accession Number
647628149
Title
Highlighting Genetic Differences between Barlow's Disease and Fibroelastic
Deficiency via Genome-Wide Association Study Meta-Analyses.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Feirer N.; Weber M.; Knoll K.; Miranda L.; Yu M.; Li L.; Lahm H.; Kameric
M.; Doppler S.; Gottmann I.; Lichtner P.; Berger K.; Lek M.; Lange R.;
Schunkert H.; Hagege A.; Bouatia-Naji N.; Muller-Myhsok B.; Trenkwalder
T.; Gruber P.; Krane M.; Dressen M.
Institution
(Feirer, Knoll, Kameric, Lichtner, Schunkert, Trenkwalder) German Heart
Center Munich, School of Medicine and Health, Technical University of
Munich, Munich, Germany
(Weber) Boehringer Ingelheim, Ulm, Germany
(Miranda) Max Planck Institute of Biochemistry, Munich, Germany
(Yu) Fudan University, Shanghai, China
(Li) Munich Heart Alliance, Munchen, Germany
(Lahm, Doppler, Gottmann, Lange, Krane, Dresen) Department of
Cardiovascular Surgery, Institute Insure, German Heart Center Munich,
Munich, Germany
(Berger) Institut fur Epidemiologie und Sozialmedizin, Munster, Germany
(Lek, Gruber) Yale School of Medicine, Division of Cardiac Surgery, Yale,
United States
(Hagege) European Hospital Georges Pompidou, Paris, France
(Bouatia-Naji) Universite de Paris, Paris, France
(Muller-Myhsok) Department of Translational Research in Psychiatry, Max
Planck Institute of Psychiatry Munich, Munich, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Subtypes of mitral valve prolapse (MVP) show a broad spectrum,
including the phenotypes fibroelastic deficiency (FED) and Barlow's
disease. However, the underlying genetic differences have not yet been
analyzed in detail. This study highlights novel risk loci specific for FED
and Barlow's disease, respectively. Method(s): The cohort included
all consecutive patients who underwent mitral valve surgery for
degenerative MVP at the Department of Cardiovascular Surgery or presented
with symptomatic MVP at the Department of Cardiology at the German Heart
Center Munich between March 2002 and January 2021. The cohort was
subdivided into the phenotypes FED and Barlow's disease, based on clinical
and morphological characteristics. Intermediate phenotypes were excluded
from the subgroup analysis. Subgroups were analyzed via GWAS and
investigated in meta-analyses with GWAS datasets stratified from data from
the MVP France study. Phenome-wide association study (PheWAS) was
performed with datasets from UK Biobank. Result(s): Within our cohort
of 2,140 MVP patients, 84.5% (n = 1,809) suffered from severe mitral
regurgitation that required surgery. The MVP France cohort included 1,412
patients and 2,439 controls, resulting in 3,552 patients and 11,439
controls included in our analyses. GWAS meta-analysis included 997 FED
cases and 788 Barlow's disease cases. Two genome-wide significant loci (p
< 5e-8) associated with Barlow's disease were identified. For Barlow's
disease, 35 further SNPs also showed a significant correlation (p < 5e-5)
in 32 risk loci. In association with FED, one highly significant (p < 5e-
8) locus was identified. Further 35 SNPs showed a significant FED
correlation (p < 5e-5) in 30 risk loci. PheWAS revealed an association
with paroxysmal supraventricular tachycardia for one locus correlating
with FED on chromosome 4 and for one locus correlating with Barlow's
disease on chromosome 10. Also, associations with left ventricular
hypertrophy and ventricular arrhythmia were revealed for risk loci that
correlate with Barlow's disease. Conclusion(s): This study presents
the first GWAS identifying risk loci associated with FED and Barlow's
disease. PheWAS links lead SNPs to several other cardiac conditions. These
findings could initiate a paradigm shift in understanding the genetic
differences between FED and Barlow's disease.

<93>
Accession Number
647628226
Title
Safety and Efficacy of Contemporary Rapid Deployment Valves-A Comparative
Analysis.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Wilbring M.; Alexiou K.; Matschke K.; Wrobel A.S.; Kappert U.; Arzt S.
Institution
(Wilbring, Alexiou, Matschke, Wrobel, Kappert, Arzt) Department of Cardiac
Surgery, University Heart Center Dresden, Dresden, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Presently two differently designed rapid deployment valves
(RDV) are commercially available-the Edwards INTUITY and the Corcym
Perceval Plus. This study compares valve performances in a large
consecutive cohort. Method(s): All consecutive isolated aortic valve
replacements (AVR) or AVR in combination with CABG were included between
2016 and 2022 using either the INTUITY (n = 309) or the Perceval Plus (n =
338). Multiple valve procedures or non-IFU-conform implantations were
ruled out. The final study group consisted of 647 patients. Preoperative
aortic annular diameter (CT scan and 3D echocardiography), intraoperative
adverse events (AE), predischarge hemodynamic parameters as well as
permanent pacemaker implantation (PPI) rates were analyzed. Predischarge
transthoracic echocardiography was performed by a single examiner between
postoperative day 5 and 6. Result(s): Mean preoperative annular
diameter differed not significantly between both groups (INTUITY 24.7 +/-
2.4 mm versus Perceval Plus 24.2 +/- 2.2 mm; p = 0.06). Intraoperative AE
were likewise counterbalanced by means of valve malpositioning (INTUITY
3.6% versus Perceval Plus 2.4%; p = 0.49), repeated x-clamp (INTUITY 2.9%
versus Perceval Plus 2.4%; p = 0.49), and use of a different prosthesis
(INTUIYT 4.2% versus Perceval Plus 1.8%; p = 0.10). Postoperative mean
effective orifice area generally differed not significantly (INTUITY 1.73
+/- 0.25 cm versus Perceval Plus 1.70 +/- 0.23 cm ; p = 0.15), but was
significantly larger with the Perceval Plus in patients with an aortic
annulus <=23 mm (n = 114; Perceval Plus 1.59 +/- 0.22 cm versus INTUITY
1.44 +/- 0.18 cm ; p = 0.04). Postoperative PVL (>trace) was less frequent
in Perceval Plus (2.4% versus 5.5%; p = 0.04) and PPI rate was comparable
(INTUITY 6.2% versus Perceval Plus 5.9%; p = 1.00). No case of valve
thrombosis was documented. Conclusion(s): Both RDVs are safe and
highly effective with mainly comparable hemodynamic outcomes at a high
safety profile with low rates of permanent pacemaker implantations. The
INTUITY had higher rates of PVL, whereas the Perceval Plus provided larger
EOAs in smaller aortic annulus.

<94>
Accession Number
2034949430
Title
Transcatheter aortic valve replacement in quadricuspid aortic valve: a
systematic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2025. Article
Number: 1572251. Date of Publication: 2025.
Author
Khalifa M.A.; Hashim H.T.; Shimal A.A.; Riyas Mohamed F.R.; Ragunathan S.;
Al Sakini A.S.; Elbadawi M.H.; Irfan M.R.; Moqbel I.; Almualed M.M.;
Al-Ghuraibawi M.; Al-Aboudi B.S.
Institution
(Khalifa, Moqbel) Faculty of Medicine, Cairo University, Cairo, Egypt
(Hashim, Al-Ghuraibawi) College of Medicine, University of Warith
Al-Anbiyaa, Karbala, Iraq
(Shimal, Al Sakini) College of Medicine, University of Baghdad, Baghdad,
Iraq
(Riyas Mohamed, Irfan) College of Medicine, Alfaisal University, Riyadh,
Saudi Arabia
(Ragunathan) Panimalar Medical College and Research Institute, Chennai,
India
(Elbadawi) Faculty of Medicine, University of Khartoum, Khartoum, Sudan
(Almualed) College of Medicine, King Abdulaziz University, Jeddah, Saudi
Arabia
(Al-Aboudi) Faculty of Medicine, University of Kufa, Najaf, Iraq
Publisher
Frontiers Media SA
Abstract
Background: While Transcatheter Aortic Valve Replacement (TAVR) is now a
standard treatment for severe aortic stenosis, its use in patients with
quadricuspid aortic valves (QAV) presents unique challenges. This review
analyzes current evidence to guide clinicians in managing aortic stenosis
in this complex valve morphology. Method(s): Following PRISMA
guidelines, a comprehensive literature search was conducted across
multiple databases up to August 15, 2024. A random-effects model was used
for meta-analysis, focusing on 30-day mortality and procedural success,
with secondary outcomes including paravalvular leak incidence, pacemaker
insertion, hemodynamic changes, and NYHA functional class improvement.
 Result(s): A total of 11 case reports/series were analyzed, involving
17 adult patients with QAV. Participants had a mean age of 73.80 +/- 5.07
years. The mean left ventricular ejection fraction was 41.6%, and the mean
annulus area was 595.5 mm2. Most patients (64.7%) underwent
transfemoral procedures, with nearly 70% receiving a J-valve or Edwards
SAPIEN 3 device. All procedures were largely successful, though 29.4%
experienced leakage or regurgitation. Aortic pre-dilation was done in
41.2% of cases. The mean procedural duration was 102 min, with a
fluoroscopic duration of 15 min. No patients experienced aortic
post-dilation, and one (5.8%) had an atrioventricular block within 30 days
post-procedure. Conclusion(s): TAVR is an effective and growing
treatment for high-risk patients with aortic valve disease, including
those with QAV. While it has high success rates and challenges (i.e.,
post-operatively). Future studies should focus on long-term valve
durability. Copyright 2025 Khalifa, Hashim, Shimal, Riyas Mohamed,
Ragunathan, Al Sakini, Elbadawi, Irfan, Moqbel, Almualed, Al-Ghuraibawi
and Al-Aboudi.

<95>
Accession Number
2033391590
Title
Impact of Continuation Versus Interruption of Oral Anticoagulation During
TAVI on Health-Related Quality of Life.
Source
Catheterization and Cardiovascular Interventions. 105(6) (pp 1329-1337),
2025. Date of Publication: 01 May 2025.
Author
van Ginkel D.J.; Bor W.L.; Aarts H.M.; Dubois C.; Backer O.D.; Rooijakkers
M.J.P.; Rosseel L.; Veenstra L.; Delewi R.; ten Berg J.M.
Institution
(van Ginkel, Bor, ten Berg) Department of Cardiology, St. Antonius
Hospital, Nieuwegein, Netherlands
(Aarts, Delewi) Department of Cardiology, Amsterdam UMC, Amsterdam,
Netherlands
(Aarts) Department of Cardiology, University Medical Center Utrecht,
Utrecht, Netherlands
(Dubois) Department of Cardiovascular Medicine, University Hospital
Leuven, Leuven, Belgium
(Backer) The Heart Center, Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark
(Rooijakkers) Department of Cardiology, Radboud University Medical Center,
Nijmegen, Netherlands
(Rosseel) Department of Cardiology, Hartcentrum Aalst, Aalst, Belgium
(Veenstra, ten Berg) Department of Cardiology, Maastricht University
Medical Center, Maastricht, Netherlands
(Veenstra, ten Berg) Cardiovascular Research Institute Maastricht (CARIM),
Maastricht, Netherlands
Publisher
John Wiley and Sons Inc
Abstract
Background: One-third of patients undergoing TAVR have a concomitant
indication for oral anticoagulation. The impact of continuation as
compared to interruption of oral anticoagulation during TAVR on
health-related quality of life is unknown. Aim(s): To investigate the
impact of continuation as compared to interruption of oral anticoagulation
on health-related quality of life. Method(s): The POPular PAUSE TAVI
(Periprocedural Continuation vs. Interruption of Oral Anticoagulant Drugs
during Transcatheter Aortic Valve Implantation) trial was an
international, open-label, randomized, clinical trial performed at 22
European sites. Health-related quality of life was assessed using the
Kansas City Cardiomyopathy Questionnaire (KCCQ) and Short Form-12 (SF-12)
before, and at 1 and 3 months after TAVR. Result(s): A total of 8
patients were included: 431 were assigned to continuation and 427 to
interruption of oral anticoagulation. Before TAVR, the mean overall KCCQ
summary score was 53.6 (+/-26.0). At 1 month, the mean change in KCCQ
summary score as compared to baseline was +11.4 points (95% confidence
interval [CI] 8.0-14.8) in the continuation group and +12.2 points (95% CI
8.8-15.6) in the interruption group (difference -0.7 points; 95% CI -4.6
to 3.1). At 3 months, the mean change was +11.0 points (95% CI 7.3-14.6)
versus +13.8 points (95% CI 10.2-17.4), respectively (difference -2.8
points; 95% CI -7.1 to 1.5). Mean changes in SF-12 physical and mental
component summary scores showed no differences between both groups at 1
and 3 months after TAVR. Conclusion(s): In patients undergoing TAVR
with a concomitant indication for oral anticoagulation, continuation as
compared to interruption of oral anticoagulation during TAVR did not
significantly impact health-related quality of life up to 3 months after
TAVR. Copyright © 2025 Wiley Periodicals LLC.

<96>
Accession Number
2034255657
Title
RETRACTION: Risk Factors Associated With Surgical Site Infections in
Patients Undergoing Cardiothoracic Surgery: A Systematic Review and
Meta-Analysis(International Wound Journal, (2024), 21, 4, (e14573),
10.1111/iwj.14573).
Source
International Wound Journal. 22(4) (no pagination), 2025. Article Number:
e70526. Date of Publication: 01 Apr 2025.
Author
Zhang Y.; Tan S.; Chen S.; Fan X.
Publisher
John Wiley and Sons Inc
Abstract
RETRACTION: Y. Zhang, S. Tan, S. Chen, and X. Fan, "Risk Factors
Associated With Surgical Site Infections in Patients Undergoing
Cardiothoracic Surgery: A Systematic Review and Meta-Analysis,"
International Wound Journal 21, no. 4 (2024): e14573,
https://doi.org/10.1111/iwj.14573. The above article, published online on
15 December 2023, in Wiley Online Library
(http://onlinelibrary.wiley.com/), has been retracted by agreement between
the journal Editor in Chief, Professor Keith Harding; and John Wiley &
Sons Ltd. Following an investigation by the publisher, all parties have
concluded that this article was accepted solely on the basis of a
compromised peer review process. The editors have therefore decided to
retract the article. The authors did not respond to our notice regarding
the retraction. Copyright © 2025 The Author(s). International
Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons
Ltd.

<97>
Accession Number
2039206194
Title
Temporal Trends and Severity of Postoperative Delirium in Cardiac Surgery:
Insights from a Systematic Review and Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Shamsi T.; Janga S.R.; Baskaran N.U.; Rangasamy V.; Ramachandran R.V.;
Chen M.; Ganesh S.; Novack V.; Subramaniam B.
Institution
(Shamsi, Janga, Baskaran, Rangasamy, Chen) Beth Israel Deaconess Medical
Center, Boston, MA, United States
(Ramachandran) University of Washington Medicine, Seatle, WA, United
States
(Ganesh) New York Institute of Technology College of Osteopathic Medicine,
New York, NY, United States
(Novack) Soroka University Medical Center, Beer-Sheva, Israel
(Subramaniam) Harvard Medical School, Sadhguru Center for a Conscious
Planet, Beth Israel Deaconess Medical Center, Boston, MA, United States
Publisher
W.B. Saunders
Abstract
Postoperative delirium (POD) is one of the most common neurocognitive
complications following cardiac surgery, typically occurring within 72
hours and leading to serious consequences, including falls, prolonged
hospitalization, and increased healthcare costs. Annually, over two
million cardiac surgeries, including coronary artery bypass grafting, are
performed worldwide. This study systematically reviews and meta-analyzes
the incidence, duration, time to onset, and severity of delirium following
cardiac surgery. No previous comprehensive analysis has addressed all
these outcomes, particularly regarding temporal patterns and severity of
POD. A systematic review was performed following PRISMA guidelines. The
studies included adult patients who underwent cardiac surgery and were
assessed for delirium using validated tools. Statistical analyses included
random-effects meta-analysis for incidence rates and subgroup analyses.
Twenty-seven studies involving 5,126 participants from 2009 to March 2024
were included. The overall incidence of POD was 25.1% (95% confidence
interval [CI]: 21.8%-28.3%), with a mean duration of 2.378 days (95% CI:
2.086-2.671), and onset occurring at 1.706 days (95% CI: 1.198-2.214).
Only three studies assessed the severity of delirium, reporting a maximum
Confusion Assessment Method score of 9.308 (95% CI: 7.309-11.307) on a
scale of 0 to 19. Subgroup analyses were conducted to examine
heterogeneity but revealed no significant differences in outcomes.
Therefore, a meta-regression analysis focusing on age, surgery duration,
assessment length, study design, and assessment tools was performed. The
incidence and burden of POD highlight the need for regular screening and
effective management strategies. Copyright © 2025 Elsevier Inc.

<98>
Accession Number
647628181
Title
Sutureless Aortic Valve Replacement Superior to Transcatheter Aortic Valve
Implantation: A State-of-the-Art Systematic Review, Meta-Analysis.
Source
Thoracic and Cardiovascular Surgeon. Conference: 54th Annual Meeting of
the German Society for Thoracic and Cardiovascular Surgery, DGTHG. Hamburg
Germany. 73(Supplement 1) (no pagination), 2025. Date of Publication: 01
Jan 2025.
Author
Ali-Hasan-Al-Saegh S.; Takemoto S.; Shafiei S.; Yavuz S.; Arjomandi Rad
A.; Amanov L.; Merzah A.; Salman J.; Ius F.; Kaufeld T.; Schmack B.; Popov
A.F.; Sabashnikov A.; Ruhparwar A.; Weymann A.
Institution
(Ali-Hasan-Al-Saegh) MHH, Hannover, Germany
(Takemoto) Harvard Medical School, Boston, United States
(Shafiei) Clinic for Cardiac and Thoracic Vascular Surgery, Marburg,
Germany
(Yavuz) Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
(Arjomandi Rad) Imperial College London, London, United Kingdom
(Amanov, Merzah, Salman, Ius, Kaufeld, Ruhparwar) Hannover Medical School,
Hannover, Germany
(Schmack, Popov, Weymann) Department of Cardiothoracic, Transplant and
Vascular Surgery, Hannover Medical School, Hannover, Germany
(Sabashnikov) Royal Brompton and Harefield NHS Foundation Trust,
Harefield, United Kingdom
Publisher
Georg Thieme Verlag
Abstract
Background: The management of patients with aortic valve pathologies can
sometimes fall into a gray zone, where the optimal treatment approach is
not straightforward. The comparative benefits of sutureless aortic valve
replacement (SUAVR) using the bioprosthesis versus transcatheter aortic
valve implantation (TAVI) for the gray zone of aortic valve replacement
procedures remain a topic of debate. To further explore this issue, we
conducted a study with pairwise, singlearm, and Kaplan-Meier-based
meta-analyses to compare the outcomes of SUAVR with the bioprosthesis
versus TAVI, as well as to evaluate the efficacy, safety, and durability
of SUAVR with the bioprosthesis over mid-term and long-term followup
periods. Method(s): The PubMed, PubMed Central, OVID Medline,
Cochrane Library, Embase, and Web of Science databases were systematically
searched. All study types were included, except study protocols and animal
studies, without time restrictions. The final search was performed in May
2024. Result(s): No statistically significant differences were
observed in permanent pacemaker implantation (PPI) rates between the two
groups. SUAVR showed a lower incidence of new-onset myocardial infarction
but was associated with higher rates of new-onset atrial fibrillation and
major bleeding. TAVI had higher rates of left bundle branch block and
major vascular complications. Conclusion(s): Our findings show that
SUAVR has a lower incidence of complications and a favorable mid-term
overall survival compared with TAVI. SUAVR has more advantages compared
with TAVI and can be considered a valuable and promising option for the
grey zone of aortic valve pathologies.

<99>
Accession Number
647628022
Title
CardioAlex 2024.
Source
European Heart Journal, Supplement. Conference: CardioAlex 2024.
Alexandria Egypt. 26(Supplement 5) (no pagination), 2024. Date of
Publication: 01 Sep 2024.
Author
Anonymous
Publisher
Oxford University Press
Abstract
The proceedings contain 7 papers. The topics discussed include: clinical
characteristics and management of patients with heart failure in Egypt:
real-world insights from iCaReMe Global Registry; impact of age at
intervention on three-dimensional RV functions post percutaneous pulmonary
valvuloplasty; incidence of in-hospital MACE in patients presented with
acute STEMI in the presence of CTO in non-IRA; Is dabigatran a good
alternative to warfarin in patients with atrial fibrillation accompanied
by valvular and nonvalvular heart diseases? a systematic review and
meta-analysis; is LVH a must in an amyloid heart?; main predictor of post
CABG mortality and morbidity at National Heart Institute; and sudden
cardiac death initiative: a national campaign to raise awareness of sudden
cardiac death.

<100>
Accession Number
2039206823
Title
Heyde's syndrome: A systematic review of case reports.
Source
BMJ Open Gastroenterology. 9(1) (no pagination), 2022. Article Number:
e000866. Date of Publication: 09 May 2022.
Author
Saha B.; Wien E.; Fancher N.; Kahili-Heede M.; Enriquez N.; Velasco-Hughes
A.
Institution
(Saha, Wien, Fancher, Kahili-Heede, Enriquez, Velasco-Hughes) John A.
Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI,
United States
(Wien, Enriquez) Internal Medicine Residency Program, University of
Hawai'i at Manoa, Honolulu, HI, United States
(Velasco-Hughes) Queen's Medical Group Hospitalist Program, Queen's
Medical Center, Honolulu, HI, United States
Publisher
BMJ Publishing Group
Abstract
Objective Heyde's syndrome (HS), a rare condition characterised by a
unique relationship between severe aortic stenosis and angiodysplasia, is
often diagnosed late increasing the risk for a prolonged hospital course
and mortality in the elderly. The leading hypothesis explaining the
aetiology of HS is acquired von Willebrand syndrome (AVWS) but not all
studies support this claim. While individual cases of HS have been
reported, here we present the first systematic review of case reports and
focus on the prevalence of AVWS. Design A systematic search was conducted
through PubMed/MEDLINE, CINAHL-EBSCO, Web of Science and Google Scholar
since inception. The resulting articles were screened by two independent
reviewers based on inclusion criteria that the article must be a case
report/series or a letter to the editor in English describing HS in an
adult patient. Results Seventy-four articles encompassing 77 cases met the
inclusion criteria. The average age was 74.3+/-9.3 years old with a slight
female predominance. The small intestine, especially the jejunum, was the
most common location for bleeding origin. Capsule endoscopy and double
balloon enteroscopy were superior at identifying bleeding sources than
colonoscopy (p=0.0027 and p=0.0095, respectively) and
oesophagogastroduodenoscopy (p=0.0006 and p=0.0036, respectively). The
mean duration from symptom onset to diagnosis/treatment of HS was
23.8+/-39 months. Only 27/77 cases provided evidence for AVWS. Surgical
and transcutaneous aortic valve replacement (AVR) were superior at
preventing rebleeding than non-AVR modalities (p<0.0001). Conclusion
Further research is warranted for a stronger understanding and increased
awareness of HS, which may hasten diagnosis and optimal
management. Copyright © Author(s) (or their employer(s)) 2022.
Re-use permitted under CC BY-NC. No commercial re-use. See rights and
permissions. Published by BMJ.

<101>
Accession Number
2034972741
Title
Comparative outcomes of Myval versus contemporary transcatheter heart
valves: a systematic review and meta-analysis.
Source
Cardiovascular Intervention and Therapeutics. (no pagination), 2025. Date
of Publication: 2025.
Author
Ozbay M.B.; Degirmen S.; Gullu A.; Nriagu B.N.; Ozen Y.; Celebi O.O.;
Yayla C.
Institution
(Ozbay) Department of Medicine, Penn Medicine Princeton Medical Center,
Plainsboro, NJ, United States
(Degirmen, Nriagu) Department of Medicine, Metropolitan Hospital Center,
New York, NY, United States
(Gullu) Department of Medicine, North Alabama Medical Center, Florence,
AL, United States
(Ozen) Department of Cardiology, Faculty of Medicine, Selcuk University,
Konya, Turkey
(Celebi, Yayla) Department of Cardiology, Ankara City Hospital, University
of Health Sciences, Ankara, Turkey
Publisher
Springer
Abstract
Transcatheter aortic valve replacement is a key intervention for high-risk
patients with severe aortic stenosis. Myval, a newer transcatheter heart
valve (THV), shows promise, but a comprehensive comparison with other THVs
is lacking. This study evaluates the safety and efficacy of Myval compared
with contemporary THVs. A systematic review and meta-analysis of six
studies involving 2335 patients was performed. Primary outcomes included
all-cause mortality, cardiovascular mortality, new permanent pacemaker
implantation (PPI), device success, early safety, acute kidney injury,
stroke, vascular complications, and valve regurgitation. Myval was
associated with significantly lower rates of new PPI (RR, 0.62; 95% CI
0.45-0.86; P =.004), higher rates of device success (RR, 1.08; 95% CI
1.01-1.16; P =.02), and early safety (RR, 1.15; 95% CI 1.05-1.27; P =.003)
compared with contemporary THVs. No significant differences were observed
in all-cause mortality, cardiovascular mortality, acute kidney injury,
stroke, vascular complications, and valve regurgitation. Myval may offer
better short-term outcomes in terms of new PPI, device success, and early
safety compared with contemporary THVs. Larger, prospective studies with
longer follow-ups are needed to confirm these findings. Copyright
© The Author(s) under exclusive licence to Japanese Association of
Cardiovascular Intervention and Therapeutics 2025.

<102>
Accession Number
2039167611
Title
Erector spinae plane block complementary analgesic to enhance recovery
after cardiac surgery: A prospective double-blinded randomized controlled
trial.
Source
Saudi Journal of Anaesthesia. 19(3) (pp 327-333), 2025. Date of
Publication: 01 Jul 2025.
Author
Zabani I.A.; Alamoudi D.; Alhroub K.; Alhassoun A.; Tawfik G.; Alzanbagi
A.; Alzahrani F.; Zia F.; Almuqati R.; Tayeb A.; Alsayouri Z.; Saad H.
Institution
(Zabani, Alamoudi, Alhroub, Alhassoun, Tawfik, Alzanbagi, Alzahrani, Zia,
Almuqati, Tayeb, Alsayouri, Saad) Departments of Anesthesiology, King
Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Post-sternotomy pain is a significant challenge in cardiac
surgeries. Effective pain management can reduce opioid reliance and lower
pain scores, contributing to shorter hospital stays. The erector spinae
plane block (ESPB) has shown promise as an analgesic for various surgical
procedures. Given the frequency of sternotomies in our center and the
associated prolonged pain that delays intensive care unit (ICU) discharge,
we aimed to assess the impact of ESPB on postoperative opioid (fentanyl)
use and pain levels up to 48 h after extubation. Method(s): This
study was a prospective, double-blind, randomized controlled trial
involving 80 adult patients (ASA III) scheduled for cardiac surgery.
Participants were randomized into two groups: the ESPB group (n = 40;
bilateral 0.25% bupivacaine, 20 mL) and a control group (n = 40; no ESPB).
The main outcomes measured were fentanyl use post-surgery and pain scores
using the visual analog scale (VAS). Secondary outcomes included
intraoperative fentanyl use, time to first analgesic dose, extubation
timing, and ICU stay duration. SPSS v.26 was used for statistical
analysis. Result(s): The ESPB group had significantly reduced
fentanyl consumption during intubation (150 [0-800] vs. 950 [30-5260], P <
0.0001), at 3 h post-extubation (25 [0-50] vs. 0 [0-200], P = 0.034), 12 h
post-extubation (0 [0-80] vs. 0 [0-200], P = 0.002), over 12 h total (0
[0-100] vs. 30 [0-600], P = 0.01), at 24 h (0 [0-100] vs. 30 [0-900], P =
0.003), and at 48 h (0 [0-100] vs. 50 [0-1200], P = 0.001). VAS scores
were consistently lower for the ESPB group at rest at multiple points up
to 48 h (P < 0.0001). Additionally, the ESPB group required less
intraoperative fentanyl (P = 0.001), had shorter ICU stays (P = 0.009),
and faster extubation times (P = 0.013). The time to first analgesic and
paracetamol use did not differ significantly (P = 0.97 and 0.255,
respectively). Conclusion(s): The findings suggest that ESPB is an
effective addition to multimodal anesthesia for cardiac surgery,
significantly reducing pain and opioid use, and improving postoperative
outcomes. Copyright © 2025 Saudi Journal of Anesthesia.

<103>
Accession Number
2039207308
Title
The Protective Effect of Remote Ischemic Preconditioning on Acute Kidney
Injury Following Pediatric Cardiac Surgery: A Systematic Review and
Meta-Analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Cheng P.; Wang G.; An Y.
Institution
(Cheng, Wang, An) Department of Thoracic Surgery, Children's Hospital of
Chongqing Medical University, National Clinical Research Center for Child
Health and Disorders, Ministry of Education, Key Laboratory of Child
Development and Disorders, Chongqing Key Laboratory of Structural Birth
Defect and Reconstruction, Chongqing, China
Publisher
W.B. Saunders
Abstract
Cardiac surgery in children is a major risk factor for acute kidney injury
(AKI) because of the high risk of AKI due to the combination of
hemodynamic instability, ischemia-reperfusion injury, and inflammation.
However, the protective role of remote ischemic preconditioning (RIPC) in
this setting is unclear. This systematic review and meta-analysis was
conducted to assess whether RIPC reduces the incidence of AKI in pediatric
cardiac surgery patients. PubMed, EMBASE, and the Cochrane Library were
systematically searched for randomized controlled trials (RCTs) of RIPC in
pediatric cardiac surgery. The primary outcome indicator was the incidence
of postoperative AKI, and secondary outcome indicators included serum
creatinine (sCr) level, tumor necrosis factor (TNF)-alpha level, and
intensive care unit (ICU) length of stay (LOS). Six RCTs with a total of
1,098 patients were included in the analysis. RIPC significantly reduced
the incidence of AKI (odds ratio, 0.38; 95% confidence interval,
0.25-0.60; p < 0.00001; I2 = 38%). There was no significant effect on
postoperative sCr, TNF-alpha levels and ICU LOS (p > 0.05 for all; I2
>80%). Sensitivity analyses showed a large impact of some studies on the
results. The data indicate that RIPC significantly reduced the incidence
of AKI after pediatric cardiac surgery, showing its potential
renoprotective effect. Although the effect on other postoperative
indicators was not significant, high heterogeneity limits the certainty of
the conclusions. Future studies should focus on multicenter, large-scale
trials with detailed subgroup analyses to explore the mechanism of action
and effects of RIPC in different patient populations. Copyright ©
2025 Elsevier Inc.

<104>
Accession Number
647618792
Title
Letter to the editor "meta-analysis of longitudinal comparison of
transcatheter versus surgical aortic valve replacement in patients at low
to intermediate surgical risk".
Source
International journal of surgery (London, England). (no pagination),
2025. Date of Publication: 05 Jun 2025.
Author
Roshanravan N.; Tarighat F.; Parvizi R.
Institution
(Roshanravan) Cardiovascular Research Center, Tabriz University of Medical
Sciences, Tabriz, Iran, Islamic Republic of

<105>
Accession Number
647618639
Title
The role of Blended Learning in Enhancing Self-Efficacy and Medication
Adherence in Cardiac Rehabilitation for Patients Undergoing Coronary
Artery Bypass Surgery: A Randomised Control Trial: Blended learning in
cardiac rehabilitation.
Source
Archives of physical medicine and rehabilitation. (no pagination), 2025.
Date of Publication: 03 Jun 2025.
Author
Veisi G.; Pakrad F.; Gobbens R.; Mohammadi Y.; Majidi L.
Institution
(Veisi) Student Research Committee, Hamadan University of Medical
Sciences, Hamadan, Iran, Islamic Republic of
(Pakrad) Chronic Diseases (Home Care) Research Center, Institute of
Cancer, Avicenna Health Research, Institute, Hamadan University of Medical
Sciences, Hamadan, Iran, Islamic Republic of
(Gobbens) Faculty of Health, Sport and Social Work, Inholland University
of Applied Sciences, Netherlands; Zonnehuisgroep Amstelland, Amstelveen,
Netherlands; Department Family Medicine and Population Health, Faculty of
Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;
Department of Tranzo Academic Centre Transformation in Care and Welfare,
Faculty of Behavioural and Social Sciences, Tilburg University,
Netherlands
(Mohammadi) Modeling of Noncommunicable Diseases Research Center,
Institute of Health Sciences and Technologies, Avicenna Health Research
Institute, Hamadan University of Medical Sciences, Hamadan, Iran;
Department of Epidemiology, School of Public Health, Hamadan, University
of Medical Sciences, Hamadan, Iran
(Majidi) Department of Physical Medicine and Rehabilitation, Faculty of
Medicine, Hamadan University of Medical Sciences, Hamadan, Iran, Islamic
Republic of
Abstract
OBJECTIVE: This study aimed to evaluate the effectiveness of a traditional
cardiac rehabilitation (CR) program compared to an augmented program that
integrates traditional cardiac rehabilitation with face-to-face training
sessions and remote assistance facilitated through an application based on
the Knowledge, Attitude, and Practice (KAP) model for individuals
undergoing coronary artery bypass graft (CABG) surgery. DESIGN: A
randomized controlled trial with a blinded outcome assessment was used
(IRCT20230902059333N1). SETTING: A major heart center in a middle-income
country. PARTICIPANTS: Of the 80 patients referred to the cardiac
rehabilitation program during the study, 70 patients were successfully
enrolled, reaching the target sample size. Participants were randomly
assigned in a 1:1 ratio, resulting in 35 patients per group. INTERVENTION:
In addition to traditional cardiac rehabilitation, patients participated
in four in-person training sessions throughout the rehabilitation process
and received three months of follow-up support via the app after
completing the program. MAIN OUTCOME MEASURES: Medication adherence and
self-efficacy were assessed before the initiation of cardiac
rehabilitation (CR), immediately following the completion of CR, and three
months post-completion of CR. RESULT(S): There were no significant
demographic differences between the intervention and control groups.
However, throughout the study, significant differences emerged in favor of
the 3 group concerning medication adherence and self-efficacy (p<0.001).
The intervention group showed substantial and continuous improvements in
medication adherence and self-efficacy scores, which were evident from the
first month and persisted over time. CONCLUSION(S): Implementing a
blended learning approach in cardiac rehabilitation has demonstrated
benefits in medication adherence and self-efficacy, highlighting the
necessity for further research and clinical application. Copyright
© 2025. Published by Elsevier Inc.

<106>
Accession Number
2039207887
Title
Meta-analysis of transcatheter edge-to-edge repair vs surgery for
secondary mitral regurgitation.
Source
Cardiovascular Revascularization Medicine. (no pagination), 2025. Date of
Publication: 2025.
Author
Singh S.; Shabbir M.A.; Tiwari N.; Bliden K.; Tantry U.S.; Gurbel P.A.;
Kanjwal M.Y.; Lundgren S.W.
Institution
(Singh) Department of Medicine, Sinai Hospital of Baltimore, Baltimore,
MD, United States
(Shabbir, Tiwari, Lundgren) Division of Cardiology, University of Nebraska
Medical Center, Omaha, NE, United States
(Bliden, Tantry) Sinai Center for Thrombosis Research, Sinai Hospital of
Baltimore, Baltimore, MD, United States
(Gurbel, Kanjwal) Division of Cardiology, Sinai Hospital of Baltimore,
Baltimore, MD, United States
Publisher
Elsevier Inc.
Abstract
Background: Transcatheter edge-to-edge repair (TEER) in patients with
secondary mitral regurgitation (MR) has shown variable outcomes in
clinical studies when compared with mitral valve surgery. We conducted a
meta-analysis to reconcile the data. Method(s): Online databases were
searched for studies assessing TEER vs surgery for secondary MR. The
outcomes of interest were length of hospital stay, all deaths, heart
failure (HF) rehospitalization, mitral valve reintervention, implantation
of left ventricular assist device (LVAD), stroke and recurrence of grade 3
or 4 MR. Pooled odds ratios (OR) and standardized mean difference (SMD),
with 95 % confidence intervals (CI) were calculated. Result(s): Eight
studies (1 randomized and 7 observational) with a total of 1436 patients
(TEER n = 826, surgery n = 610) were included. Length of hospital stay was
shorter in the TEER group (SMD -2.50, 95 % CI -4.65 to -0.35, p = 0.02).
No significant differences were found between the two groups with respect
to all deaths (p = 0.80), HF rehospitalization, mitral valve
reintervention, implantation of LVAD and stroke. Recurrence of grade 3 or
4 MR was higher in the TEER group (OR 5.33, 95 % CI 2.57 to 11.03, p <
0.00001). Conclusion(s): In patients with secondary MR, TEER and
surgery have comparable outcomes such as mortality, except for the lower
recurrence of grade 3 or 4 MR in the surgical group. Thus, TEER may be the
first approach in such patients, except in low surgical risk cases who
need other concomitant cardiac surgeries. Copyright © 2025
Elsevier Inc.

<107>
Accession Number
647617968
Title
A Randomized Controlled Trial Comparison of Subcuticular Suture and
Adhesive Strip for Cosmetic Outcome in Median Sternotomy Closure in
Patient Undergoing Cardiac Surgery.
Source
Aesthetic plastic surgery. (no pagination), 2025. Date of Publication: 05
Jun 2025.
Author
Songvasin S.; Winaikosol K.; Karunasumetta C.
Institution
(Songvasin, Karunasumetta) Cardiothoracic Surgery, Srinagarind Hospital
and Queen Sirikit Heart Center of the Northeast, Khon Kaen, Thailand
(Winaikosol) Plastic Surgery, Srinagarind Hospital, Khon Kaen, Thailand
(Karunasumetta) Division of Cardiothoracic Surgery, Faculty of Medicine,
Khon Kaen University, 123/2000 Mittraphap Road, Khon Kaen, Thailand
Abstract
BACKGROUND: The median sternotomy incision is a common approach in cardiac
surgery, often leading to noticeable scar formation that can impact
patients' quality of life. This study aims to compare outcomes between
subcuticular suture and adhesive strip (Steri-stripTM, 3M HealthCare)
closure techniques for median sternotomy incisions in cardiac surgery
patients. METHOD(S): In this prospective randomized controlled trial,
112 patients undergoing cardiac surgery (August 2020 to September 2021)
were assigned to either the adhesive strip or subcuticular suture group.
Wound assessments occurred on postoperative days 3, 7, and before
discharge, monitoring for infection and dehiscence. Follow-ups at 1-2
weeks, 3 months, and 6 months used scar scales, including Vancouver Scar
Scale (VSS), Manchester Scar Scale (MSS), and Patient and Observer Scar
Assessment Scale (POSAS). RESULT(S): Out of a total of 112 patients,
6 were excluded. All remaining patients were completely followed up. No
significant differences were observed in VSS, MSS, POSAS outcomes, or
wound complications during postoperative follow-ups. Adhesive strip
closure took 0.49 minutes, significantly less than 7.27 minutes for
subcuticular sutures (P < 0.001). Furthermore, the total cost of adhesive
strips was lower than the subcuticular suture group. CONCLUSION(S):
The adhesive strips application for skin closure of median sternotomy
wounds was found to be non-inferior to subcuticular sutures in terms of
clinical outcomes and postoperative wound complications. Additionally,
this approach resulted in reduced operative time and proved to be
cost-effective in hospital care. LEVEL OF EVIDENCE I: This journal
requires that authors assign a level of evidence to each article. For a
full description of these Evidence-Based Medicine ratings, please refer to
the Table of Contents or the online Instructions to Authors
www.springer.com/00266 . Copyright © 2025. Crown.

<108>
Accession Number
2039083599
Title
Transcatheter vs. surgical aortic valve replacement in women: The RHEIA
trial.
Source
European Heart Journal. 46(22) (pp 2079-2088), 2025. Date of Publication:
07 Jun 2025.
Author
Tchetche D.; Pibarot P.; Bax J.J.; Bonaros N.; Windecker S.; Dumonteil N.;
Nietlispach F.; Messika-Zeitoun D.; Pocock S.J.; Berthoumieu P.; Swaans
M.J.; Timmers L.; Rudolph T.K.; Bleiziffer S.; Leroux L.; Modine T.; Van
Der Kley F.; Auffret V.; Tomasi J.; Stastny L.; Hengstenberg C.; Andreas
M.; Leclercq F.; Gandet T.; Mascherbauer J.; Trescher K.; Prendergast B.;
Vasa-Nicotera M.; Chieffo A.; Mares J.; Wesselink W.; Rakova R.; Kurucova
J.; Bramlage P.; Eltchaninoff H.
Institution
(Tchetche, Dumonteil) Groupe Cardiovasculaire Interventionnel, Clinique
Pasteur, 45 avenue de Lombez, Toulouse, France
(Pibarot) Department of Cardiology, Quebec Heart & Lung Institute, Laval
University, Quebec City, QC, Canada
(Bax) Department of Cardiology, Leiden University Medical Center, Leiden,
Netherlands
(Bonaros, Stastny) Department of Cardiac Surgery, Medical University of
Innsbruck, Innsbruck, Austria
(Windecker) Department of Cardiology, Inselspital, University of Bern,
Bern, Switzerland
(Nietlispach) HeartCenter im Park, Hirslanden Klinik im Park, Zurich,
Switzerland
(Messika-Zeitoun) Division of Cardiology, University of Ottawa Heart
Institute, Ottawa, ON, Canada
(Pocock) Department of Medical Statistics, London School of Hygiene &
Tropical Medicine, London, United Kingdom
(Berthoumieu) Department of Cardiac and Thoracic Surgery, Clinic Pasteur,
Toulouse, France
(Swaans) Department of Cardiology, St. Antonius Hospital, Nieuwegein,
Netherlands
(Timmers) Department of Cardiology, St Antonius Ziekenhuis Nieuwegein,
Nieuwegein, Netherlands
(Rudolph) Clinic for General and Interventional Cardiology/Angiology,
Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany
(Bleiziffer) Department of Thoracic and Cardiovascular Surgery, Heart and
Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany
(Leroux) Department of Interventional Cardiology, Cardiology Hospital of
the Haut-Leveque, University of Bordeaux, Pessac, France
(Modine) Service Medico-chirurgical de Cardiologie, CHU de Bordeaux,
Pessac, France
(Van Der Kley) Hart Long Centrum, Leids Universitair Medisch Centrum,
Leiden, Netherlands
(Auffret) Service de Cardiologie, CHU de Rennes, Inserm LTSI U1099,
Universite de Rennes 1, Rennes, France
(Tomasi) Chirurgie Thoracique, Cardiaque et Vasculaire, CHU Rennes -
Hopital de Pontchaillou, Rennes, France
(Hengstenberg) Division of Cardiology, Department of Internal Medicine II,
Medical University of Vienna, Vienna, Austria
(Andreas) Department of Cardiac Surgery, Medical University of Vienna,
Vienna, Austria
(Leclercq) Department of Cardiology, Montpellier University Hospital,
Montpellier, France
(Gandet) Chirugie Cardiaque, CHU Montpellier - Hopital Arnaud de
Villeneuve, Montpellier, France
(Mascherbauer) Department of Internal Medicine 3/Cardiology, University
Hospital Sankt Polten, Karl Landsteiner University of Medical Science,
Krems, Austria
(Trescher) Department of Heart Surgery, University Hospital Sankt Polten,
Karl Landsteiner University of Medical Science, Krems, Austria
(Prendergast) St. Thomas' Hospital, London, United Kingdom
(Vasa-Nicotera) Cardiology Department, Hospital Sindelfingen-Boblingen,
Sindelfingen, Germany
(Chieffo) Interventional Cardiology Unit, IRCCS San Raffaele Scientific
Institute, Milan, Italy
(Mares) Department of Data Science, Institute for Clinical and
Experimental Medicine, Prague, Czechia
(Wesselink, Rakova, Kurucova) Edwards Lifesciences, Prague, Czechia
(Bramlage) Institute for Pharmacology and Preventive Medicine,
Cloppenburg, Germany
(Eltchaninoff) Inserm U1096, CHU Rouen, Department of Cardiology, Univ
Rouen Normandie, Rouen, France
Publisher
Oxford University Press
Abstract
Background and Aims Although women with severe symptomatic aortic stenosis
have more complications than men when undergoing surgical valve
replacement, they are under-represented in clinical trials. The Randomized
researcH in womEn all comers wIth Aortic stenosis (RHEIA) trial
investigates the balance of benefits and risks of transcatheter aortic
valve implantation (TAVI) vs. surgery in women. Methods Women were
randomized 1:1 to transfemoral TAVI with a balloon-expandable valve or
surgery. The primary composite endpoint was death, stroke, or (valve,
procedure or heart failure related) rehospitalization at 1 year.
Non-inferiority testing with a pre-specified 6% margin and superiority
testing were performed in the as-treated population. Results At 48
European centres, 443 women underwent randomization, and 420 were treated
as randomized. Mean age was 73 years, and the mean estimated surgical risk
of death was 2.1% (Society of Thoracic Surgeons risk score). Kaplan-Meier
estimates of the primary endpoint event rates at 1 year were 8.9% in the
TAVI and 15.6% in the surgery group. This difference of -6.8% with an
upper 95% confidence limit of -1.5% demonstrated the non-inferiority of
TAVI (P <. 001). The two-sided 95% confidence interval of -13.0% to -.5%
further resulted in superiority (P =. 034). The 1-year incidence of the
primary endpoint components was:. 9% with TAVI vs. 2.0% with surgery for
death from any cause, 3.3% vs. 3.0% for stroke, and 5.8% vs. 11.4% for
rehospitalization. Conclusions Among women with severe aortic stenosis,
the incidence of the composite of death, stroke, or rehospitalization at 1
year was lower with TAVI than with surgery. Copyright © 2025 The
Author(s). Published by Oxford University Press on behalf of the European
Society of Cardiology. All rights reserved.

<109>
Accession Number
2039190729
Title
Comparative Efficacy of Dexmedetomidine versus Midazolam Infusion for
Peri-Extubation Sedation in Adult Cardiac-Surgical Patients: A Prospective
Randomised Study.
Source
International Journal of Current Pharmaceutical Review and Research. 17(4)
(pp 1517-1521), 2025. Date of Publication: 2025.
Author
Sharma A.; Rohilla L.; Yadav S.; Shrivastava A.
Institution
(Sharma) SPS Hospitals, Punjab, Ludhiana, India
(Rohilla) Park Hospital, Rajasthan, Behror, India
(Yadav) RBIPMT, New Delhi, India
(Shrivastava) Anesthesia and Critical care, Punjab, Ludhiana, India
Publisher
Dr. Yashwant Research Labs Pvt. Ltd.
Abstract
Background: Smooth emergence and early extubation after cardiac surgery
demand a sedative that preserves haemodynamic stability without prolonging
ventilation. Midazolam is still widely used, yet dexmedetomidine-an
alpha-2 adrenoceptor agonist with sympatholytic and analgesic-sparing
properties-may confer advantages. Method(s): Sixty adult patients
scheduled for elective cardiac surgery under general anaesthesia were
randomised to receive either dexmedetomidine (0.2-0.7 microg
kg-1 h-1; Group D, n = 30) or midazolam (0.04-0.2 mg
kg-1 h-1; Group M, n = 30) from 15 min before skin
closure until extubation. Both infusions targeted a Richmond
Agitation-Sedation Scale (RASS) 0 to -2 and were combined with fentanyl
0.25 microg kg-1 h-1. Haemodynamic indices (SBP,
DBP, MAP, HR), sedation depth, pain (VAS), ventilation duration, rescue
analgesia, and adverse events were recorded. Result(s): Baseline
demographics were comparable. From 45 min after infusion initiation until
60 min post-extubation, SBP, DBP, MAP and HR were consistently lower in
Group D (p < 0.05). Median pain scores from extubation to 120 min were
lower with dexmedetomidine (VAS 2 [IQR 2-3] vs 3 [2-4]; p < 0.01),
translating into 17% less fentanyl rescue (60.7 +/- 19.2 vs 72.7 +/- 22.0
microg; p = 0.032). Ventilation time shortened by 20 min (116 +/- 22 vs
137 +/- 28 min; p = 0.002). Bradycardia (n = 2) and hypotension (n = 1)
occurred only in Group D but required no intervention. Conclusion(s):
Dexmedetomidine provided superior haemodynamic attenuation, analgesia, and
earlier readiness for extubation compared with midazolam, without
clinically relevant adverse effects. It represents a valuable alternative
for peri-extubation sedation in adult cardiac-surgical
patients. Copyright © 2025 Dr. Yashwant Research Labs Pvt. Ltd..
All rights reserved.

<110>
Accession Number
647595782
Title
Single-stage pulmonary vein isolation combined with percutaneous
implantation of left atrial appendage occluder in patients with recent
onset ischemic stroke and atrial fibrillation (PILOS-AF): a study protocol
of randomized controlled trial.
Source
Cardiology journal. (no pagination), 2025. Date of Publication: 03 Jun
2025.
Author
Wybraniec M.T.; Hoffmann A.; Bochenek T.; Lelek M.; Wita M.; Szydlo K.;
Lasek-Bal A.; Gasior M.; Kalarus Z.; Ptaszynski P.; Kazmierczak J.;
Mizia-Stec K.; Wita K.
Institution
(Wybraniec, Hoffmann, Bochenek, Lelek, Wita, Szydlo, Mizia-Stec, Wita) 1st
Department of Cardiology School of Medicine in Katowice, Medical
University of Silesia, Katowice, Poland
(Wybraniec, Hoffmann, Bochenek, Lelek, Wita, Szydlo, Lasek-Bal,
Mizia-Stec, Wita) Upper-Silesian Medical Center, Katowice, Poland
(Wybraniec, Mizia-Stec) European Reference Network on Heart Diseases-ERN
GUARD-HEART, Amsterdam, Netherlands
(Lasek-Bal) Department of Neurology, School of Health Sciences, Medical
University of Silesia in Katowice
(Gasior) 3rd Department of Cardiology, Faculty of Medical Sciences in
Zabrze, Medical University of Silesia in Katowice, Poland, Silesian Center
for Heart Diseases in Zabrze, Poland 6Department of Cardiology, Congenital
Heart Diseases and Electrotherapy, Faculty of Medical Sciences in Zabrze,
Medical University of Silesia, Katowice, Silesian Center for Heart
Diseases in Zabrze, Zabrze, Poland
(Kalarus) Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Faculty of Medical Sciences in Zabrze, Medical University
of Silesia, Katowice, Silesian Center for Heart Diseases in Zabrze,
Zabrze, Poland
(Ptaszynski) Department of Electrocardiology, Medical University of Lodz,
Lodz, Poland
(Kazmierczak) Department of Cardiology, Pomeranian Medical University,
Szczecin, Poland

<111>
Accession Number
2039197035
Title
72185 , Surgical vs. Medical Treatment of Post-TAVR Endocarditis: A
Meta-Analysis of Outcomes and Insights From Contemporary Cohorts.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100507. Date of Publication: 01 Jun 2025.
Author
Magouliotis D.; Sicouri S.; Baudo M.; Cabrucci F.; Yamashita Y.; Ramlawi
B.
Institution
(Magouliotis, Sicouri, Baudo, Cabrucci, Yamashita) Lankenau Institute for
Medical Research, Wynnewood, PA, United States
(Ramlawi) Lankenau Heart Institute, Wynnewood, PA, United States
Publisher
Elsevier B.V.
Abstract
Background: Infective endocarditis (IE) following transcatheter aortic
valve replacement (TAVR) is a rare but devastating complication. Given the
complexity of these patients and limited data, the benefit of surgery
versus sole medical therapy remains uncertain, especially regarding early
and intermediate outcomes. Method(s): We conducted a meta-analysis of
three contemporary studies evaluating outcomes of surgical versus medical
management for post-TAVR IE. Primary endpoints included 30-day mortality
and 1-year survival. Secondary endpoints were early postoperative
complications. We also compared microbiological profiles, baseline
demographics, and prosthesis types. A combined forest plot summarized key
outcomes. Result(s): Among 1,557 patients with post-TAVR IE, only 155
(10%) underwent surgery. Operated patients were younger (median 73 vs 79
years) and less often female (23% vs 39.6%), with similar rates of kidney
disease, pacemaker presence, and valve type. Balloon-expandable prostheses
were used in 57% of surgical and 50% of medically treated patients. The
most common pathogens were Enterococcus (25%), Staphylococcus aureus
(22%), and Streptococcus species (21%). The distribution of pathogens was
broadly similar between groups, except for Streptococcus species, more
prevalent in medically treated patients. Surgery was associated with a
nonsignificant reduction in 30-day mortality (OR 0.79 [95% CI 0.48-1.30])
and a trend toward improved 1-year survival (OR 1.91 [95% CI 0.36-10.22]),
despite high heterogeneity. Postoperative complications of surgery
included acute renal failure (10%) and a trend toward longer
hospitalizations (20 vs. 18 days), though this difference was not
statistically significant and early mortality remained low.
 Conclusion(s): Despite underutilization, surgery may offer a survival
advantage for carefully selected patients with post-TAVR IE, particularly
in those with guideline-based indications. While short-term outcomes
remain comparable, emerging data support reevaluation of operative
thresholds. Multidisciplinary decision-making and earlier referral to
experienced centers may be pivotal in improving survival in this high-risk
population. Copyright © 2025

<112>
Accession Number
2039197072
Title
71850 , Transcatheter Edge-to-Edge Repair With MitraClip for Papillary
Muscle Rupture in Acute Coronary Syndrome: A Systematic Review of 1-Year
Outcomes.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100624. Date of Publication: 01 Jun 2025.
Author
Alkhatib R.; Hatab T.; Badwan O.; Rosenzveig A.; Massad F.; Mirzai S.;
Harb S.; Puri R.; Reed G.; Krishnaswamy A.; Kapadia S.
Institution
(Alkhatib, Badwan, Massad, Harb) Cleveland Clinic Foundation, Cleveland,
OH, United States
(Hatab) Cleveland Clinic Hospital, Cleveland, OH, United States
(Rosenzveig, Reed, Krishnaswamy, Kapadia) Cleveland Clinic, Cleveland, OH,
United States
(Mirzai) Wake Forest University School of Medicine, Winston-Salem, NC,
United States
(Puri) CCF, Cleveland Heights, OH, United States
Publisher
Elsevier B.V.
Abstract
Background: Papillary muscle rupture (PMR) is a life-threatening
complication of acute coronary syndrome (ACS) with high mortality. While
mitral valve surgery is standard treatment, it carries significant risk.
This study assesses transcatheter edge-to-edge repair (TEER) outcomes for
PMR with up to 1-year follow-up data. Method(s): A systematic review
was conducted of MEDLINE/PubMed, Embase, and Cochrane databases using the
keywords ["papillary muscle rupture" AND "Acute coronary syndrome"] and
["MitraClip" OR "transcatheter edge-to-edge repair"]. The search included
studies published until January 16, 2024. Result(s): Six studies with
62 patients were included. The median age was 68, and 40% were female. All
patients (100%) had grade 3+ mitral regurgitation (MR), reduced to 8%
post-intervention. Procedural success was 93%, with 1.8 +/- 0.2 devices
used per patient. Nine patients (15%) required conversion to MV surgery.
The post-procedural mean mitral gradient was 4.3 mmHg. 82% required
mechanical circulatory support, with 60% on intra-aortic balloon pump. The
30-day mortality rate was 44%. Among survivors (n=36), only one additional
death occurred at 1-year follow-up. Functional status improved, with NYHA
class >=III decreasing from 100% pre-intervention to 35%
post-intervention. [Formula presented] Conclusion(s): TEER with the
MitraClip system represents an alternative for high-risk patients with PMR
secondary to ACS, particularly given the prohibitive surgical risk and
high mortality associated with mitral valve surgery. Although early
mortality remains high, survivors demonstrate significant improvement in
MR severity and functional capacity. Copyright © 2025

<113>
Accession Number
2039197064
Title
71690 , Transcatheter Aortic Valve Replacement (TAVR) Versus Surgical
Aortic Valve Replacement (SAVR) in Low-Risk Patients at 5 Years: An
Updated Meta-Analysis of Randomized Controlled Trials.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100627. Date of Publication: 01 Jun 2025.
Author
Goel S.
Institution
(Goel) Mount Sinai South Nassau Hospital, New York, NY, United States
Publisher
Elsevier B.V.
Abstract
Background: TAVR is increasingly utilized in younger, low-risk patients
with severe, symptomatic aortic stenosis. Understanding long-term outcomes
is essential for guiding treatment decisions in this population, which may
require future reintervention. Method(s): We conducted a systematic
search of electronic databases for randomized controlled trials (RCTs)
comparing TAVR and SAVR in low-surgical-risk patients with reported 5-year
outcomes. Pooled event rates were analyzed using a fixed-effects model and
presented as odds ratios (ORs) with 95% confidence intervals (CIs).
 Result(s): Three RCTs (PARTNER 3, Evolut Low Risk, and NOTION),
including 2,644 patients (1,371 TAVR; 1,273 SAVR), met inclusion criteria.
TAVR was non-inferior to SAVR for All-cause mortality (OR = 1.02, 95% CI:
0.81-1.29, p = 0.84), Cardiac mortality (OR = 0.88, 95% CI: 0.67-1.17, p =
0.40), Stroke (OR = 1.09, 95% CI: 0.82-1.46, p = 0.56), Myocardial
infarction (OR = 1.14, 95% CI: 0.78-1.76, p = 0.50) and Aortic valve
reintervention (OR = 0.98, 95% CI: 0.56-1.69, p = 0.94). TAVR was
associated with a significantly higher risk of new permanent pacemaker
implantation (OR = 2.71, 95% CI: 2.16-3.39, p < 0.00001), while SAVR had a
higher incidence of new-onset atrial fibrillation (OR = 0.25, 95% CI:
0.19-0.29, p < 0.00001). [Formula presented] Conclusion(s): At 5-year
follow-up, TAVR is comparable to SAVR in low-risk patients with respect to
major clinical outcomes. These findings support the continued use of TAVR
in selected low-risk patients, while emphasizing the importance of
individualized decision-making and long-term monitoring. Copyright
© 2025

<114>
Accession Number
2039196912
Title
72309 , Comparative Efficacy of Transcatheter and Surgical Treatments for
Concomitant Aortic Stenosis and Coronary Artery Disease.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100532. Date of Publication: 01 Jun 2025.
Author
Shehzad M.; Ahmad M.; Shehzad D.; Hazaveh S.; Yoon S.-H.; Kampaktsis P.;
Wengrofsky P.; Basman C.; Kaple R.
Institution
(Shehzad, Hazaveh, Yoon, Kampaktsis, Wengrofsky, Basman) Hackensack
University Medical Center, Hackensack, NJ, United States
(Ahmad) Khyber Medical College, Peshawar, Pakistan
(Shehzad) University of South Dakota, Sioux Falls, SD, United States
(Kaple) Hackensack University Medical Center, New Jersey, NJ, United
States
Publisher
Elsevier B.V.
Abstract
Background: Aortic stenosis (AS) and coronary artery disease (CAD) often
coexist, complicating management in elderly patients. While surgical
aortic valve replacement (SAVR) with coronary artery bypass grafting
(CABG) remains standard, transcatheter aortic valve replacement (TAVR) and
percutaneous coronary intervention (PCI) offer less invasive alternatives.
This systematic review and meta-analysis compared clinical outcomes of
TAVR + PCI versus SAVR + CABG in patients with both AS and CAD.
 Method(s): A systematic literature search was performed across
MEDLINE, Embase, and Cochrane databases through March 2025. Studies
included randomized controlled trials, cohort studies, and comparative
observational designs involving patients undergoing either TAVR + PCI or
SAVR + CABG. Primary and secondary outcomes included 30-day and long-term
mortality, myocardial infarction, stroke, major bleeding, acute kidney
injury, atrial fibrillation, pacemaker implantation, repeat
revascularization, vascular complications, and hospital length of stay.
Two reviewers independently extracted data and assessed study quality
using the Cochrane Risk of Bias Tool and Newcastle-Ottawa Scale. A
random-effects meta-analysis was performed using STATA. Result(s):
Fourteen studies met inclusion criteria; 13 were eligible for quantitative
synthesis. Compared to SAVR + CABG, TAVR + PCI was associated with lower
risk of 30-day MI (RR 0.68), stroke (RR 0.82), major bleeding (RR 0.44),
AKI (RR 0.44), atrial fibrillation (RR 0.20), and shorter hospital stay
(RR 0.38). SAVR + CABG showed benefits in reduced 30-day vascular
complications (RR 2.60), long-term repeat revascularization (RR 4.72), and
lower pacemaker implantation (RR 2.29). No significant difference was
observed in 30-day or long-term mortality between strategies.
 Conclusion(s): TAVR + PCI demonstrates favorable short-term outcomes
and may be particularly advantageous for high-surgical-risk patients. In
contrast, SAVR + CABG remains a robust strategy, particularly in lowering
future revascularization and conduction-related complications. These
findings emphasize the need for individualized, multidisciplinary
decision-making when treating patients with concomitant AS and
CAD. Copyright © 2025

<115>
Accession Number
2039197018
Title
71518 , Impact of Prior History of Hospitalization for Heart Failure on
Clinical Outcomes After Transcatheter Aortic Valve Replacement in Patients
With Severe Aortic Stenosis: A Systematic Review and Meta-Analysis.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100577. Date of Publication: 01 Jun 2025.
Author
Obi O.; Nweze U.; Asonye P.; Lajczak P.; Eltawansy S.; Calistro C.;
Kaushal R.; Vathappallil P.; Di Caro F.; Gailot A.
Institution
(Obi) New York Institute of Technology College of Osteopathic Medicine,
Old Westbury, New York, United States
(Nweze) University of Massachusetts Global, Aliso Viejo, CA, United States
(Asonye) University of Illinois at Chicago, Chicago, IL, United States
(Lajczak) Medical University of Silesia, Katowice, Poland
(Eltawansy) Jersey Shore University Medical Center, Monroe, NJ, United
States
(Calistro, Kaushal, Vathappallil, Di Caro) New York Institute of
Technology College of Osteopathic Medicine New York, Old Westbury, New
York, United States
(Gailot) American University of the Caribbean School of Medicine, Cupecoy,
Sint Maarten (Dutch part), United States
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is the
alternative treatment option for patients with severe aortic stenosis
where surgical aortic valve replacement is contra-indicated. There is
limited data regarding the impact of rehospitalization for heart failure
on clinical outcomes post-TAVR in patients with severe aortic stenosis.
 Method(s): We systematically searched PubMed, Embase, and Cochrane
library for observational studies comparing the impact of prior history of
hospitalization for heart failure on clinical outcomes in patients with
severe aortic stenosis post-TAVR. The primary outcome was all-cause
mortality. Pooled odds ratios (ORs) and mean differences (MDs) with 95%
confidence intervals (CIs) were calculated using a random-effects model.
 Result(s): We included 6 observational studies consisting of 21,099
patients of which 8726 (41.4%) patients had TAVR for severe aortic
stenosis and also had prior history of hospitalization for heart failure.
The mean age was 87.2 +/- 10.5 years and 68.4 % were male sex. The pooled
analysis showed that patients with severe aortic stenosis readmitted for
heart failure post-TAVR have increased incidence of all-cause mortality
(OR = 2.00; 95% CI [1.29; 3.10]; I2 = 78%; p = 0.002), AKI (p < 0.001),
bleeding (p < 0.001) and hospital length of stay (p < 0.01) compared to no
history of readmission for heart failure. However, there were no
significant differences between groups for ICU length of stay (p = 0.06),
moderate or severe aortic regurgitation (p = 0.427), moderate or severe
tricuspid regurgitation (p = 0.205), PPI (p = 0.089), stroke (p = 0.664)
and vascular complications (p = 0.472). Readmission for heart failure
significantly reduced the aortic mean gradient (p < 0.01), aortic valve
area (p < 0.01), and LVEF (p < 0.01) but patients with no history of
readmission for heart failure have reduced incidence of moderate or severe
mitral regurgitation (p < 0.001). Conclusion(s): A prior history of
hospitalization for heart failure is associated with worsen clinical
outcomes of all-cause mortality, AKI, bleeding and hospital length of stay
in patients with severe aortic stenosis post-TAVR. Copyright ©
2025

<116>
Accession Number
2039196922
Title
71639 , Transcatheter Aortic Valve Replacement in Systolic Heart Failure
and Moderate Aortic Stenosis: Ischemic vs. Non-Ischemic Cardiomyopathy -
Insights From the TAVR UNLOAD Trial.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100584. Date of Publication: 01 Jun 2025.
Author
von Stein P.; Guthoff H.; Thompson J.; Spitzer E.; Pibarot P.; Bax J.;
Tijssen J.; Chuang M.; Kobayashi Y.; Abu-Much A.; Popma A.; Cohen D.;
Redfors B.; Leon M.; Van Mieghem N.
Institution
(von Stein, Kobayashi) CRF, New York, NY, United States
(Guthoff) Cologne University Hospital, Cologne, Germany
(Thompson, Abu-Much, Redfors) Cardiovascular Research Foundation, New
York, NY, United States
(Spitzer) Cardialysis, Rotterdam, Netherlands
(Pibarot) Quebec Heart and Lung Institute, Quebec, QC, Canada
(Bax) Leiden University Medical Center, Leiden, Netherlands
(Tijssen) Amsterdam UMC, Location AMC, Naarden, Netherlands
(Chuang) CRF, Newton, MA, United States
(Popma) CRF Clinical Trials Center, New York, NY, United States
(Cohen) St. Francis Hospital, New York, NY, United States
(Leon) Newyork-Presbyterian Columbia University Irving Medical Center, New
York, NY, United States
(Van Mieghem) Erasmus University Medical Center, Rotterdam, Netherlands
Publisher
Elsevier B.V.
Abstract
Background: In the TAVR UNLOAD trial (NCT02661451), transcatheter aortic
valve replacement (TAVR) was not superior to clinical aortic stenosis
surveillance (CASS) in patients with moderate aortic stenosis (AS) and
heart failure with reduced ejection fraction (HFrEF). Whether outcomes
differ between ischemic (ICM) and non-ischemic cardiomyopathy (NICM)
remains unclear and is the focus of this analysis. Method(s): The
TAVR UNLOAD trial was an international, randomized controlled trial that
enrolled HFrEF patients with moderate AS, eligible for transfemoral TAVR.
From 01/2017-12/2022, participants were randomized 1:1 to TAVR or CASS.
The primary endpoint for this sub-analysis was 1-year change in left
ventricular ejection fraction (LVEF). Secondary endpoints included Kansas
City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) change,
all-cause mortality, and HF hospitalizations (HFH), within 1-year.
 Result(s): A total of 178 patients (age 77.4+/-9.2 years; 20.8%
female; 55.6% NYHA class>=III; LVEF 39.0+/-9.1%) were randomized to TAVR
(n=89) or CASS (n=89); 66.3% had ICM (TAVR 64.0%, CASS 68.5%, p=0.60). In
ICM, LVEF increased by 3.2+/-11.3% with TAVR (p=0.018) and 4.0+/-8.5% with
CASS (p=0.014). In NICM, LVEF increased by 7.0+/-10.9% (p=0.005) with TAVR
and 4.8+/-10.1% with CASS (p=0.10). No interaction was observed between
treatment and etiology for LVEF change (p=0.76). KCCQ-OS improved with
TAVR in ICM (60.0+/-23.1 to 72.4+/-23.6, p<0.001) and NICM (58.9+/-24.0 to
72.3+/-23.6, p=0.01), but not with CASS (ICM: 52.2+/-21.8 to 55.9+/-26.4,
p=0.33; NICM: 63.6+/-23.1 to 65.8+/-24.7; p=0.66). No interaction between
treatment and etiology was observed for KCCQ-OS change (p=0.75). In ICM,
1-year mortality was numerically lower with TAVR (7.2%) and CASS (17.0%,
p=0.10), with numerically lower HFH (19.6% vs. 31.1%, p=0.16). In NICM,
rates were similar for mortality (12.9% vs. 8.0%, p=0.65) or HFH (16.1%
vs. 12.3%, p=0.81). Conclusion(s): No differential treatment effects
of TAVR vs. CASS were observed across cardiomyopathy subtypes in patients
with moderate AS and HFrEF. Further subgroup analyses are warranted to
identify patients who may derive benefit from TAVR in moderate AS and
HFrEF. Copyright © 2025

<117>
Accession Number
2039197022
Title
71948 , Transradial vs Transfemoral Secondary Access for Transfemoral
TAVR.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100514. Date of Publication: 01 Jun 2025.
Author
Krishna M.; Ezenna C.; Joseph M.; Mouslmani M.; Nouri A.; Rossi R.; Chi
K.Y.; Sanchez L.; Nanna M.; Goldsweig A.
Institution
(Krishna) Government Medical College Thiruvananthapuram, Kerala,
Mavelikara, India
(Ezenna) University of Massachusetts - Baystate Medical Center,
Springfield, MA, United States
(Joseph) Government Medical College Thiruvananthapuram, Kerala,
Thodupuzha, India
(Mouslmani, Nouri, Rossi) Yale School of Medicine, New Haven, CT, New
Haven, CT, United States
(Chi) Jacobi Medical Center, Bronx, NY, United States
(Sanchez) Clinico Lozano Blesa University Hospital, Zaragoza, Spain
(Nanna) Yale School of Medicine, New Haven, CT, United States
(Goldsweig) University of Massachusetts-Baystate, Springfield, MA, United
States
Publisher
Elsevier B.V.
Abstract
Background: A quarter of vascular complications associated with
transfemoral (TF) transcatheter aortic valve replacement (TAVR) are
related to TF secondary access. Transradial (TR) secondary access may
provide a safer alternative, but aggregate data from many studies will be
necessary to support future guideline recommendations for secondary access
site selection. Method(s): We systematically searched PubMed, Scopus,
and Cochrane Central databases for studies comparing TR and TF secondary
access during TAVR. Outcomes of interest included vascular and bleeding
complications, mortality, transient ischemic attack (TIA)/stroke, acute
kidney injury (AKI), and contrast and fluoroscopy doses. Random effects
models were used to generate risk ratios (RRs) with 95% confidence
interval (CIs). Result(s): Systematic review identified 8 studies (1
randomized controlled trial, 7 observational) with 15,221 patients, 22% of
whom underwent TF-TAVR with TR secondary access. Major vascular
complications (RR 0.62; 95%CI 0.51-0.74; p<0.001; I2=0%), major and
life-threatening bleeding (RR 0.54; 95%CI 0.45-0.64; p<0.001; I2=0%),
minor bleeding (RR 0.66; 95%CI 0.53-0.81; p<0.001; I2=0%), all-cause
mortality (RR 0.45; 95%CI 0.35-0.57; p<0.001; I2=0%), TIA/stroke (RR 0.64;
95%CI 0.41-0.99; p=0.04; I2=32%), and severe AKI (RR 0.48; 95%CI
0.38-0.60; p<0.001; I2=0%) were significantly lower with TR secondary
access. Contrast volume and fluoroscopy time were comparable for both.
[Formula presented] Conclusion(s): TR secondary access offers greater
safety than TF secondary access for TF-TAVR. TR secondary access should be
widely adopted and recommended by future guidelines. Copyright ©
2025

<118>
Accession Number
2039197295
Title
71430 , Long-Term Outcomes of Balloon Aortic Valvuloplasty Versus
Surgical Aortic Valvuloplasty in Pediatric Patients With Isolated
Congenital Aortic Valve Stenosis: A Systematic Review and Meta-Analysis.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100600. Date of Publication: 01 Jun 2025.
Author
Atta K.; Abdelaziz A.; Gadelmawla A.F.; Sobhy A.; Murad M.R.; AbdelAziz
M.; Shirokova A.; Samoshkina E.
Institution
(Atta) National Research Mordovia State University, Saransk, Russian
Federation
(Abdelaziz, Murad, AbdelAziz) Faculty of Medicine, Al-Azhar University,
Cairo, Egypt
(Gadelmawla) Faculty of Medicine, Menoufia University, Menoufia, Egypt
(Sobhy) Faculty of Medicine, Kafr El-Shiekh University, Kafr El-Shaikh,
Egypt
(Shirokova, Samoshkina) Department of Pediatrics of the Medical Institute,
National Research Mordovia State University, Saransk, Russian Federation
Publisher
Elsevier B.V.
Abstract
Background: Congenital aortic valve stenosis (CAS) is the most type of
ventricular outflow obstruction accounting for 5% of congenital heart
diseases. Surgical aortic valvuloplasty (SAV) and balloon aortic
valvuloplasty (BAV) are the most common primary interventions, with
conflict data regarding their long-term assessment. Method(s): We
searched PubMed, Scopus, WOS, and the Cochrane Library for relevant
observational studies that reported long-term outcomes of BAV versus SAV
in patients with CAS. The primary outcome was the rate of 10-year aortic
valve replacement (AVR), while other secondary outcomes were rates of
10-year reintervention, and reduction in peak aortic valve gradient
(PAGP). All clinical outcomes were analyzed according to the age of
included children. Result(s): A total of nine observational trials
including 1704 patients (four studies with patients aged <1 year and five
with >1 year, 71.8% males, and median follow-up of 10 years) were
included. The pooled estimate of children aged less than one year and aged
more than one year showed that SAV had similar rates of AVR as BAV (RR=
0.79, 95% CI: 0.62 to 1.01, p= 0.06), and (RR= 0.82, 95% CI: 0.43 to 1.57,
p= 0.54). However, SAV was associated with lower 10-years reintervention
rates (RR= 0.76, 95% CI: 0.6 to 0.96, p= 0.02), and reduction in PAGP (MD=
11.53, 95% CI: 18.66 to 4.41, p< 0.001) in patients aged more than 1 year.
[Formula presented] Conclusion(s): When addressing CAS in pediatric
patients especially in infants and young children, SAV is associated with
similar long-term AVR rates as BAV, but with lower incidence of long-term
reintervention rates, and reduction in PAGP. Copyright © 2025

<119>
Accession Number
2039197090
Title
71851 , Outcomes of Transcatheter Tricuspid Valve Replacement Across
Devices: A Comprehensive Pooled Analysis.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100615. Date of Publication: 01 Jun 2025.
Author
Hatab T.; Alkhatib R.; Badwan O.; Rosenzveig A.; Massad F.; Kritya M.;
Mirzai S.; Harb S.; Puri R.; Reed G.; Krishnaswamy A.; Kapadia S.
Institution
(Hatab) Cleveland Clinic Hospital, Cleveland, OH, United States
(Alkhatib, Badwan, Massad, Harb) Cleveland Clinic Foundation, Cleveland,
OH, United States
(Rosenzveig, Reed, Krishnaswamy, Kapadia) Cleveland Clinic, Cleveland, OH,
United States
(Kritya) HMH, Houston, TX, United States
(Mirzai) Wake Forest University School of Medicine, Winston-Salem, NC,
United States
(Puri) CCF, Cleveland Heights, OH, United States
Publisher
Elsevier B.V.
Abstract
Background: The FDA recently approved the EVOQUE Transcatheter Tricuspid
Valve Replacement (TTVR) System (Edwards Lifesciences, Irvine, CA) for the
treatment of severe TR. However, comparative outcomes among different TTVR
platforms remain unclear. This study aims to systematically review and
pool the outcomes of various TTVR platforms. Method(s): We conducted
a systematic review of MEDLINE/PubMed, Embase, and Cochrane databases
using the keywords ["tricuspid"] and ["transcatheter valve replacement"]
and ["valve replacement"]. The search included studies published from the
inception of each database until December 15, 2024. Result(s): A
total of 16 studies were included, comprising 774 patients. The
distribution of studies was as follows: 9 on LuX-Valve, 5 on EVOQUE, 1 on
CardioValve, 1 on NaviGate, and 1 on MonarQ. Among patients, 70% were
female, 87% had atrial fibrillation, and 33% had chronic kidney disease.
The median LVEF was 55% (IQR: 55-60). At baseline, 96% of patients
had>=severe TR, and 82% were in NYHA class III/IV. In-hospital and 30-day
mortality were lower in EVOQUE patients compared to other TTVR platforms
(0.6% vs 6% and 2.4% vs 8.3%, respectively). However, the incidence of new
PPM implantation was higher in EVOQUE patients (13.2% vs 4.8%).
Residual>=severe TR and NYHA III/IV status at the last follow-up were
comparable between groups. [Formula presented] Conclusion(s): The
EVOQUE system is associated with lower short-term mortality but a higher
incidence of new PPM implantation than other TTVR platforms, while all
devices demonstrate similar effectiveness in reducing TR severity and
improving functional status. Copyright © 2025

<120>
Accession Number
2039197075
Title
71658 , Impact of Sodium Glucose Co-Transporter 2 Inhibitors on Clinical
Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A
Systematic Review and Meta-Analysis.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100587. Date of Publication: 01 Jun 2025.
Author
Obi O.; Lajczak P.; Eltawansy S.; Nweze U.; Unegbe C.; Asonye P.; Gailot
A.
Institution
(Obi) New York Institute of Technology College of Osteopathic Medicine,
Old Westbury, New York, United States
(Lajczak) Medical University of Silesia, Katowice, Poland
(Eltawansy) Jersey Shore University Medical Center, Monroe, NJ, United
States
(Nweze) University of Massachusetts Global, Aliso Viejo, CA, United States
(Unegbe) Sutton Primary Care Networks, London, United Kingdom
(Asonye) University of Illinois at Chicago, Chicago, IL, United States
(Gailot) American University of the Caribbean School of Medicine, Cupecoy,
Sint Maarten (Dutch part), United States
Publisher
Elsevier B.V.
Abstract
Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors improve
cardiovascular outcomes in patients with heart failure, diabetes, and
coronary artery disease. However, their impact on outcomes during
transcatheter aortic valve implantation (TAVI) remains unclear. This study
examines the impact of SGLT2 inhibitor on clinical outcomes in patients
undergoing TAVI. Method(s): PubMed, Embase and Cochrane databases
were systematically searched for both randomized controlled trials and
observational studies comparing the impact of SGLT2-inhibitors on clinical
outcomes in patients post-TAVR, with primary outcome of interest being
all-cause mortality. We pooled odds ratio (OR) along with their 95%
confidence intervals (CIs). We examined heterogeneity using I2 statistics
and studies with high heterogeneity were examined with random-effect
model. Result(s): We included 1 RCT and 2 observational studies
consisting of 65,684 patients of which 6,352 (9.7%) patients were treated
with SGLT2-inhibitors during TAVI. The mean age of included patients was
81.2 years and 58.8% were men. The pooled odds ratio analysis showed no
significant differences between groups for all-cause mortality (OR = 0.58;
95% CI [0.31, 1.08]; p = 0.09; Figure 1). Similarly, there were no
significant differences between groups for the outcomes of cardiovascular
death (OR = 0.48; 95% CI [0.15, 1.60]; p = 0.23) and rehospitalization for
heart failure (HF) (OR = 0.54; 95% CI [0.24, 1.04]; p = 0.06). [Formula
presented] Conclusion(s): Our meta-analysis showed no significant
differences between groups for all-cause mortality, cardiovascular death
and rehospitalization for HF. Copyright © 2025

<121>
Accession Number
2039197312
Title
71882 , Impact of Cardiac Damage Staging in Patients With Moderate Aortic
Stenosis and Reduced Left Ventricular Ejection Fraction: Insights From the
TAVR UNLOAD Trial.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100614. Date of Publication: 01 Jun 2025.
Author
Kobayashi Y.; Thompson J.; Chuang M.; Spitzer E.; Pibarot P.; Bax J.;
Tijssen J.; Hahn R.; Cristell N.; Vives A.; Abu-Much A.; Popma A.; Cohen
D.; Redfors B.; Leon M.; Van Mieghem N.
Institution
(Kobayashi, Vives) CRF, New York, NY, United States
(Thompson, Cristell, Abu-Much, Redfors) Cardiovascular Research
Foundation, New York, NY, United States
(Chuang) CRF, Newton, MA, United States
(Spitzer) Cardialysis, Rotterdam, Netherlands
(Pibarot) Quebec Heart and Lung Institute, Quebec, QC, Canada
(Bax) Leiden University Medical Center, Leiden, Netherlands
(Tijssen) Amsterdam UMC, Location AMC, Naarden, Netherlands
(Hahn) Columbia Unversity College of Physicians, New York, NY, United
States
(Popma) CRF Clinical Trials Center, New York, NY, United States
(Cohen) St. Francis Hospital, New York, NY, United States
(Leon) Newyork-Presbyterian Columbia University Irving Medical Center, New
York, NY, United States
(Van Mieghem) Erasmus University Medical Center, Rotterdam, Netherlands
Publisher
Elsevier B.V.
Abstract
Background: Cardiac damage predicts outcomes in patients with symptomatic
severe aortic stenosis (AS) following aortic valve replacement (AVR). In
patients with moderate AS and reduced left ventricular ejection fraction,
the TAVR UNLOAD trial (NCT02661451) showed that pre-emptive transcatheter
AVR (TAVR) improved quality-of-life compared to clinical aortic stenosis
surveillance (CASS). Method(s): In the TAVR UNLOAD trial, 178
patients were randomized to TAVR or CASS. Cardiac damage was staged as:
left ventricular damage (Stage 1), left atrial or mitral valve damage
(Stage 2), pulmonary vasculature or tricuspid valve damage (Stage 3), or
right ventricular damage (Stage 4). Major adverse cardiovascular and
cerebrovascular events (MACCE: death, disabling stroke,
disease-related/heart failure hospitalization) and the change in Kansas
City Cardiomyopathy Questionnaire (KCCQ) score at 1 year were compared
between patients with left-heart damage (LH damage: Stage 1+2) and
right-heart damage (RH damage: Stage 3+4). Models adjusted for treatment,
cardiac damage stage, and their interaction were constructed.
 Result(s): At 1 year, RH damage (28%) had a trend towards association
with higher odds of MACCE vs. LH damage (Odds Ratio=2.08, p=0.065). There
was no significant difference in the relationship between the treatment
and MACCE between RH vs. LH damage (p-interaction=0.27). There was a
difference in the relationship between treatment and KCCQ in patients with
LH damage and those with RH damage (p-interaction=0.01). Among patients
with LH damage, there was no association between the treatment and the
change in KCCQ (p=0.61). However, among patients with RH damage, TAVR was
associated with improvement in KCCQ compared with CASS (beta=0.67,
p=0.02). Conclusion(s): While there was a trend indicating RH damage
may be associated with worse outcomes, there was no differential effect by
cardiac damage. Better symptomatic improvement with TAVR compared to CASS
was seen in patients with RH damage, suggesting the benefit of early
intervention in patients with RH damage. Copyright © 2025

<122>
Accession Number
2039196916
Title
72045 , Complete Transcatheter vs. Surgical Strategies for Aortic
Stenosis With Coronary Artery Disease: A Meta-Analysis of Randomized and
Propensity-Matched Studies.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100523. Date of Publication: 01 Jun 2025.
Author
Baudo M.; Leone P.P.; Sicouri S.; Magouliotis D.; Yamashita Y.; Cabrucci
F.; Sturla M.; Latib A.; Ramlawi B.
Institution
(Baudo, Sicouri, Magouliotis, Yamashita, Cabrucci) Lankenau Institute for
Medical Research, Wynnewood, PA, United States
(Leone, Sturla) Montefiore Medical Center, New York, NY, United States
(Latib) Montefiore Medical Center, Bronx, NY, United States
(Ramlawi) Lankenau Heart Institute, Wynnewood, PA, United States
Publisher
Elsevier B.V.
Abstract
Background: Coronary artery disease is commonly found in patients with
severe aortic stenosis. While guidelines recommend surgical aortic valve
replacement (SAVR) combined with coronary artery bypass grafting (CABG) as
first-line treatment, a completely percutaneous strategy emerges as a
promising alternative, especially for high-risk surgical patients.
 Method(s): A systematic review was conducted from inception until
December 2024 for randomized and propensity-score studies comparing
SAVR+CABG and transcatheter aortic valve implantation (TAVI) with
percutaneous coronary intervention (PCI). Kaplan-Meier derived individual
patient data was retrieved when available. Result(s): Six studies met
our inclusion criteria with a total of 1,998 patients: 990 in the
SAVR+CABG group and 1,007 in the TAVI+PCI group. TAVI+PCI group reported
higher rates of postoperative moderate/severe aortic regurgitation
(p<0.001), permanent pacemaker implantation (p=0.005) and major vascular
complication (p<0.001) when compared to the SAVR+CABG group. Postoperative
reintervention (p=0.020), atrial fibrillation (p<0.001), and acute kidney
injury (p=0.001) rates were significantly lower in the TAVI+PCI group. At
follow-up, TAVI+PCI showed a lower risk of all-cause mortality in the
first 19 days, with a reversal at 84 days favoring SAVR+CABG. [Formula
presented] Conclusion(s): In patients with severe aortic stenosis and
coronary artery disease, all-cause mortality varied over time between
TAVI+PCI and SAVR+CABG. TAVI+PCI showed a survival advantage in the early
period, whereas SAVR+CABG was favored in the mid-term. Extended follow-up
is needed to validate these findings. Copyright © 2025

<123>
Accession Number
2039183676
Title
POS1042 GALECTIN-3 AND MYOCARDIAL DYSFUNCTION IN PATIENTS WITH PSORIATIC
ARTHRITIS.
Source
Annals of the Rheumatic Diseases. Conference: EULAR 2025: European
Congress of Rheumatology. Barcelona Spain. 84(Supplement 1) (pp 1145),
2025. Date of Publication: 01 Jun 2025.
Author
Guajardo-Jauregui N.; Colunga-Pedraza I.J.; Galarza-Delgado D.A.;
Cardenas-de la Garza J.A.; Azpiri-Lopez J.R.; Flores-Alvarado D.E.;
Arvizu-Rivera R.I.; Garza-Flores O.A.; Gonzalez-Melendez A.; Polina-Lugo
R.L.
Institution
(Guajardo-Jauregui, Colunga-Pedraza, Galarza-Delgado, Cardenas-de la
Garza, Azpiri-Lopez, Flores-Alvarado, Arvizu-Rivera, Garza-Flores,
Gonzalez-Melendez, Polina-Lugo) Hospital Universitario "Dr. Jose Eleuterio
Gonzalez", Monterrey, Mexico
Publisher
Elsevier B.V.
Abstract
Background: Psoriatic arthritis (PsA) is an immune-mediated condition
associated with an increased risk of cardiovascular events due to
disease-specific characteristics. Galectin-3 (Gal-3) is a
beta-galactoside-binding protein involved in cellular adhesion,
proliferation, differentiation, and apoptosis. It is expressed by
endothelial cells and fibroblasts, contributing to the secretion of
multiple pro-inflammatory cytokines. This protein promotes angiogenesis
and fibrosis in various tissues and is considered a biomarker for heart
failure, coronary disease, and cardiovascular mortality [1]. However,
there is limited information regarding Gal-3 as a cardiovascular risk
biomarker in patients with PsA. Objective(s): This study aimed to
associate Gal-3 levels with echocardiographic parameters and disease
characteristics in PsA patients. Method(s): This was a
cross-sectional study including 78 patients diagnosed with PsA, according
to the 2006 CASPAR classification criteria, aged >18 years. Patients with
a history of major cardiovascular events were excluded. All study
participants underwent transthoracic echocardiography performed by two
certified cardiologists blinded to clinical information. Blood samples
were collected to analyze laboratory studies, including Gal-3 levels using
the ELISA method (Abcam, Cambridge, UK). Disease activity was assessed
using the Disease Activity Index for Psoriatic Arthritis (DAPSA), the
Psoriasis Area Severity Index (PASI), and the Nail Psoriasis Severity
Index (NAPSI). Correlations between Gal-3 levels and other variables were
analyzed using Spearman's correlation coefficient (rs). A p-value < 0.05
was considered statistically significant. Result(s): The mean age of
PsA patients was 52.12 +/- 11.91 years, and the median Gal-3 level was
11.5 (5.9-18.1) ng/mL. Clinical and demographic characteristics are shown
in Table 1. A moderate positive correlation was observed between Gal-3 and
global longitudinal strain (GLS) (rs = 0.305, p = 0.021), a low negative
correlation between Gal-3 and left ventricular ejection fraction (LVEF)
(rs = -0.255, p = 0.024), a moderate positive correlation between Gal-3
and PASI (rs = 0.331, p = 0.003), a low positive correlation between Gal-3
and DAPSA (rs = 0.237, p = 0.037), and a moderate positive correlation
between Gal-3 and C-reactive protein (CRP) (rs = 0.332, p = 0.003) (Figure
1). No significant correlations were found with other variables. A
multivariate analysis adjusted for age, body mass index, glycated
hemoglobin, systolic blood pressure, and non-HDL cholesterol showed that
Gal-3 levels were independently associated with worse GLS (beta = 0.358, p
= 0.013). Conclusion(s): In this study, elevated Gal-3 levels were
independently associated with impaired GLS, a parameter reflecting early
and subclinical left ventricular dysfunction. Normal GLS values range from
-18% to -22%, with more positive values indicating worse myocardial
strain. Additionally, higher Gal-3 concentrations were associated with
lower LVEF, indicative of left ventricular systolic dysfunction, as well
as higher PASI and DAPSA scores, which measure skin and joint disease
activity, respectively, and elevated CRP levels, an acute-phase reactant.
Gal-3 levels may be a useful biomarker for myocardial dysfunction and
disease activity in patients with PsA. REFERENCES: [1] Wu C, Lv Z, Li X,
Zhou X, Mao W, Zhu M. Galectin-3 in Predicting Mortality of Heart Failure:
A Systematic Review and Meta-Analysis. The Heart Surgery Forum
2021;24(2):E327-32. [Figure presented][Figure presented] Acknowledgements:
NIL. Disclosure of Interests: None declared. © The Authors 2025. This
abstract is an open access article published in Annals of Rheumatic
Diseases under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the
publisher make any representation as to the accuracy of the content. The
authors are solely responsible for the content in their abstract including
accuracy of the facts, statements, results, conclusion, citing resources
etc. Copyright © 2025 © Author(s) (or their employer(s))
2025. No commercial re-use. See rights and permissions. Published by
Elsevier Inc.

<124>
Accession Number
2039197040
Title
71597 , Safety and Efficacy of Covered Stents for Managing Vascular
Access Complications After Transfemoral Transcatheter Aortic Valve
Replacements: A Systematic Review and Meta-analysis.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100569. Date of Publication: 01 Jun 2025.
Author
Mahmoud M.; Cote C.; Elkhateeb O.; Jessula S.
Institution
(Mahmoud) Halifax Infirmary, Moncton, NB, Canada
(Cote, Elkhateeb) Dalhousie University, Halifax, NS, Canada
(Jessula) Halifax Infirmary, Halifax, NS, Canada
Publisher
Elsevier B.V.
Abstract
Background: Vascular access complications (VACs) after transfemoral
transcatheter aortic valve replacements (TAVR) range from 10-20%.
Percutaneous management of VACs with covered stents is minimally invasive
and appealing in this high-risk population. However, their long-term
efficacy and safety remain unclear. The objective of this study is to
evaluate the safety and efficacy of covered stents in managing VACs post
transfemoral TAVR. Method(s): We performed a systematic review and
meta-analysis of observational studies per PRISMA 2020 guidelines.
Eligible studies included patients who had undergone transfemoral TAVR and
subsequently developed a VAC managed with covered stenting. Data
extraction was performed independently by two reviewers. Result(s): A
comprehensive literature search identified 39 articles of which 13 met
inclusion criteria. 6729 patients underwent transfemoral TAVR with 746
(11.1%) VACs, 521 (69.8%) of which were treated percutaneously. All
patients were intermediate to high risk. Short-term stent-related
complications were 1.9%, with an overall technical success rate of 96%.
Coverage of the profunda femoris artery contributed to 47.62% of technical
failures, 60% of which were symptomatic. Long-term follow-up was available
in 9 studies with a median duration of 24.2 months. Long-term complication
rates were 4.4%. Stent fractures were rare (4 cases). Primary patency
rates were high across studies; however, heterogeneity in reporting was
high. The 30-day mortality rate was 2.4%, with deaths attributed to
comorbidities, procedural complications, or the severity of the initial
VAC, and no stent-related mortalities. Conclusion(s): Covered stents
appear to be a safe and effective intervention in the intermediate to
high-risk TAVR population. Complications may be underreported due to
limited long-term surveillance and publication biases. Copyright
© 2025

<125>
Accession Number
647596977
Title
Effect of Watching Nature-based Videos With Virtual Reality Glasses on
Surgical Fear and Anxiety in Patients Scheduled for Open Heart Surgery.
Source
Journal of perianesthesia nursing : official journal of the American
Society of PeriAnesthesia Nurses. (no pagination), 2025. Date of
Publication: 02 Jun 2025.
Author
Gul S.; Yalcinturk A.A.
Institution
(Gul) Department of Nursing, Institute of Health Sciences, University of
Uskudar, Istanbul, Turkey; Operating Room Department, Haydarpasa Number
Training and Research Hospital, Istanbul, Turkey
(Yalcinturk) Department of Psychiatric Nursing, Hamidiye Faculty of
Nursing, Health Sciences University, Uskudar, Istanbul, Turkey
Abstract
PURPOSE: The purpose of the study was to examine the effect of watching
nature-based videos with virtual reality (VR) glasses on surgical fear and
anxiety in patients scheduled for open heart surgery. DESIGN: The present
study used a randomized-controlled experimental design. METHOD(S):
The study was conducted between December 2023 and February 2024 at a
cardiovascular surgery training and study hospital in Istanbul. The
patients were randomly divided into 2 groups as the experimental (n = 30)
and control groups (n = 30). After the experimental group was informed
about the preoperative preparation, they watched a nature-based video with
VR glasses. The control group was informed only about preoperative
preparation. The data were collected by using the "Personal Information
Form," "Surgical Fear Questionnaire," and "State-Trait Anxiety Inventory."
FINDINGS: When the post-test mean scores of Surgical Fear Questionnaire
were evaluated, they were found to be 35.80 +/- 12.26 in the experimental
group and 55.60 +/- 10.91 in the control group. The post-test mean scores
of the patients in the experimental group were significantly lower than
those of the patients in the control group (P < .05). The post-test mean
scores of the patients on State-Trait Anxiety Inventory-I were were 42.03
+/- 6.99 in the experimental group and 63.80 +/- 6.65 in the control
group. The post-test mean scores of the patients in the experimental group
were significantly lower than those of the control group (P < .05).
 CONCLUSION(S): Watching nature-based videos with VR glasses reduced
both surgical fear and anxiety in patients scheduled for open heart
surgery. Copyright © 2025 The American Society of PeriAnesthesia
Nurses. Published by Elsevier Inc. All rights reserved.

<126>
Accession Number
2039196923
Title
71655 , Impact of Prior History of Stroke on Clinical Outcomes in
Patients With Severe Aortic Stenosis Following Transcatheter Aortic Valve
Replacement: A Systematic Review and Meta-Analysis.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100604. Date of Publication: 01 Jun 2025.
Author
Obi O.; Nweze U.; Lajczak P.; Eltawansy S.; Asonye P.; Gailot A.
Institution
(Obi) New York Institute of Technology College of Osteopathic Medicine,
Old Westbury, New York, United States
(Nweze) University of Massachusetts Global, Aliso Viejo, CA, United States
(Lajczak) Medical University of Silesia, Katowice, Poland
(Eltawansy) Jersey Shore University Medical Center, Monroe, NJ, United
States
(Asonye) University of Illinois at Chicago, Chicago, IL, United States
(Gailot) American University of the Caribbean School of Medicine, Cupecoy,
Sint Maarten (Dutch part), United States
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is an
alternative treatment option for symptomatic patients with severe aortic
stenosis and deemed inoperable or at high risk for conventional surgery.
Stroke is one of the most serious complications post-TAVR affecting
patients' survival and quality of life. We aimed to explore the impact of
prior history of stroke on outcomes in patients following TAVR.
 Method(s): PubMed, Embase and Cochrane databases were systematically
searched for observational studies comparing the impact of prior history
of stroke versus no prior stroke in patients with severe aortic stenosis
post-TAVR, with primary outcomes of mortality (eg in-hospital, 30-day and
1-year). We pooled odds ratio (OR) along with their 95% confidence
intervals (CIs). We examined heterogeneity using I2 statistics and studies
with high heterogeneity were examined with random-effect model.
 Result(s): We included 7 observational studies consisting of 259,871
patients of which 5,733 (2.2%) patients with severe aortic stenosis
post-TAVR had prior history of stroke. The mean age of these patients was
67.3 +/- 5.2 years and 82.1% were men. The pooled odds ratio analysis
showed that patients with prior history of stroke have higher incidence of
in-hospital (p < 0.00001), 30-day (p < 0.00001) and 1-year (p = 0.03)
mortalities compared to patients without prior history of stroke.
Similarly, prior history of stroke significantly increased the incidence
of AKI (p = 0.02), bleeding (p < 0.00001), vascular complications (p =
0.02), stroke (p = 0.002) and myocardial infarction (MI) (p < 0.00001)
compared to patients without prior history of stroke. However, there was
no significant differences between groups for permanent pacemaker
implantation (PPM) (p = 0.12) and new-onset atrial fibrillation (NOAF) (p
= 0.16). Conclusion(s): Our meta-analysis showed that patients with
prior history of stroke who underwent TAVR due to severe aortic stenosis
had higher rate of in-hospital, 30-day and 1-year mortalities which could
be explained by the higher incidence of bleeding. Based on these findings,
TAVR should be considered with caution in patients with severe aortic
stenosis with prior history of stroke. Copyright © 2025

<127>
Accession Number
647589089
Title
Preoperative carbohydrate loading reduces length of stay after major
elective, non-cardiac surgery when compared to fasting: a systematic
review and meta-analysis.
Source
Scientific reports. 15(1) (pp 19119), 2025. Date of Publication: 31 May
2025.
Author
Sebestyen A.R.; Turan C.; Szemere A.; Virag M.; Ocskay K.; Dembrovszky F.;
Szabo L.; Hegyi P.; Engh M.A.; Molnar Z.
Institution
(Sebestyen, Turan, Szemere, Dembrovszky, Szabo, Hegyi, Engh, Molnar)
Centre for Translational Medicine, Semmelweis University, Ulloi ut 26,
Budapest, Hungary
(Sebestyen, Ocskay) Heim Pal National Pediatric Institute, Budapest,
Hungary
(Turan, Szemere, Molnar) Department of Anaesthesiology and Intensive
Therapy, Semmelweis University, Budapest, Hungary
(Virag) Szent Gyorgy University Teaching Hospital of Fejer County,
Szekesfehervar, Budapest, Hungary
(Virag, Dembrovszky, Szabo, Hegyi) Institute for Translational Medicine,
Medical School, University of Pecs, Pecs, Hungary
(Hegyi) Institute of Pancreatic Diseases, Semmelweis University, Budapest,
Hungary
(Molnar) Department of Anesthesiology and Intensive Therapy, Faculty of
Medicine, Poznan University of Medical Sciences, Poznan, Poland
Abstract
Preoperative fasting is a worldwide routine even though the most recent
Enhanced Recovery After Surgery (ERAS) Guidelines recommend preoperative
carbohydrate loading instead of fasting, but with low quality of evidence.
Our aim was to compare the effects of preoperative carbohydrate loading to
fasting and placebo in patients undergoing elective major non-cardiac
surgery under general anaesthesia. Our systematic search was conducted on
15th of October 2021 in five databases, Medline, Embase, Central, Web of
Science and Scopus, and updated on November 12th, 2024. We included
randomized controlled trials that compared the carbohydrate loading
(CHO-group) with fasting or with placebo. Main outcomes were length of
hospital stay (LOS), postoperative glucose levels on postoperative,
postoperative insulin levels, and C-reactive protein (CRP) levels. Our
search revealed 44 eligible articles for data extraction. LOS was shorter
in the CHO group as compared to the No-CHO group (MD: - 0.56 [95% CI: -
1.10, - 0.02]). There were no clinically significant differences between
the CHO and No-CHO groups regarding the postoperative glucose, insulin and
CRP levels. This meta-analysis found that preoperative CHO-loading as
compared to preoperative fasting or placebo shortened the length of
hospital stay in patients undergoing major elective, non-cardiac surgery.
Although several details are still to be unveiled, these data provide
further support that preoperative carbohydrate loading could be beneficial
in this patient population. Copyright © 2025. The Author(s).

<128>
Accession Number
2039197002
Title
71610 , Sentinel Cerebral Embolic Protection During Transcatheter Aortic
Valve Replacement: An Updated Meta-Analysis of Randomized Controlled
Trials.
Source
Structural Heart. Conference: New York Valves: The Structural Heart
Summit. New York United States. 9(Supplement 1) (no pagination), 2025.
Article Number: 100580. Date of Publication: 01 Jun 2025.
Author
Goel S.; Hooda A.; Krishnamoorthy P.; Khera S.; Kini A.; Sharma S.
Institution
(Goel) Mount Sinai South Nassau Hospital, New York, NY, United States
(Hooda) The Mount Sinai Hospital, New York, NY, United States
(Krishnamoorthy) Icahn School of Medicine at Mount Sinai, New York, NY,
United States
(Khera, Sharma) Mount Sinai Health System, New York, NY, United States
(Kini) Mount Sinai Heart Health System, New York, NY, United States
Publisher
Elsevier B.V.
Abstract
Background: Periprocedural stroke during TAVR remains a significant
concern, prompting the use of cerebral embolic protection devices (CEPDs)
such as the Sentinel to mitigate embolic burden. Despite its mechanistic
rationale, RCTs assessing Sentinel have yielded heterogeneous results
especially for disabling stroke. To clarify its clinical utility, we
performed an updated meta-analysis of RCTs evaluating Sentinel CEPD during
TAVR. Method(s): A systematic literature search was performed for all
RCTs comparing Sentinel CEPD with standard TAVR. Outcomes analyzed
included all strokes, disabling stroke, non-disabling stroke, transient
ischemic attack (TIA) and All-cause mortality. Random-effects models were
used to estimate pooled risk ratios (RRs) and 95% confidence intervals
(CIs). Heterogeneity was assessed via I2 statistics.
 Result(s): A total of five RCTs met the inclusion criteria,
comprising 11,097 patients (Sentinel CEPD: 5609; Control: 5491). Sentinel
CEPD was not associated with significant reduction in total stroke (2.37%
vs 2.58%, RR: 0.88, 95% CI: [0.70-1.11], p=0.29, I2=
0),disabling stroke (1.01% vs 1.38%, RR: 0.74, 95% CI: [0.53-1.04],
p=0.08, I2= 20), non-disabling stroke (1.35% vs 1.20%, RR:
1.04, 95% CI: [0.75-1.44], p=0.80, I2= 0), or TIA (0.35% vs
0.27%, RR: 1.28, 95% CI: [0.66-2.47], p=0.47, I2= 0).
Additionally, Sentinel did not reduce all-cause mortality (0.73% vs 0.65%,
RR: 1.09, 95% CI: [0.70-1.69], p=0.71, I2= 0). [Formula
presented] Conclusion(s): For patients undergoing TAVR, routine use
of Sentinel CEP did not decrease the incidence of all strokes, disabling
stroke, non-disabling stroke, TIA and All-cause mortality. Copyright
© 2025

<129>
Accession Number
2034677167
Title
Systematic review and meta-analysis of the use of micrografting technology
in humans.
Source
Journal of International Medical Research. 53(5) (no pagination), 2025.
Article Number: 03000605251337859. Date of Publication: 01 May 2025.
Author
Almujaydil R.; Yan Y.; Kuswandani S.; Alotaibi F.; Suvan J.; Nguyen L.;
D'Aiuto F.
Institution
(Almujaydil, Yan, Kuswandani, Alotaibi, D'Aiuto) Periodontology Unit, UCL
Eastman Dental Institute, UCL, United Kingdom
(Almujaydil) Periodontology Unit, College of Dentistry, Qassim University,
Saudi Arabia
(Alotaibi) Department of Oral and Maxillofacial Surgery and Diagnostic
Sciences, College of Dentistry, Prince Sattam bin Abdulaziz University,
Saudi Arabia
(Suvan) Oral Sciences, University of Glasgow Dental School, School of
Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life
Sciences, University of Glasgow, United Kingdom
(Nguyen) Biomaterials and Tissue Engineering, UCL Eastman Dental
Institute, United Kingdom
Publisher
SAGE Publications Ltd
Abstract
Aim: To critically assess the evidence on micrografting technology to
evaluate its effectiveness when used alone or as an adjunct to
regenerative treatment in various medical and dental applications.
 Method(s): Seven electronic databases, including Cochrane Central
Register of Controlled Trials (CENTRAL), Medline Ovid, Embase Ovid,
Cumulative Index to Nursing and Allied Health Literature EBSCOhost, Web of
Science Core Collection, System for Information on Grey Literature in
Europe, and Bielefeld Academic Search Engine, were searched until 15 July
2024. Risk of bias assessment and qualitative and quantitative
(random-effect models) analyses were conducted. Result(s): A total of
55 studies were identified. Most studies (n = 24) reported on burns,
followed by 10 studies on ulcers/wounds, 7 on androgenetic alopecia, 3 on
vitiligo, 3 on cartilage and bone defects, and 1 on coronary artery bypass
graft surgery. Dental applications included sinus lift (three studies),
socket preservation (two studies), and intrabody defects (two studies). A
meta-analysis of four studies on the management of burns confirmed that
micrografting led to reduced healing periods compared with other grafting
techniques (weighted mean difference: -0.98, 95% confidence interval:
-1.84 to -0.12, p = 0.03), with a high level of heterogeneity (83.57%) and
risk of bias. Conclusion(s): Micrografting technology may lead to
shorter healing time and improved patient morbidity. Copyright ©
The Author(s) 2025.

EPICORE Embase Updates

Saturday, June 28, 2025

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

No comments:

Post a Comment

Followers

Blog Archive

About Me